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Abstract
The 11 molecule comprises a ligand for the androgen receptor (AR), which is
crucial to progression and survival of many prostate cancers, tethered to a DNA-
damaging aniline mustard. The compound was designed to exhibit selective toxicity
toward prostate cancer cells by forming sites of 11I 3-DNA damage to which AR binds,
physically blocking access of repair enzymes while becoming unavailable to activate
transcription of pro-survival genes. Previous studies have demonstrated the ability of
11 3 to damage DNA, retain affinity for AR when covalently adducted to DNA, and
prevent selectively the growth of prostate xenograft tumors implanted in mice.
Here we demonstrate that 11 promotes phosphorylation and nuclear localization
of AR, resulting in receptor association with androgen response elements. However, 11 3
only weakly drives AR transcriptional activity, and instead moderately antagonizes AR-
mediated transcription elicited by natural androgens. Furthermore, 1103 dramatically
decreases steady-state levels of AR protein. Collectively, these activities limit the
expression of androgen-regulated genes and could control toxicity in AR-expressing
prostate cancers.
Despite possessing an ability to modulate AR transcriptional activity, 110 is not
selectively toxic toward the AR-positive member of an otherwise isogenic pair of prostate
cancer cell lines derived from PC3 cells, which do not depend on AR-mediated gene
expression for growth or survival. Therefore, the extraneous presence of AR does not
increase 1113 toxicity. LNCaP cells are not rescued from toxicity by addition of high-
affinity AR ligand, raising doubts about AR involvement in the mechanism of toxicity in
these cells as well.
To further assess AR involvement in 110 toxicity, an analogue with -I10-fold
lower affinity for AR, 17a-OH- 1113, was synthesized and shown to produce measurably
reduced AR-driven transcription compared with 11 3. 17a-OH- 11 3 is less toxic to AR-
positive cell lines; however, this differential toxicity persists in an AR-null cell line,
further suggesting that AR is uninvolved in 11 toxicity.
Global transcriptional profiling has been conducted to assess other potential
mechanisims for I113 toxicity and has uncovered an ability of 11 3 to activate
cholesterol/lipid biosynthetic pathways and a response to unfolded protein while down-
regulating genes related to DNA damage repair. The unfolded protein response
represents an attractive potential mechanistic explanation for selective toxicity toward
cancerous cells, which may be related to an ability of 11 3 to perturb biological
membranes.
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Chapter 1: Introduction
- Chapter 1 -
Cancer
Cancer is a conglomerate of multiple and varied diseases, each sharing the
common characteristics of uncontrolled, invasive cell growth. Together, this group of
diseases accounts for 13% of current annual human mortality (Boyle and Levin, 2008), or
even as much as 25% of all deaths in the U.S. (Jemal et al. 2008). It is a disease that
affects both genders, all races, and all levels of income. It is, however, a disease that
predominantly affects the aged. Cancers are now understood to be diseases of the genetic
material, our DNA, and it is generally agreed that mutation of this genetic material is at
the heart of cancer development. Mutation can occur through single base substitution
resulting in coding for an alternate amino acid, or through larger scale chromosomal
rearrangements. Epigenetic mechanisms are increasingly being appreciated. Such
mechanisms could involve differential placement of 5-methylcytosine in regulatory
regions (Jones and Baylin, 2002), or by way of post-translational modification of
structural proteins involved in chromatin packaging (Herranz and Esteller, 2007). In
most cases in which gene mutations are involved, several mutations are required to
convert a normal cell into a malignant neoplasm. The mutations are necessary in order
for cells to gain the now well-accepted "hallmarks" of cancer: limitless replicative
potential (immortality), autonomy in growth signals, insensitivity to anti-growth signals,
resistance to apoptosis (cell suicide), sustained angiogenesis (coercion of neighboring
cells to reroute blood supply to the expanding tumor), and ultimately, invasive, metastatic
capacity (ability to break off from a primary tumor, enter the bloodstream, establish a
new clone elsewhere and take up root) (Hanahan and Weinberg, 2000). An additional
noteworthy hallmark of cancer has been proposed-a metabolic switch from oxidative
phosphorylation to glycolytic metabolism (Warburg, 1930), which has important
implications in cancer detection and treatment. A common method for detection of
tumors is use of ' 8 F fluorodeoxyglucose positron emission tomography (FDG-PET),
which is successful due to the increased rate of glucose utilization by solid tumors.
It is due to this need (Hanahan and Weinberg, 2000) for several successive
mutations that cancer is primarily a disease of the aged, although unique cases exist that
create a predisposition to the childhood cancers, due to their development from cell types
that reach maximum numbers at this stage (Stiller, 2004). Also, osteosarcomas peak in
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adolescence due to rapid long bone growth during this stage of development (Miller et al.
1996). Any individual mutation may allow for gain of more than one function and is
likely to be selected for by providing a competitive advantage over neighboring cells.
The individual genes that become mutated in the progression of cancer can be divided
into two categories: recessive loss of function tumor suppressor genes, which normally
function to keep cell growth in check, and dominant gain of function oncogenes, which
normally function in promoting cell growth and survival. By reducing the activity of
tumor suppressor genes and increasing the activity of oncogenes, cells can gain the
requisite hallmarks and fully transition into the potentially lethal neoplasms of cancer.
Genetic mutation can take place naturally through background rates of DNA
replication errors, but it has been proposed that this background rate is not enough to
account for the heterogeneity present in advanced cancers. It is then necessary to invoke
a "mutator" phenotype, which would significantly decrease the fidelity of replication and
allow for mutations to accumulate more quickly than they would otherwise (Loeb et al.,
2008). It is unknown at what stage of cancer progression such a mutator phenotype
might arise. In addition to underlying heredity, epidemiological studies highlight several
additional factors that can increase the collective risk of developing cancer, notably
tobacco use, prolonged exposure to sunlight without adequate UV protection, exposure to
chemical carcinogens, ionizing radiation, obesity and high fat diets, excessive alcohol
use, some hormones, and exposure to certain infectious pathogens. It is not always well
understood whether these risk factors serve to increase rates of mutation or promote
tumors by enhancing growth rates; both routes are likely involved.
While cancers have been associated with thousands of different individual
mutations, there are a few common genes that are found to be mutated in multiple
different cancers of distinct lineage. At the forefront of this list is the tumor suppressor
gene TP53, mutated in more than 50% of cancers (Hollstein et al., 1994). This gene
codes for the protein p53, which is involved in maintenance of genomic integrity, cellular
senescence, and also induction of apoptosis. RB1 is a tumor suppressor gene coding for
the retinoblastoma protein, which functions in normal cells to hinder cell cycle
progression and is found altered in 5-10% of cancers (Boyle et al., 2008). CDKN2A is
the gene coding for p16, another tumor suppressor and cell cycle regulator, and is found
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mutated in 30-60% of cancers. Additional tumor suppressor genes commonly mutated
include APC (especially in colon cancers) PTEN (in several cancers), and the breast
cancer associated genes BRCAJ and BRCA2.
There are also several oncogenes commonly altered by mutation or amplification
in cancers, most notably KRAS, coding for the Ras protein and mutated in 20-30% of
cancers (Bos, 1989). Additionally important oncogenes include ERBB2 (gene for
epidermal growth factor receptor, HER2, especially important in breast cancer), MYC
(involved in cell proliferation and survival), BCL2 (inhibitor of apoptosis), CCND1
(coding for cyclin D1, promoting cell cycle progression), CTNNB1 (encoding the protein
beta-catenin), and MDM2 (encoding protein of the same name, which is a ubiquitin ligase
most notable for its role in targeting p53 for proteasomal degradation). It is noteworthy
that while these genes are overrepresented in the development of cancer, each individual
cancer often has its signature of more and less commonly mutated genes. For instance,
while KRAS is mutated in 20-30% of cancers, its mutation is very rare in breast cancers
(Bos, 1989).
Treatment of cancers follows three primary routes. First, solid tumors will be
removed by surgical excision if possible. In the same manner, directed radiotherapy can
be used with the goal of killing what is still a locally confined neoplasm. There is an
obvious difference in the case of the hematological malignancies which do not form
primary tumors and thus cannot be removed surgically. The second route of cancer
treatment is chemotherapy, in which a drug is given to a patient systemically. This route
can be used concurrently with surgery or radiation to kill micrometastases (adjuvant
therapy) or to increase effectiveness of radiotherapy. Additionally, chemotherapy is
useful or necessary in treatment of hematological cancers and advanced metastatic
cancers since they are systemic or difficult to locate and remove individually.
Chemotherapy historically involves the use of agents that target rapidly dividing
cells by interfering with DNA replication or the processes of cellular division (Hurley,
2002). Agents that target DNA include antimetabolites such as methotrexate, which
inhibits the enzyme dihydrofolate reductase and is necessary for DNA synthesis, and the
largest class of anticancer drugs, the DNA damaging agents. These include compounds
which form covalent damage to DNA, such as cisplatin, mitomycin C,
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cyclophosphamide, BCNU, chlorambucil, and melphalan. There are also agents which
do not directly damage DNA, but intercalate between stacked DNA bases and often
interfere with the unwinding action of topoisomerases. These include doxorubicin,
etoposide, mitoxantrone, and topotecan. Other chemotherapeutics interfere with cell
division by preventing mitosis, usually by inhibiting microtubule activity. Examples of
this class are paclitaxel, vincristine, and the epothilones. In addition to the historical
chemotherapeutic agents, other, newer strategies are proving successful. Monoclonal
antibodies against specific oncogenes have been used with some success, such as
trastuzumab (Herceptin) in the case of breast cancer, which targets the HER2 protein
product epidermal growth factor receptor 2. In combination with chemotherapeutics,
Herceptin has been shown to improve median survival time of breast cancer by 25%
compared with chemotherapy alone (Baselga, 2001). Angiogenesis inhibitors such as
bevacizumab (Avastin) are approved and in clinical use, and in the case of Avastin have
been shown to increase median survival time of colon cancer by 30% (Hurwitz et al.,
2004). Other small compound treatments have been developed to target cancer specific
proteins. The targets are often kinases, and the best example is imatinib (Gleevec), which
was developed to inhibit specifically the tyrosine kinase domain of the novel Bcr-Abl
fusion protein created in chronic myelogenous leukemia (CML). Gleevec has proven
much more effective than the previous standard treatment of interferon a in combination
with cytarabine (O'Brien et al., 2003). Finally, anti-hormonal treatment is commonly
used to counteract tumor progression, especially of breast and prostate cancers which
depend on hormone receptor signaling for growth and survival. This method will be
discussed in detail with reference to prostate cancer later. Due to the heterogeneity of
advanced cancers, chemotherapy treatments are usually given in combination, under the
rationale that multiple compounds with different mechanisms will achieve the most
toxicity. It is also due to this heterogeneity that cancer treatment is more effective when
detection, diagnosis, and treatment occur sooner.
In 2007, estimates of the five most common cancers diagnosed worldwide
(excepting nonmelanoma skin cancers) were lung (1,549,121), breast (1,301,867),
colon/rectum (1,167,020), stomach (1,066,543), and prostate (782,647), while the five
most lethal cancers were lung (1,351,034), stomach (800,230), liver (679,871),
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colon/rectum (602,967), and breast (464,854) (Garcia et al., 2007). In the U.S., the story
is slightly different. In 2008, the estimated most prominent new cases were cancers of
the lung (215,020), prostate (186,320), breast (184,450), colon/rectum (148,810), and
lymphoma (74,320), while most deaths were from lung (161,840), colon/rectum (49,960),
breast (40,930), prostate (28,660), and pancreatic (34,290) cancers (Jemal et al. 2008).
This exemplifies the different cancer burden profiles affecting the developed and
developing world. As further testament, the developing world was estimated to have
725,230 new cases and 569,549 deaths from stomach cancer, second only to lung cancer,
while in the U.S. stomach cancer does not make the top five list in either incidence or
deaths.
It is welcome news that cancer treatment is effective. In the U.S., the 5-year
median survival rate for all cancers has increased from 50% from 1975-1977 to 66% in
the years 1996-2002 (American Cancer Society, 2007). This increased survival is the
result of combined efforts for better and earlier screening and detection, along with
improvements in treatment ranging from more sophisticated combinations and dosing
regimens with existing therapeutics to the development of entirely new and more
effective therapeutics. Despite these advances, it hardly needs stating that cancer remains
a deadly disease with a continued need for newer, better treatments in addition to the
effective public campaigns increasing awareness of the dangers of tobacco, poor diet, and
poor hygiene. This work will highlight efforts toward development of a new treatment
for prostate cancer.
Prostate Cancer
Prostate cancer is the most frequently diagnosed non-skin cancer among males in
the U.S., with an estimated 186,320 new cases leading to 28,660 deaths in 2008 (Jemal et
al. 2008). While reported incidence of prostate cancer is subject to variable trends in
screening for prostate specific antigen (PSA), which increased from 1995 through 2002
before finally leveling off, mortality estimates are true judges of the advances being made
in detection and treatment. Prostate cancer mortality was increasing in the U.S. from the
years 1987-1991 by an annual percentage change (APC) of 3.0. However, incidence
began to decrease from 1991-1994 by an APC of -0.6, and from 1994-2005 the mortality
- Chapter 1 -
has been steadily decreasing, by a -4.1 APC (Jemal et al. 2008). While it was anticipated
that these kinds of improvements in overall survival might occur as a result of increased
testing for PSA, studies have dismissed increased testing as significantly extending
overall survival (U.S. Preventive Services Task Force, 2002; Concato et al., 2006). The
reason that increased PSA screening does not necessarily translate into increased survival
is probably the combined effects of late age at diagnosis and the inherent slow growth of
prostate tumors. Thus, while increased testing will lead to many more diagnoses of
prostate cancer, patients will often die with, rather than from, this disease. It remains to
be determined what the exact causes for recent decreasing mortality from prostate cancer
are, whether indicative of better treatment or other as yet undiscovered factors such as
changes in diet (Oliver et al., 2001). One very intriguing possibility is that accelerated
use of statins in controlling cholesterol is actually shown to have an inverse relationship
with advanced prostate cancer (Platz et al., 2006), thus potentially providing a fortuitous
and unintentional effect on prostate cancer survival.
Despite PSA screening not necessarily resulting in increased overall survival of
prostate cancer, its utility in detecting cancer is undisputed. In fact, a recent study
demonstrates the potential that a single PSA test given to men aged 44 to 50 could
accurately predict prostate cancer incidence up to 25 years later (Lilja et al. 2007). PSA
is a 34 kDa glycoprotein produced almost exclusively by the prostate. Its normal
function is as a serine protease, fragmenting fibronectin and seminogelin and resulting in
the liquefaction of semen, allowing sperm to swim freely and achieve successful
fertilization (Lilja et al. 1987). The prostate gland is composed of a layer of secretory
epithelial cells, surrounded by basal cells and a basement membrane. PSA is produced
by the epithelial cells, from which it is secreted into the lumen and becomes part of
seminal fluid. Disruption of the basal cells and basement membrane is a common
occurrence in prostate cancer, and this disruption allows PSA to enter the circulation
where it can be detected by a routine blood test (Balk et al., 2003). Even in healthy
males, PSA is normally present in blood, albeit at very low levels. Any disruption to the
architecture of the prostate can result in a significant increase in the serum concentration
(Bostwick 1994), which can unfortunately lead to many unnecessary biopsies in
conditions such as benign prostatic hyperplasia or local infection. Additionally, it is not
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altogether uncommon for prostate tumors to develop significantly without circulating
PSA levels reaching the accepted high-risk cutoff of 4.0 ng/mL. In one study, 449 of
2950 men (15.2%) with PSA readings below 4.0 ng/mL were diagnosed with prostate
cancer following biopsy (Thompson et al., 2004). However, circulating PSA levels above
10 ng/mL are very predictive of prostate cancer (Catalona et al., 1991). Therefore, while
PSA testing as a gauge of prostate cancer is subject to significant levels of both false
positives and false negatives that must be eliminated, its utility remains. PSA is also
quite valuable for following disease progression. Monitoring of serum PSA levels can be
helpful in detecting effectiveness of primary surgery and radiation (Hudson et al., 1989),
disease relapse after primary treatment (Killian et al., 1985), and the utility of anti-
hormonal therapy and predicted duration of remission in advanced stages (Miller et al.
1992). Finally, constant efforts are being made to use PSA detection in more
sophisticated ways such as monitoring the relative change over time rather than use of a
single reading.
Prostate Cancer Risk Factors
The underlying causes of prostate cancer are not very well understood. The only
well established risk factors are age, race, and family history. Old age is the most
predictive factor for prostate cancer, with a mean patient age of 72-74, and 85% of
diagnoses occurring after age 65 (Gr6nberg 2003). However, preneoplastic lesions have
been detected in men in their twenties and are frequent for men in their fifties (Sakr et al.,
1993). There is wide variation among different ethnic and geographical populations, with
extremes of 70-fold different risk between Chinese of the Tianjin region (1.9 per
100,000) and African-Americans (137 per 100,000) (Parkin et al., 1997). The reduced
risk to Asians is widely recognized and has been attributed to differences of lifestyle and
the Asian diet's inclusion of phytoestrogens contained in soy products and general
exclusion of more fatty foods (Adlercreutz and Mazur, 1997). Migration studies have
shown that Japanese men (low incidence), having moved to the U.S., increase their risk
of developing clinical stage cancer. Yet, the increased risk is not on par with those of
Caucasians or African Americans, both demonstrating an environmental effect and at the
same time implicating genetics as a significant factor. However, it has also been shown
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that the rates of histological presentation of prostate cancer (upon autopsy) are much
more similar in these different populations than clinical presentation, suggesting that
some of these factors may have more to do with disease progression than incidence
(Breslow et al., 1977).
Family history is a strong risk factor. Men with an affected father or brother are
twice as likely to develop prostate cancer (Steinberg et al., 1990). Put another way, 10-
15% of prostate cancer patients have at least one affected relative (Hayes et al., 1995;
Whittemore et al., 1995). This familial association has been mapped to several gene loci,
leading to identification of many genes with potential association, including ELAC2
(Tavtigian et al., 2001), RNASEL (Carpten et al. 2002), MSR1 (Xu et al. 2002), CHEK2
(Chk2 checkpoint homolog (S. pombe)) (Wu et al. 2006), CAPZB (Berry et al., 2000),
VDR (Vitamin D Receptor), and PON1 (Deutsch et al., 2004). More research is
warranted to clarify further each of these genes' impacts upon prostate cancer
susceptibility, in addition to biochemical studies to uncover potential mechanistic
explanations in most cases.
Certain genes are commonly mutated during disease progression of both familial
and sporadic prostate cancers. Inactivation of the tumor suppressor gene PTEN has been
associated with prostate cancer. One study found that 23% of first time diagnosis
patients have lost this gene, increasing to 59% of advanced metastatic disease cases
(Schmitz et al., 2007). These data implicate PTEN inactivation as a potential early event
in progression to more advanced stage of disease. PTEN (phosphatase and tensin
homolog) functions in negative regulation of the Akt signaling pathway, thus serving as a
cell cycle control, with additional functions related to apoptosis and angiogenesis. An
additional factor that may be involved in early stages of prostate cancer progression is the
loss of tumor suppressor CDKN2A (pl6). p16 is also a cell-cycle regulating protein,
functioning to inhibit cyclin dependent kinase 4, thus preventing progression from GI to
S in the cell cycle. It is frequently inactivated in numerous cancers, and finds
inactivation by homozygous deletion or promoter methylation at a low frequency in
prostate cancer (Rocco and Sidransky, 2001). RB1 is also inactivated in over 30% of
localized prostate cancers (Ittmann and Wieczorek, 1996).
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The best correlation between inactivation of a single gene and prostate cancer
exists for glutathione S-transferase pi 1 (GSTP1), which is silenced by promoter
hypermethylation in greater than 90% of diseased patients (Meiers et al., 2007).
Furthermore, this hypermethylation already exists in a vast majority of pre-cancerous
prostatic intraepithelial neoplasia (PIN), despite no detection of hypermethylation in
normal tissue samples. GSTP1 functions in the detoxification of reactive oxygen species
(ROS) and other electrophilic toxins. A full understanding of how this protein influences
prostate cancer progression is currently lacking, but this gene is a good candidate as a
forebear to the mutator phenotype. Finally, a fusion between the androgen responsive
gene TMPRSS2 and the ETS oncogenes ERG, ETV1, or ETV4 occurs in a majority of
prostate cancers (Tomlins et al., 2007). ERG or ETV1 are found overexpressed in 57%
of prostate cancers, and in greater than 90% of these cases, a TMPRSS2 fusion is
concurrent (Tomlins et al., 2005). The fusion is not found in benign prostatic tissue.
Another handful of genes are commonly mutated in advanced prostate cancer, but
detected primarily following progression to a hormone refractory state. These include
recognizable examples such as amplification of MYC (Emmert-Buck et al., 1995), BCL2
(McDonnell et al. 1992), ERBB2 (Ross et al. 1997), and the androgen receptor (AR)
(Abate-Shen & Shen 2000), and inactivation or mutation of TP53 (Hall et al. 1995) and
CDKNIB (p27) (Fernmndez et al., 1999).
Prostate Cancer Treatment
The five-year survival rate of prostate cancer in the U.S. has improved from 69%
to nearly 100% within the past twenty-five years, demonstrating improvements made in
disease management (American Cancer Society, 2007). Treatment of prostate cancer
often begins with detection of an elevated PSA count or an irregularity of size, shape, or
texture of the prostate gland detected by digital rectal examination (DRE). Subsequently,
a tumor biopsy is usually performed in order to assign a stage and prognosis. The most
important parameter of staging is whether or not the tumor is still confined to the
prostate. Prognosis is good with progression-free cure rates exceeding 90% for locally
confined prostate adenocarcinoma. When a tumor is locally confined, treatment consists
of primarily three options. One option is to do nothing at all, in what is termed "watchful
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waiting." Due to the inherently slow growth of prostate cancers and taking into account
the elderly average age at diagnosis, treatment with intent to cure is not always
warranted. In this case, monitoring of PSA levels would continue as a metric of disease
progression, and a re-evaluation would take place in the event of a sudden spike. The
second option is complete removal of the prostate gland by radical prostatectomy, while
the third option seeks to destroy the cancerous tissue by directed radiation. It has long
been recognized that prostate cancer is fueled by androgens (Huggins and Hodges, 1941),
and another option, which in locally confined cancer, is generally only used in
conjunction with prostatectomy or radiation therapy, is anti-hormonal therapy.
Additionally, if the cancer has already spread outside of the prostatic boundary, or if there
is an increase in PSA level following initial prostatectomy or radiotherapy indicative of
relapse, anti-hormonal therapy is likely to be the next standard treatment.
Anti-hormonal therapy encompasses all efforts to reduce the circulating
concentration of androgens that fuel prostate cancer growth. The first method widely
used was orchiectomy, or surgical removal of the testicles. Surgical castration gave way
to "chemical castration," which encompasses a few different strategies. The first of these
involves interfering with the luteinizing hormone releasing hormone (LHRH) system.
The hypothalamus responds to the presence of various steroids by producing LHRH.
LHRH then travels to the pituitary gland where it binds to its receptor and induces release
of luteinizing hormone (LH), which then travels to the testes and increases production of
testosterone. By interfering with this cascade at any level, the circulating level of
androgens can be reduced. LHRH agonists were developed to interfere with this process,
and in use initially cause a spike of testosterone production (and associated flare of
symptoms), but in prolonged use lead to lower LH release and resultant serum
testosterone levels. Newer LHRH antagonists perform the same function while
eliminating the initial flare that increases symptoms. Despite the development of these
new agents, LHRH agonists have become the preferred method of androgen ablation in
the United States. In addition to the testes, the adrenal gland produces low levels of
androgen and can provide some fuel to hormone-starved prostate cells. Adrenalectomy
was initially attempted as corollary treatment with some success, but compounds have
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since been developed to prevent adrenal steroid synthesis, with ketoconazole serving as
the current standard (Pont et al., 1982).
While these efforts all aim at reducing circulating androgen levels, the ultimate
target of any of these treatments is a reduction of signaling mediated by the androgen
receptor. This has also been achieved more directly, by creating antagonists of AR
activity that bind directly to AR in target prostate cancer cells and disrupt normal
signaling. This class includes the steroidal cyproterone acetate, as well as non-steroidal
anti-androgens flutamide (Eulexin) and bicalutamide (Casodex). Total androgen
blockade involves the concurrent use of AR antagonists along with surgical or medical
castration. While these efforts at interfering with AR signaling are all effective at
reducing pain and other symptoms, it is inevitable that prostate cancer not eradicated by
prostatectomy or radiation will progress through anti-hormonal therapy to an androgen
independent state termed hormone refractory prostate cancer (HRPC). At this stage of
prostate cancer progression, treatments generally involve more traditional cytotoxic
chemotherapy. The only current FDA-approved treatments for advanced hormone-
refractory prostate cancer are therapies of mitoxantrone, docetaxel, and estramustine,
often in conjunction with prednisone, but there are several new treatments being
developed. The most successful of these treatments, docetaxel, provides less than 2.5
months of extended survival (Mike et al., 2006). Many elderly patients at this stage of
disease choose not to undergo cytotoxic chemotherapy merely to gain two months of
quality minimized life. It is clear that better treatments are needed in the management of
HRPC, and the work described herein represents one such approach to a new potential
treatment.
The Androgen Receptor
The androgen receptor is a type I ligand-activated member of the steroid receptor
family of nuclear receptors. This family also includes the estrogen receptor (ER),
glucocorticoid receptor (GR), progesterone receptor (PR), and mineralocorticoid receptor
(MR). Only one AR gene has been discovered, located in single copy on the X
chromosome at Xqll.2-ql2 (Trapman et al. 1988; Chang et al. 1988; Lubahn et al.
1988). The complete gene is over 90 kb long, spanning 8 exons and coding for a protein
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of 910-920 amino acids. Two variable-length stretches within the N-terminal domain
(NTD) resulting from trinucleotide repeats of glutamine (CAG) and glycine (GGN) in the
AR gene account for the different protein lengths observed. Reports have demonstrated
that shorter CAG repeats correlate with higher AR transcriptional activity and increased
risk of prostate cancer (Giovannucci et al., 1997).
The primary function of the AR is as a transcription factor mediating expression
of a select set of genes. Its function is crucial in development and maintenance of the
male sexual phenotype, and its involvement in prostate cancer progression is also well
studied and established. AR is primarily expressed as an apparent 110 kDa protein (AR-
B), which is post-translationally modified by immediate phosphorylation to yield a
protein running as 112 kDa by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) (Wong et al. 2004). An additional 87 kDa protein (AR-A), created from
truncation of the NTD resulting from loss of the first 187 amino acids, has been detected
in several tissues, but is less thoroughly studied, and its importance is unknown (Wilson
& McPhaul 1996). Any mention of the AR to follow refers to AR-B, the more well
understood full-length form.
AR Structure and Organization
The AR protein, like all steroid receptors, is composed primarily of three separate
modular domains-the N-terminal domain, DNA binding domain (DBD), and ligand-
binding domain (LBD). Within the NTD, Activation Function 1 (AF-1) located between
amino acids 101 and 370, is necessary for greatest transcriptional activation following
hormonal exposure, while a second Activation Function 5 (AF-5), located between amino
acids 360 and 485, allows for constitutive receptor activity in absence of ligand (Jenster
et al., 1995) (Figure 1.1). In fact, LBD deletion results in constitutive activity of the
receptor that does not depend on AF-1 activity but requires AF-5, implicating the LBD in
a functional repression of AF-1 in a full length receptor lacking ligand, and repression of
AF-5 once ligand is present. Additionally, the NTD contains a dimerization surface
composed of amino acids 1-36 which includes the 23FQNLF2 7 motif, involved in intra-
and inter-molecular interaction with the C-terminus that is elicited by androgen
stimulation (Schaufele et al., 2005). The region from 370-494 within AF-5 is also
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required for the interaction between the N and C termini resulting in transcriptional
activation (Brinkmann et al. 1999). The DNA binding domain, spanning amino acids
559-624, is the most conserved domain among steroid receptors and consists of two zinc
fingers, each having four cysteine residues bound to a zinc ion and responsible for
binding to androgen response elements (ARE's) present in target gene promoters. A
small hinge region from amino acids 624-676 contains the nuclear localization sequence
responsible for redistribution of AR from cytoplasm into the nucleus upon hormonal
stimulation. Amino acids 676-919 compose the LBD, containing Activation Function 2
(AF-2), which, during hormone stimulation, interacts with either the 23FQNLF 27 motif of
the NTD or with a co-activator protein carrying a similar LXXLF or FXXLF motif
(Dubbink et al., 2004). A distinct second region outside of AF-2 but within the LBD is
involved in interaction with 433WHTLF4 37 within AF-5. The LBD, as its name portends,
also contains the binding pocket which receives either testosterone or the more potent
androgen 50x-dihydrotestosterone (DHT). Finally, a nuclear export signal is also located
in this LBD region (Saporita et al., 2003).
To date, no crystal structures of full length steroid receptors have been solved.
However, several structures have been solved for the LBD portions of these proteins. All
of the steroid receptors' LBDs display a very similar three-dimensional structure,
composed of 10-12 alpha helices arranged in an anti-parallel, three-layered "alpha-helical
sandwich". The AR LBD shares the most sequence identity with PR, GR, and MR (all
around 50%) (Marhefka et al., 2001), and is actually composed of 11 helices, lacking H2
present in other nuclear steroid receptors (numbering remains the same for the other
complementary helices so that comparison is easier). Together, H5, the N-terminal
portion of H3, and the C-terminal regions of HIO and HII form the bulk of the
hydrophobic binding pocket (Figure 1.2). Upon androgen binding, H12 shifts and closes
over the binding pocket, assisting in ligand retention (Zhou et al. 1995). Additionally, the
conformational changes that take place upon ligand binding allow formation of the
functional AF-2 surface, necessary for binding of co-activator proteins and for
amino/carboxyl terminal (N/C) interaction.
The DNA binding domain structures of several steroid receptors have also been
solved. The DBD of all steroid receptors is a well-conserved region consisting of three
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alpha-helices containing two zinc-fingers, in addition to a C-terminal extension (CTE).
The first zinc finger contains a stretch of five amino acids called the P-box, which
directly interacts with the major groove of DNA and provides the majority of sequence
discrimination. The second zinc finger contains another stretch of five amino acids called
the D-box, containing the major residues involved in DNA-dependent receptor
dimerization (Umesono and Evans, 1989). Amino acids within the CTE also confer
DNA-dependent DBD dimerization for the AR (Schoenmakers et al., 1999, 2000;
Haelens et al., 2001). The AR, PR, GR, and MR all recognize very similar or identical
DNA sequences, raising the long-standing questions of how these receptors elicit specific
responses with such degeneracy in response elements. Definitive answers are still
lacking, but it is believed that specificity comes from differences in steroid metabolism,
receptor expression (Strihle et al., 1989), chromatin structure (List et al., 1999), and
cofactor expression and recruitment to active transcriptional complexes (MUiller et al.,
2000). The AR is unique in that it binds to the consensus inverted repeat sequence
AGAACAnnnTGTTCT (classical ARE) (Nelson et al., 2002), in addition to direct repeat
sequence AGAACAnnnAGAACA (selective ARE) (Shaffer et al., 2004), allowing an
extra level of potential specificity. For the GR (Luisi et al., 1991) and ER (Schwabe et
al., 1993), crystal structures show that the respective DBD's bind to an inverted repeat
hormone response element in a head-to-head fashion. As such, it is assumed that the AR
DBD also dimerizes in a head-to-head fashion on classical inverted repeat response
elements. It was further surmised that binding to the selective ARE's would be in a head-
to-tail fashion, matching the underlying response element arrangement. However, the
structure of a-crystallized AR DBD bound to a selective ARE demonstrates that even
when bound to a direct repeat response element, dimerization is in a head-to-head fashion
(Shaffer et al., 2004). In this binding mode, one AR monomer binds to its respective
hexameric half site response element with high affinity while the other binds with lower
affinity, demonstrating the importance of the DBD dimerization interface in AR-specific
DNA binding.
Finally, the NTD of steroid receptors are not amenable to crystal structure
analysis, presumably due to structural flexibility in this region. The NTD is the least
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conserved among the steroid receptor domains, and as such, is likely to be heavily
involved in receptor-specific effects.
AR Transcriptional Activation
AR binds to both T and DHT with Kd's of -InM and 0.1nM respectively.
Testosterone is reduced by the enzyme 5-reductase in some target tissues including the
prostate to convert it to the more potent androgen DHT. In absence of androgen, the AR
resides predominantly in the cytoplasm in a large complex of heat shock proteins
including Hsp90, Hsp70, and Hsp56 (Veldscholte et al., 1992), immunophilins such as
FKBP52 (Cheung-Flynn et al., 2005), co-chaperones, and tetratricopeptide repeat-
containing proteins (Buchanan et al., 2007). However, ligand binding induces
conformational changes in the LBD that allow AR to be released from chaperone
proteins, become phosphorylated, translocate into the nucleus, auto-dimerize, interact
with co-activator proteins, bind to androgen response elements (ARE's) in the promoters
of target androgen genes, and recruit machinery to induce transcription of these genes
(Brinkmann et al., 1999). Additionally, ligand binding is essential for nuclear retention
of AR, as the transfer of cells into a medium lacking androgen allows for export of AR to
the cytoplasm. Up to four rounds of cycling from cytoplasmic to nuclear location has
been demonstrated for the AR prior to receptor degradation (Roy et al. 2001).
Several phosphorylation sites have been established in the AR, including serines
16, 81, 94, 256, 308, 424, and 650 (Gioeli et al., 2002). Serine 94 is constitutively
phosphorylated, while each of the others display elevated phosphorylation upon androgen
exposure. Serine 650 phosphorylation was also stimulated by protein kinase A, protein
kinase C, and epidermal growth factor signaling, while serine 81 was shown to have the
highest stoichiometric phosphorylation in response to hormone (Gioeli et al., 2002).
Another unique and incompletely understood feature of AR activation is the N/C
terminal interaction that occurs upon androgen stimulation. This interaction was first
established through use of mammalian two-hybrid assays (Langley et al., 1995). More
recent fluorescence resonance energy transfer (FRET) studies have shown convincingly
that intramolecular N/C interaction occurs within -3.5 minutes of androgen addition,
followed 6 minutes later by intermolecular interaction of N and C termini (dimerization).
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Furthermore, these results showed that no receptor dimerization occurred in the
cytoplasm, while N/C interaction occurred equally in cytoplasmic and nuclear
compartments (Schaufele et al., 2005). These results suggest that dimerization requires
nuclear compartment-specific events to occur. The active AF-2 region of the LBD
created by addition of androgen has posed somewhat of a conundrum, because this region
interacts with either the 23FQNLF 27 motif of the NTD, or with co-activator proteins
containing LXXLF motifs, suggesting these two activities compete. In fact, experiments
have shown that the active AF-2 prefers interaction with FXXLF over LXXLF motifs
(He et al. 2000). Additional experiments demonstrate that N/C interaction occurs
predominantly in mobile receptors, while co-activator binding occurs preferentially once
AR is bound to DNA (van Royen et al., 2007). This result suggests that the N/C terminal
interaction may serve to stabilize the receptor and maintain androgen binding until DNA
binding occurs, at which time association of co-activator proteins can take over and assist
in transcriptional activation.
The activation functions within the AR interact with co-activator and co-repressor
proteins, assisting in the recruitment of chromatin remodeling enzymes as well as
providing additional levels of transcriptional regulation. The most widely understood co-
activator proteins are those of the p160 family, including steroid receptor coactivator 1
(SRC1) (Ofiate et al., 1995), transcriptional intermediary factor 2 (TIF2) (also known as
glucocorticoid receptor interacting protein 1 (GRIP1) (Voegel et al., 1996), and amplified
in breast cancer 1 (AIB1/SRC3) (Anzick et al., 1997). Recruitment of these factors
influences transcription directly via histone acetyltransferase (HAT) activity and
indirectly by creating a platform for recruitment of secondary co-activators with
chromatin remodeling activities. Alternatively, recruitment of co-repressor proteins
including nuclear receptor co-repressor 1 (NCoR1) (Cheng et al., 2002) and the silencing
mediator of retinoic and thyroid hormone receptor (SMRT) (Liao et al. 2003), which both
inhibit transcription, occurs in the presence of androgens and is increased in the presence
of AR antagonists or partial agonists. Co-repressor binding requires extension of the
p160 co-activator protein binding LXXLL-like motif to an LXX-I/H-IXXX-L/I motif,
known as a CoRNR box (Hu & Lazar 1999). Re-positioning of helix 12 away from
helices 3-5 is believed to allow for the larger CoRNR box containing three helical turns
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instead of the two turns seen in LXXLL-like motifs. Presumed helix 12 displacement
and additional conformational changes in the LBD are involved in increased association
of co-repressor proteins with mifepristone (RU-486) bound AR (Hodgson et al., 2008).
Several other co-regulators of transcriptional activity have been studied and catalogued
and exemplify the complex regulatory mechanisms driving transcription through the AR
(Chmelar et al., 2007).
AR Regulation
AR is eventually degraded via the ubiquitin-proteasome pathway after an
unknown number of transcriptional events. A conserved PEST sequence thought to be
important for protein tagging by ubiquitylation is present within the hinge region of AR,
and use of proteasome inhibitors increases steady-state AR protein levels (Sheflin et al.,
2000). It has been further demonstrated that AR can form a complex with Akt and
Mdm2, which promote phosphorylation-dependent AR ubiquitylation (Lin et al. 2002).
However, it is also well established that proteasome activity is necessary for AR
transcriptional activity (Lin et al. 2002). One study has shown that the S1 subunit of the
19S proteasomal cap interacts with the PSA promoter, and that proteasome inhibition
prevents release of the receptor from the PSA promoter (Kang et al., 2002). Combined
with the finding that consecutive rounds of nucleocytoplasmic shuttling of receptor lead
to less effective nuclear translocation of AR (Tyagi et al. 2000), it is likely that
proteasome activity modulates the number of transcriptional events in which one receptor
may participate. The ability for a single AR to undergo multiple rounds of transcription
once again makes it unique relative to the other steroid receptors which typically are
degraded by the proteasome after a single round of replication.
AR Involvement in Prostate Cancer
The AR is involved in prostate cancer development at every stage. AR turns on
the expression of several genes involved in promotion of growth and survival. As such,
cells which maintain AR signaling have a slight growth advantage over neighboring cells
and will persist. Men who were castrated at a young age, or who have deficiency in 5ca-
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reductase or other androgen insensitivity syndrome mutations do not develop prostate
cancer. Men with shorter CAG repeats in the AR gene corresponding to shorter
polyglutamine tracts have higher AR transcriptional activity (Chamberlain et al., 1994),
which corresponds to an increased risk and a statistically earlier onset of prostate cancer
(Giovannucci et al., 1997). Thus, expression of genes mediated by AR is a causal factor
in prostate cancer. Several androgen-regulated genes have been identified, with PSA the
most thoroughly studied due to its utility in detection of prostate cancer and monitoring
of progression. However, while some theorize that PSA plays a causal role in prostate
cancer progression (Williams et al. 2007), it is not a good candidate for a pro-growth or
pro-survival gene.
AR acts as a master regulator of the G1-S cell cycle phase progression, increasing
expression of cyclin-dependent kinases (CDK) 2 and 4, as well as down regulating
expression of p16 (Lu et al. 1997). Androgens also induce expression of cyclins D , D2,
and D3 and phosphorylation and inactivation of RB (Xu et al. 2006). These
transcriptional and translational changes mediated by the AR promote cells into the S
phase of replication and enhance proliferation. Due to the dependence on AR signaling
for prostate cancer progression, the first line therapy in metastatic prostate cancer
treatment is inhibition of AR signaling by lowering circulating androgen levels and/or the
use of AR antagonists. However, it is a certainty that prostate cancer will progress from
an androgen-dependent stage into hormone-refractory disease. The progression to HRPC
can take several routes, including mutations within the AR LBD that allow promiscuity
for other ligands, amplification and over-expression of AR that increases transcription
from low levels of circulating androgen, increased expression of co-activator proteins and
increased local production of androgens. So-called 'outlaw' pathways can also take over,
in which case growth factors such as insulin-like growth-factor-i (IGF-1), keratinocyte
growth factor (KGF), and epidermal growth factor (EGF) are able to promote AR
activation in absence of any androgen (Culig et al., 1994). HER-2 overexpression is also
able to activate AR in the absence of AR ligand, but requires AR protein expression
(Craft, Shostak, et al., 1999). In each of these mechanisms of androgen independence,
AR presence is required despite ability of prostate cancers to progress in absence of
normal levels of circulating androgen.
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Other mechanisms exist that can allow progression in complete absence of AR,
known as bypass pathways. Effective bypass involves the use of other signaling
pathways to stimulate androgen-independent cells to proliferate. BCL2 is a gene thought
to be involved in bypass pathways, as it is not normally expressed in prostate epithelial
cells, but is commonly expressed in PIN and in HRPC (Colombel et al., 1993). Because
BCL2 is anti-apoptotic, its overexpression could allow prostate cancer cells to proliferate
despite lacking AR signaling. In fact, it is thought that BCL2 overexpression, along with
family members BCL-X and MCL-1 (Krajewska et al., 1996), is partially responsible for
the low success rate in treatment of prostate cancer with traditional cytotoxic
chemotherapy regimens (Osborne et al. 1992; Smith et al. 1993; Williamson et al. 1996;
van Brussel et al. 2000).
A final hypothesis to consider in the progression to HRPC is that there are
"lurker" cells present which do not depend on androgens for growth (Isaacs 1999). This
hypothesis presupposes the development of prostate cancer from an epithelial prostate
stem cell. In such a scenario, most of the cells descending from these stem cells would
differentiate into androgen-dependent cells and comprise the majority of a tumor, while
androgen-independent progenitor cells remained present at low levels. Androgen
deprivation therapy would provide a selective pressure that increases the proportion of
cells having independence from androgen signaling and ultimately lead to clinical
presentation of HRPC. Support for this hypothesis is provided by experimental evidence
of clonal expansion of androgen independent cells within an androgen-dependent tumor
(Craft, Chhor, et al., 1999). Despite progression of prostate cancer to a hormone
refractory state, a majority of prostate cancers continue to express and depend on AR
signaling (van der Kwast et al. 1991; Visakorpi et al. 1995; Gregory et al. 1998;
Holzbeierlein et al. 2004; Mohler et al. 2004). The AR therefore remains an excellent
target of new therapeutics, but these therapeutics need to be designed such that they
inhibit AR signaling in novel ways. Our work described herein will discuss the use of
cytotoxic chemotherapeutics designed to utilize the ubiquitous expression of AR in
prostate cancers as a mechanism of enhanced toxicity.
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Cisplatin
The use of DNA damaging agents is historically verified as one of the most
successful cancer treatment strategies. However, there are two primary shortcomings to
this therapy: 1) Toxicity to healthy somatic cells is high, and 2) resistance can be
achieved by increased DNA repair activity in cancerous cells, rendering them less
sensitive to alkylation damage (Harris 1985; Masuda et al. 1988; Andrews 1994; T. Fojo
2001; Wang et al. 2001). One chemotherapeutic DNA damaging agent that appears to
have overcome these limitations is cis-diamminedichloroplatinum(II) (cisplatin).
Cisplatin is one of few true success stories in the chemotherapeutic field, as its use in
combination therapy of testicular cancer affords 5-year survival rates of greater than 95%
(Horner et al., 2009). This rate represents a dramatic improvement from just three and a
half decades ago when, prior to the introduction of cisplatin, the cure rate for testicular
cancer was only 23% (Huang et al. 2008). It is well established that the anticancer
activity of cisplatin comes from its ability to modify DNA covalently. Studies have
shown that E. coli and eukaryotic cells lacking crucial DNA repair enzymes are 3-10 fold
more sensitive to cisplatin than their wild-type counterparts (Kartalou & Essigmann
2001). The levels of cisplatin-DNA adducts formed in blood cells of ovarian and
testicular cancer patients are directly correlated with clinical response (Reed et al. 1986).
Finally, while cisplatin can react with other cellular macromolecules, it is believed that
the level of adduction to these molecules is too low to be of importance at therapeutically
relevant doses (Pascoe & Roberts 1974; Akaboshi et al. 1992).
Cisplatin is a neutral, square planar molecule composed of a central Pt(II)
coordinated to two chloride and two ammonia groups, with the chloride ligands in the cis
configuration (Figure 1.3). Interestingly, when the chloride ligands are coordinated in the
trans geometry (trans-diamminedichloroplatinum(II), or trans-DDP), the resulting
compound is ineffective as a chemotherapeutic agent. Cisplatin is administered
intravenously and remains coordinated to its chloride ligands in the blood, where the free
chloride concentration is -100 mM. However, upon entry into a tumor cell where the
chloride concentration is -4 mM, water is able to replace chloride ligands relatively
rapidly (tl/2 = 2 hrs for substitution of the first chloride ligand by water) (Johnson et al.
1980; Bancroft et al. 1990). It is this cationic aquated species which can more easily
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undergo nucleophilic attack by DNA, forming N7 adducts with guanine and adenine
(tl/2= 0.1 hr) along with intra- and inter-strand crosslinks between these bases
(t/2= 2.1 hrs) (Bancroft et al., 1990). Studies performed in vitro demonstrate that the
majority of adducts created are 1,2-d(GpG) intrastrand crosslinks (65%), followed by
25% intrastrand 1,2-d(ApG), 5-10% intrastrand 1,3-d(GpG), and a minor quantity of
interstrand crosslinks and monoadducts (Kartalou & Essigmann 2001). Importantly, a
similar profile is observed in cancer patient samples (Fichtinger-Schepman et al., 1987).
Therapeutically inactive trans-DDP is incapable of forming 1,2-d(GpG) or 1,2-d(ApG)
adducts due to its geometry, instead favoring formation of intrastrand crosslinks between
N7 of guanines or between guanine and N3 of cytosine, always separated by at least one
base (Kartalou & Essigmann 2001). In addition, trans-DDP forms significantly more
interstrand crosslinks than cisplatin, as much as 20% of all adducts, primarily between
complementary guanine and cytosine residues (Brabec and Leng, 1993).
The structure of the major 1,2-d(GpG) cisplatin adduct has been solved,
demonstrating that this adduct causes bending of the DNA helix toward the major groove
by 500 or more along with unwinding by more than 20' (Takahara et al. 1995; Takahara
et al. 1996; Gelasco & Lippard 1998). This bending narrows the major groove and
widens and flattens the minor groove. Structures of 1,2-d(ApG) (Fouchet et al., 1997)
and 1,3-d(GpG) (van Garderen and van Houte, 1994) adducts have also been obtained,
demonstrating that 1,2-d(ApG) is very similar to 1,2-d(GpG), while 1,3-d(GpG) causes
slightly more helical distortion. The crystal structure of a single interstrand G-G
crosslink has been solved, and in this case bending is toward the minor groove by 470
along with unwinding by 700, while cytosine bases complementary to adducted guanines
are extruded from the helix (Coste et al., 1999).
Cisplatin Forms DNA Adducts That Attract Specific Binding of Several Proteins
It was quickly recognized that cisplatin adducted DNA was able to recruit the
association of a variety of proteins to its sites of damage. Several of these containing a
high-mobility group (HMG) domain have been shown to display affinity specifically
toward clinically useful cisplatin adducts while displaying negligible affinity for trans-
DDP adducts. These proteins bind specifically to the 1,2-d(GpG) and 1,2-d(ApG), but
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not the 1,3 adducts of cisplatin, thus providing explanation for why trans-DDP adducts
do not recruit them (Toney et al. 1989; Pil & Lippard 1992). Within this class of
proteins, human upstream binding factor (hUBF) is most notable due to its exceptional
affinity for 1,2-d(GpG) adducts of cisplatin. The equilibrium dissociation constant (Kd)
of hUBF for cisplatin adducts is 60 pM, while the Kd of hUBF for its natural response
element, in the promoters of ribosomal RNA (rRNA) is 18 pM, making a cisplatin adduct
an attractive and likely important binding site (Treiber et al., 1994). These observations
have elicited two potential mechanistic explanations for the efficacy of cisplatin: 1)
cisplatin adducts recruit proteins including those possessing an HMG domain, which bind
with enough affinity to interfere with DNA repair processes, and 2) because hUBF is a
transcription factor that is responsible for regulating the transcription of rRNA, titrating
this transcription factor from its normal promoter sites results in less rRNA being
transcribed, and the cell is rendered more sensitive. These two mechanistic explanations
will hereafter be referred to by the terms "repair shielding" and "transcription factor
hijacking," respectively (Figure 1.3).
Evidence supporting the repair shielding hypothesis is provided by experiments
that demonstrate inhibited in vitro excision repair by cell extracts when the HMG
proteins HMG1, mtTFA, tsHMG, or SRY are added (Huang et al., 1994; Zamble et al.,
1996; Trimmer et al., 1998). Furthermore, addition of steroidal hormones to breast
cancer cells expressing corresponding steroid receptors increases expression of HMGI
protein and in so doing increases cisplatin sensitivity (He et al. 2000). Additionally, S.
cerevisiae cells knocked out for Ixrl protein (a member of the HMG family) are 2-6 fold
less sensitive to cisplatin and are found to maintain fewer adducts (Brown et al. 1993;
McA'Nulty & Lippard 1996).
Evidence for the transcription factor hijacking hypothesis is provided by the
finding that cisplatin adducts, at levels lower than those detected in cancer patients, can
effectively compete with ribosomal promoter sites for binding to hUBF (Treiber et al.,
1994). Reconstituted in vitro transcriptional assays demonstrate that cisplatin adducts
can hinder rRNA transcription, and that addition of excess hUBF can counteract this
inhibition (Zhai et al. 1998). Even more impressive, this same inhibited ribosomal RNA
transcription occurs in vivo (Jordan and Carmo-Fonseca, 1998). Thus, while there are
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many more hypotheses and potential explanations for the impressive anticancer activity
of cisplatin, there is good evidence that transcription factor hijacking and/or repair
shielding are important factors that can collectively influence toxicity.
Fatal Engineering
Unfortunately, despite the stellar success of cisplatin in combination treatment of
testicular cancers, it is less effective for treatment of other tumors. As such, an endeavor
was undertaken to re-engineer DNA damaging agents using the lessons learned from
cisplatin, rationally incorporating features that would allow them to work by the
mechanisms of repair shielding and transcription factor hijacking. We proposed that by
chemically tethering a nitrogen mustard DNA damaging moiety to a steroid receptor
ligand, the mechanisms responsible for toxicity of cisplatin could be recapitulated and
expanded into other cancers. It is important to address the novelty of this idea, as the
connection of a DNA damaging agent to a steroid is not a new idea (Fredholm et al.
1978; Leclercq et al. 1983; Lam et al. 1987; Knebel & von Angerer 1988; Kubota et al.
1988; Eisenbrand et al. 1989; Brix et al. 1990; Roth et al. 1995; Hannon et al. 2006). In
most of these cases, the goal is to achieve selective delivery and accumulation of a toxic
agent in cells expressing the target protein; in fact, the tether is often intentionally
designed to be labile. Our strategy is unique in its maintenance of a stable linkage
between the DNA damaging region and the protein recognition domain, thus maintaining
high affinity for a steroid receptor even when covalently bound to DNA. In this way it is
thought that repair shielding can occur through tight binding of steroid receptors to sites
of damage and associated hindrance of repair enzymes. Additionally, by recruiting these
receptors away from their normal transcription response elements in the promoters of
genes often involved in proliferation and survival, transcription factor hijacking would
occur and increase cytotoxicity.
Design of Agents that form DNA Damage that Recruits the Estrogen Receptor
The first attempt at achieving these goals was aimed at gaining selective toxicity
toward cells expressing high levels of the estrogen receptor (ER), a situation occurring in
breast and ovarian cancers (Slotman and Rao, 1988; Fernm et al., 1990) To this end, 2-
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(4'-hydroxyphenyl)-3-methyl-5-hydroxy-indole (2PI) ligand for the ER was tethered
through an alkylaminocarbamate chain to a 4-(3-aminopropyl)-N,N-(2-chloroethyl)-
aniline group (Rink et al., 1996) (Figure 1.4). An aniline nitrogen mustard was chosen as
the DNA damaging agent because of its lower reactivity than alkyl mustards, making it
more selective for DNA, in addition to its proven clinical use in anticancer agents such as
chlorambucil (Figure 1.4) and melphalan. Furthermore, nitrogen mustards form DNA
adducts which are easily repaired, yet are more toxic to cells incapable of repairing them
(De Silva et al., 2000; Panasci et al., 2002), affording the opportunity to enhance this
form of DNA damage by limiting its repair. The linkage between these two functional
groups was designed in order to permit DNA damage to occur while maintaining high
affinity to the ER through the 2PI group. A secondary amine assists in solubility, and as
it is expected to bear a positive charge at physiological pH (pKa 20 amine -9-10), is
thought to assist in association with the polyanionic phosphate backbone of DNA.
Additionally, a carbamate was chosen to link the two halves of the molecule
synthetically, due to its resistance to cellular enzymatic activity which could otherwise
cleave the molecule in two (Cho et al., 1993).
A series of compounds was synthesized with variation in linker lengths in order to
optimize dual capacities of DNA damage and ER affinity (Figure 1.5). An additional
control molecule was made by incorporation of a 2-(4'-hydroxyphenyl)-3-methyl-indole
as the protein recognition domain (2PI(OH)-C6NC2, Figure 1.5), due to this modification
significantly decreasing ER affinity (von Angerer et al., 1984). All molecules were tested
for affinity to ER by measuring their ability to compete with [3H]-estradiol binding to
full-length ER in calf uterine extracts (Rink et al., 1996). Results are expressed as
relative binding affinity (RBA), defined as the molar ratio of unlabeled estradiol (E2) to
test compound necessary to reduce [3H]-estradiol occupancy by 50%. The molecule 2PI-
C6NC2 had the highest affinity to ER of the molecules tested (RBA = 7.1). As expected,
removal of the -OH group crucial to ER binding in the 2PI portion of the molecule
reduced affinity by 70-fold. Molecules were next tested for their abilities to damage self-
complementary 16-mer oligonucleotide 5'-d(ATTATTGGCCAATAAT) containing a
central GGCC, optimal for formation of preferred GNC interstrand crosslinks (Rink et
al., 1993). Overall reactivity followed a trend from 2PI-C3NC3 > 2PI-C5NC3 > 2PI-
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C6NC2 > chlorambucil > 2PI(OH)-C6NC2. Chemical fragmentation analysis
demonstrated that guanine, likely N7 (Singer, 1975; Lawley and Phillips, 1996), was the
primary site of attack, followed by adenine, likely at N3 (Pieper et al., 1989). Rink et al.
also demonstrated that DNA adducted by 2PI-C6NC2 maintained affinity for ER, albeit
significantly less affinity than the free compound (RBA -0.5), demonstrating that
adducted DNA could potentially act as a decoy binding site for ER.
Most importantly, molecules were tested for their ability to kill breast cancer
cells. An ER positive line (MCF-7) and an ER null line (MDA-MB-231) were compared
to determine if ER was a toxicity enhancing factor. Treatments were performed for two
hours before replenishing fresh media in order to minimize antagonistic effects, and after
recovery for 24 hrs, cells were re-plated at clonal density to measure survival following
several days growth (Rink et al., 1996). General toxicity followed the trend of compound
DNA damaging abilities. Importantly, the molecules with higher affinity for ER
displayed greater toxicity toward MCF-7 than MDA-MB-231 cells, whereas 2PI-C3NC3
or chlorambucil showed comparable toxicity in each cell line. Furthermore, the 2PI(OH)-
C6NC2 compound with much lower affinity to ER showed no enhanced toxicity toward
cells expressing the ER. The absence of differential sensitivity for compounds with poor
affinity to the ER is strong evidence that the differences seen with 2PI-C6NC2 and 2PI-
C5NC3 are not due to inherent differences in sensitivity to DNA damaging agents
between MCF-7 and MDA-MB-231 cells.
The combination of results with the 2PI series of compounds showed that a 6-
carbon linker between the PI portion of the molecule and the secondary amine yielded the
best affinity for ER. It is believed that this distance is optimal for the molecule to reach
into the ligand binding pocket of ER through a primarily hydrophobic patch and still
maintain the ability to modify DNA covalently. The crystal structure of ER-LBD
complexed with the antagonist ICI 164384 gives the best support to this hypothesis (Pike
et al. 2001) (Fig. 1.6). ICI 164384 is based on the core steroidal structure of estradiol, but
with a 16-atom straight chain linkage from the 7c position. As such, the steroid portion
of ICI 164384 binds upside down from the manner in which E2 is seen in crystal
structures of ER-LBD (Tanenbaum et al., 1998; Brzozowski et al., 1997). The structure
seen in Figure 1.6 gives a good clue to explain this observation, as there is no other
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obvious path of entry into the ligand binding pocket. Approximately six carbon units are
necessary in order to reach the surface of this ligand binding domain, and it is likely that
placement of a secondary amine closer to the steroid nucleus interacts unfavorably with
the hydrophobic pore of ligand binding pocket access.
Refinement of DNA Damaging Agents with Selective Toxicity Toward ER (+) Cells
A next generation ER-specific toxin was created by redesigning the ligand portion
of the ER recognition domain, in hopes of further increasing toxicity in favor of killing
ER (+) cancer cells. Toward this end, a new molecule was synthesized by maintaining
the optimized C6NC2 linker from 2PI-C6NC2, but replacing the 2PI group with E2.
Attachment was made in the 7a position of E2, based on reports that large alkyl groups
could be attached here with minimal disruption of ER affinity (Bucourt et al., 1978;
Bowler et al., 1989; DaSilva and van Lier, 1990). The completed compound, E2-7a
(Figure 1.4), was shown to have an improved affinity for ER compared with the 2PI-
C6NC2 compound (RBA = 30) (Mitra et al., 2002). Again it was demonstrated that this
compound could successfully modify DNA, making 50% of a self-complementary 16-
mer piperidine labile, and that this modified 16-mer could associate with ER-LBD as
determined by gel shift studies. Furthermore, this shift could be competed away with an
excess of E2. E2-7ca also demonstrated enhanced toxicity toward ER(+) MCF-7 cells as
compared with ER(-) MDA-MB-231 in a clonogenic survival assay performed as with
the 2PI compounds.
The next steps toward improving these compounds involved a more systematic
investigation into linker modification for the E2-7 compound (Sharma et al., 2004).
Figure 1.7 shows the structures of these compounds. In all cases, a six-carbon linker was
maintained between the steroid and first heteroatom (nitrogen in all cases except for the
carbamate), employing lessons learned from the 2PI compounds. Further modifications
were made beyond this point, incorporating a single amide bond, a single secondary
amine, a single carbamate, a guanidine, an amide combined with a guanidine, an amide
combined with a carbamate (E2-7a), two amide bonds, or two secondary amines, with
associated variation in overall linker length from 11 to 16 atoms between the steroid and
the aromatic ring of the aniline mustard (Figure 1.7). These compounds were all tested
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for their abilities to compete with E2 for binding to ER from calf uterine extracts. The
parent E2-7a compound proved to have the highest affinity for ER of the compounds
tested (RBA = 46 in this assay). However, all compounds maintained reasonably high
affinity binding to ER, with the amine, diamine, diamide, and guanidine compounds all
having RBAs of 28 and higher (Sharma et al., 2004). Next, it was shown that most of
these compounds maintained significant DNA damaging ability, with the amide and
carbamate being the exceptions. This result lends support to the hypothesis that a formal
positive charge assists in DNA adduction. In fact, the diamine compound, which would
be doubly charged, shows the greatest DNA damaging ability, modifying 79% of the 16-
mer tested (Sharma et al., 2004).
The most important measure for our designed mechanism of action is provided by
testing the adducted oligos for their ability to interact with the ER. Here it was once
again determined that E2-7a was most successful at causing a band shift (93%) indicative
of ER-LBD association with the adducted oligo (Sharma et al., 2004). The amine
compound was next best (67%), followed by the diamine and guanidine (both 38%).
Surprisingly, the amine-guanidine, despite having one of the lowest RBA's for ER, was
also able to form adducts that presumably interact with ER, producing a 93% band shift.
This result is unexplained, but is likely an experimental artifact. Unsurprisingly, the
amide and carbamate are unable to form adducts that interact appreciably with ER-LBD.
It is unclear, however, why the diamide adducts are not band shifted upon addition of
ER-LBD, as this compound maintains high affinity for ER and similar DNA damaging
ability as E2-7a. This is perhaps due to unforeseen structural variations that occur upon
DNA adduction that are specific to this compound and prevent its association with ER.
Finally, all compounds were tested for their toxicity in the ER(+) MCF-7 and ER(-)
MDA-MB-231 cells. Only E2-7a, amine, and diamine compounds maintained
significant toxicity (Sharma et al., 2004). Furthermore, each of these compounds is
selectively more toxic toward the MCF-7 cells, with E2-7a ultimately showing the
greatest efficacy.
- Chapter 1 -
Design of Agents that Form Sites of DNA Damage that Maintain Affinity for the
Androgen Receptor
We next expanded the scope of original design to include an additional target: the
androgen receptor. The majority of work presented here will focus primarily on the
compound produced as a result of these efforts. As discussed previously, the AR is a
crucial protein involved in the progression of prostate cancer and it is involved at all
stages of disease, representing a valuable target. For this molecule, the chosen protein
recognition domain with specificity for AR was based on the steroid structure of RU-486,
which was demonstrated to possess significant affinity for the AR (Fuhrmann et al.,
2000). The steroid used was a 17p-hydroxy-estra 4(5 )' 9(10)-3-one, with linker-mustard
attachment at the 11 position, following the example of RU-486 (Marquis et al. 2005).
The accumulation of information learned from molecular optimization of the 2PI and E2-
7a series of compounds was applied toward synthesis of an AR-specific toxicant,
employing the same six-carbon chain extension from the steroid nucleus, a secondary
amine, and a carbamate linkage in the C6NC2 fashion of 2PI and E2-7ac, creating the
molecule 11 P1 (Figure 1.4). In addition to 1113, a control molecule was synthesized by
replacement of chlorine atoms within the chloroethyl arms of the aniline mustard with -
OCH 3 groups to create 11 p-dimethoxy (Figure 1.4). The mechanism of nitrogen mustard
mediated DNA damage first requires the formation of an aziridinium ion by donation of
electron density from nitrogen to the carbon alpha to chlorine, removing this
electronegative atom (Colvin et al., 1976; Wilman and Conners, 1980). However, when
the more electropositive and poor leaving group -OCH 3 is present, no aziridinium ion
formation can occur, thus rendering the 1 -dimethoxy molecule incapable of DNA
damage and providing a useful control compound to test effects independent of DNA
damage.
Both 11P and 11 -dimethoxy were tested for their binding affinity to AR. In this
assay, [3H]-R1881 and test compound are allowed to compete for binding to AR in
2-(6-((8S,11S,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-
2,3,6,7,8,11,12,13,14,15,16,17 dodecahydro-1 H-cyclopenta[a]phenanthren- 1 -
yl)hexylamino)ethyl 3-(4-(bis(2-chloroethyl)amino)phenyl)propylcarbamate
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LNCaP whole cell extracts under equilibrium conditions. RBA is the molar ratio of
unlabeled R1881 vs. test compound able to compete away 50% of [3H]-R1881 binding.
113 and 1 1P-dimethoxy each display similar affinities to AR (RBA = 11.3 and 18.1,
respectively, Fig. 1.8). R1881 is a synthetic androgen with two to three fold greater
affinity for AR than the most potent natural androgen, DHT (Zhao et al., 1999).
Therefore, the RBA of 11 for AR with respect to DHT is -20, meaning 11 3 binds 1/5 as
well as DHT. Having shown that 11i possesses significant affinity for AR, experiments
were performed to test DNA damaging ability. As in the cases of 2PI and E2-7a, I 1p
displayed significant DNA damage capacity, modifying 75% of the self-complementary
16-mer as determined by piperidine cleavage. Importantly, 1 -dimethoxy did not
modify this oligonucleotide, demonstrating its inability to damage DNA. Next, adducted
oligo was purified and used in a competitive binding assay to determine affinity for 11 P-
DNA adducts, with a resulting RBA of 0.2. Due to similarity of receptor structure, 11 P,
11 3-dimethoxy and I Ip-DNA adducts were all tested for competitive binding with 3H-
progesterone to the PR. These all demonstrated a reduced but significant affinity for the
PR, with RBA's of 4.2, 3.6, and 0.04, respectively.
Compounds were tested for toxicity toward AR positive LNCaP cells. Results
showed that 11p, at concentrations > 5 lpM, was able to induce LNCaP cells to undergo a
contraction, or rounding, and subsequent detachment from tissue culture dishes within -6
hrs. Treatment with l I -dimethoxy caused similar morphological changes to cells
initially, but rather than detaching like 11P treated cells, the cells recovered their normal
morphology, appearing similar to untreated cells by 24 hrs post treatment. Several lines
of evidence demonstrated that 11 p was able to induce an apoptotic program in LNCaP
cells; treatment with concentrations > 5 ptM induced annexin-V staining, laddering of
DNA indicative of internucleosomal fragmentation, and poly-ADP-ribose polymerase
(PARP) cleavage, starting as early as 9 hrs post treatment (Marquis et al. 2005). 11 3-
dimethoxy was unable to cause any changes associated with apoptosis. However, cell
cycle analysis demonstrated that 11 P-dimethoxy caused a strong block in the G1 phase of
the cell cycle, while 113 showed no redistribution of cell cycle phasing, but only an
increase in sub-GI population cells consistent with apoptosis (Marquis et al. 2005). Due
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to the G1 block caused by 11 3-dimethoxy, both compounds were tested for their effects
on the cell cycle regulating proteins p21 and p27. Each compound caused an increase in
the levels of p27 that was not seen with the DNA damaging agent chlorambucil. In the
case of p21, both 113 and 11 3-dimethoxy initially caused a decrease of p21. However,
p21 levels in 11 -dimethoxy treated cells recovered to pre-treatment levels, while in 113
treated cells they continued to increase to several fold above untreated levels (Marquis et
al. 2005). Chlorambucil at equivalent concentrations also caused an increase in p21
levels, but without any initial drop, suggesting that the initial decrease may be a factor in
avoidance of cell cycle arrest that leads to apoptosis in cells treated with 113P. The levels
of p27 protein can be modulated by the ubiquitin-proteasome system in a reaction
requiring ubiquitylation by the E3 ligase SCFSkp2 (Carrano et al. 1999; Lu et al. 2002).
As such, Skp2 protein levels were also monitored following treatment with these
compounds and shown to display a reciprocal relationship with p27 expression in all
cases (Marquis et al. 2005).
It has been shown that high concentrations of androgens can induce p27
accumulation associated with Skp2 degradation in LNCaP cells, and this provides a
reasonable explanation for the effects on these two proteins (Tsihlias et al. 2000; Lu et al.
2002). However, there may be something unique either about the linkage between an
androgen and a DNA damaging agent, or about this particular steroid structure, because
RU-486, either alone or in combination with chlorambucil, is unable to elicit an increase
in p27 levels.
113 Has Impressive Ability to Prevent Growth of LNCaP Xenograft Tumors
It was next demonstrated that 113 possesses impressive activity in preventing
growth of LNCaP xenograft tumors implanted in NIH Swiss nu/nu mice, while
demonstrating minimal side effects of toxicity (-10% weight loss) (Figure 1.9) (Marquis
et al. 2005). Treatment consisted of a 45-day, seven course regimen of five-day cycles,
with a daily dose of 30 mg/kg injected intraperitoneally. Compared to vehicle, this
treatment regimen resulted in a 90% inhibition of growth on the final day of study
(p < 0.0001) and provides a solid foundation for continued studies into the mechanisms
responsible for tumor-specific growth inhibition.
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An additional study was performed to determine the nature and quantity of DNA
adducts formed by 113, both in tissue culture cells, as well as in tumors and livers of
mice treated with this compound (Hillier et al. 2006). First, [14C]-l 113 was used to
measure bio-distribution in treated mice. 1113 was shown to reach concentrations as high
as 128 pM in the blood within 15 minutes before quickly decreasing with a tl/2 of 1.3 hrs,
but remained above 10 pM even 24 hrs after treatment. It was also shown that the
compound remained primarily intact for at least 4 hrs following treatment, though
products eluting more quickly from HPLC consistent with metabolites do appear. The
compound was well distributed, appearing most concentrated in the liver, intestine,
spleen, lung, and fat. It began to accumulate rapidly in feces after 4 hrs, consistent with
biliary excretion (Hillier et al., 2006).
1 1-DNA adducts were detected and quantified in vitro, in cell culture, and in
vivo. First, 113 was allowed to react with salmon sperm DNA, which was then subjected
to acid hydrolysis and analyzed by HPLC. A single peak eluting earlier than parent
compound was isolated and analyzed by electrospray-ionization mass spectrometry (ESI-
MS), finding a molecule with m/z of 813.5, consistent with a structure of 113 having one
chloroethyl arm adducted to guanine and the other hydrolyzed by water (Hillier et al.
2006). Next, 113 was used to treat LNCaP cells growing in culture. After 6 hrs of
incubation, DNA was isolated, hydrolyzed, and analyzed by ESI-MS, finding the same
813.5 m/z molecular species. Different concentrations of [14C]-1 11 were then used to
treat LNCaP cells for various periods of time before isolating DNA. This DNA was
analyzed by accelerator mass spectrometry (AMS), allowing several orders of magnitude
better sensitivity than traditional scintillation counting. Adduct quantities detected were
directly proportional to concentration of [14C]-1113 in tissue culture media, producing
from 0.3 to 1.0 adducts per 106 bases within 4 hrs (Hillier et al. 2006). Furthermore,
these adducts continued to accumulate after 10 ptM treatment at a rate of 0.25 adducts per
106 base pairs per hour.
Adduct formation in liver and xenografted LNCaP tumors was also assessed.
First, unlabeled 1113 was used in a 45 mg/kg single intraperitoneal (IP) dose before
isolating liver sample four hrs later. DNA was isolated, hydrolyzed, and analyzed by
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ESI-MS as with in vitro samples, once again detecting a species of m/z 813.5 consistent
with a guanine mono-adduct (Hillier et al. 2006). [14C]-1113 was next used to treat tumor
bearing mice at a concentration of 50 mg/kg for 4 hrs. Liver and tumor were both
isolated before purifying DNA and analyzing by AMS. Adduct levels were determined
to be -10x higher in liver than tumor. However, the level of adducts detected in LNCaP
tumors was determined to be -0.2 adducts per 106 base pairs, similar to the quantity
produced in cultured cells treated with 2.5 pM 1113 for the same duration (Hillier et al.
2006).
Finally, due to the significantly higher level of adduct formation occurring in
mouse liver, blood serum levels of four markers of hepatotoxicity were measured. At the
therapeutically effective dose of 30 mg/kg, none of these markers was affected, although
higher doses did cause changes consistent with hepatotoxicity. Due to the low overt
toxicity seen over a 45-day seven-course regimen of treatment with 30 mg/kg (Marquis et
al. 2005), there is little collective cause for concern that hepatotoxicity is problematic.
Based on these studies, the important conclusions to be drawn are that: 1) 113 has
good bioavailability, reaching concentrations in blood even greater than those toxic to
LNCaP cells in culture, 2) 111 forms adducts with guanine both in cultured cells and in
vivo and to a similar extent in each, demonstrating relatively similar levels of compound
getting to cells in each scenario, and most importantly 3) 111 is selectively toxic to the
LNCaP tumor cells growing in the mouse, and not the mouse itself.
No extensive testing was conducted with the 1113 compounds in order to
determine the level of involvement of AR, as was performed with the 2PI and E2-7a
compounds. However, unpublished results from Dr. Robert Croy (Figure 1.10)
demonstrate that among three cell lines (LNCaP, AR(+); PC3, AR(-); DU145, AR(-)),
there is enhanced toxicity toward the AR positive LNCaP cells.
My work presented here will more rigorously address the involvement of AR in
the mechanism of toxicity of 1113, by using isogenic cell lines altered only in expression
of AR, by experiments using competition for binding to AR with a high-affinity ligand
for the AR, and by synthesis of an 1113 analogue with reduced affinity to AR. The work
explores the nature of interaction between 11 3 and AR within tissue culture cells, finding
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that 11 3 causes AR redistribution to a nuclear compartment and binding at promoters of
AR target genes, but also antagonizes AR mediated transcription and enhances receptor
degradation. This work will also address potential explanations for the toxicity caused by
11 3 that is clearly independent of AR status, by way of gene expression microarray
profiling of LNCaP cells treated with 11 3, 1 1-dimethoxy, and other control compounds.
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Androgen Receptor Structural
Organization
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Fig 1.1 Organization and Structure of the Androgen Receptor.
Schematic organization of the AR gene and protein showing
functional domains (reprinted with permission from Gao et al.
2005, Chem. Rev. 105, 3352).
Exon 1
919
- Chapter 1 -
Androgen Receptor Ligand Binding
Domain Structure
A H9
H6
Fig 1.2 Crystal structure of AR ligand binding domain with DHT
bound. Structure is based on 1137.pdb A. Front view; B.
Ligand view (reprinted with permission from Gao et al. 2005,
Chem. Rev. 105, 3352)
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Possible Mechanisms for the
Toxicity of Cisplatin
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Fig 1.3 The impressive toxicity of cisplatin towards testicular cancer may be
explained by the mechanisms shown. A. Repair shielding: Cisplatin forms sites of
DNA damage which are capable of recruiting binding of specific proteins. In this
manner, a damage site will be less accessible by DNA repair enzymes. B.
Transcription factor hijacking: In some cases (i.e. hUBF), the protein which binds to
sites of DNA damage is a transcription factor. When affinity of DNA adducts is similar
to the affinity of this transcription factor for its response element (hUBF Kd is 60 pM
and 18 pM, respectively), there will be diminution in its ability to drive transcription,
and this can increase toxicity. Figure reprinted with permission from Rink et al. 1996.
E > Expression of
Essential Gene
I \
I I I
B. Adduct Hijacks
Transcription Factor
Q410 t
- Chapter 1 -
Relevant Structures
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Fig 1.4 Structures of compounds relevant to text
A. cis-Diamminedichloroplatinum (11) (cisplatin) B.
Chlorambucil C. 2PI-C6NC2-mustard (2PI) D. E2-7a-C6NC2-
mustard (E2-7cc) E. 11f-Compounds; 1103, R=C; 113-
Dimethoxy, R=OCH 3
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Structure and Binding Affinity for the
Estrogen Receptor of 2-Phenyl-Indole
Derivatives
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2PI(OH)-C6NC2 2 6 H 0.1
Fig 1.5 Structures of 2-phenyl-indole aniline mustard
conjugates and their corresponding relative binding affinities
(RBA) for the ER.
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Structure of Estrogen Receptor Ligand
Binding Domain Complexed with
Antagonist ICI 164384
Fig 1.6 Surface representation of ER-LBD complexed with ICI
164384, colored by helix. The 7a linkage and steric bulk forces
it to bind in an "upside-down" configuration from estradiol and
displaces helix 12, making it invisible in the structure. (Based
on 1HJ1.pdb, Pike et al. 2001 Structure 9, 145-153)
JI..
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Chemical Structures of E2-7a
Derivatives
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Fig 1.7 Chemical structures of E2-7a derivatives (Sharma et al.
2004).
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11P and 111-dimethoxy have High
Affinity for the Androgen Receptor
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Fig 1.8 Relative binding affinity of 110 compounds for the AR.
The affinity of 11P (- A -) and 11 -dimethoxy (-.0.) are
compared to the synthetic androgen R1881 (---).
compounds have similar affinity for the receptor. Figure
courtesy of Dr. Shawn Hillier.
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113 Inhibits the Growth of LNCaP
Xenografts.
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Fig 1.9 110 therapy of LNCaP xenografts in mice.
Groups of 5 mice in each group were treated with either
110 (jor with vehicle (C). A paired t-test provided a p-
value < 0.0001. Gray bars indicate treatment times (5
days on, 2 days off). Figure courtesy of Dr. Shawn
Hillier.
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AR (+) LNCaP Cells are More Sensitive
to 111 than AR (-) Cell Lines
A 100
-c
*- 10
a.
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S10 
CI
0 (N- (C H2)3-C O 2H
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SChlorambucil
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Chlorambucil Concentration (M)
Fig 1.10 Prostate cancer cells exposed to 110 (A) or
chlorambucil (B) at concentrations shown. The AR (+) LNCaP
cell line (--) shows greatest sensitivity to 110, while PC-3 (-
and DU-145 (.+.), AR (-) cell lines, are less sensitive. Each cell
line shows similar sensitivity to the DNA damaging agent,
chlorambucil. Figure courtesy of Dr. Robert Croy.
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Introduction
Prostate cancer, despite continuous advances in detection and treatment, remains a
leading killer of males in developed countries (Jemal et al., 2008). New strategies are
warranted to combat this disease, especially in later stages when chemotherapeutic
regimens do little to prolong life. We have previously described a novel potential
strategy for treatment of this disease, involving the creation of small molecules capable of
forming sites of DNA damage that will attract the androgen receptor (AR) (Marquis et al.
2005). The rationale behind this strategy stems from studies of the molecular action of
cisplatin, which is highly successful in combination therapy for the treatment of testicular
cancer, affording 5-year survival rates greater than 95% (Homer et al., 2009). Our
laboratory and others have shown that cisplatin is able to form sites of DNA damage that
can go on to recruit binding of specific transcription factors (Toney et al., 1989; Donahue
et al., 1990; Bruhn et al., 1992; Pil and Lippard, 1992; Treiber et al., 1994). Furthermore,
we have proposed that toxicity is enhanced due to limited access of repair enzymes as
well as by removal of these transcription factors from their normal transcriptional targets.
As a further test of this hypothesis and to determine whether this strategy could be
modified to expand the efficacy into other cancers, we initially designed molecules
capable of forming sites of DNA damage that recruited the estrogen receptor (ER) (Rink
et al., 1996; Mitra et al., 2002; Sharma et al., 2004), as it is highly expressed in breast and
ovarian cancers. These molecules successfully formed DNA damage sites that
maintained affinity for ER and displayed selective toxicity toward ER (+) cells, serving
as proof of principle.
We then expanded our initial scope by creating a molecule, 11131, which would
function identically as our ER-interacting compounds, but employ the AR as its target.
As with cisplatin, 1101 has the capacity to form sites of DNA damage, in this case by a
bis-2-chloroethyl aniline functionality analogous with the clinically used anticancer agent
chlorambucil. Chemically tethered to the DNA-damaging portion of 1113 is a ligand for
2-(6-((8S, 11 S, 13 S, 14S, 17S)- 17-hydroxy- 13-methyl-3-oxo-
2,3,6,7,8,11,12,13,14,15,16,17 dodecahydro-1H-cyclopenta[a]phenanthren- I1-
yl)hexylamino)ethyl 3-(4-(bis(2-chloroethyl)amino)phenyl)propylcarbamate
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the androgen receptor, 17P-OH(estra-4,9(10)-dien-3-one), with attachment at carbon 11
of the steroid structure with p (S) stereochemistry (giving rise to our shorthand
nomenclature of 11 ), analogous to RU486. The linker between these functional groups
has been optimized such that molecules have the greatest solubility and stability while
maintaining the capacity to simultaneously damage DNA and bind to AR. We propose
that by recruitment of AR to sites of DNA damage, access of repair enzymes will be
hindered, in a mechanism we term repair shielding (Figure 2.1). In non-cancerous cells
expressing less AR, the adducts would instead be easily repaired and removed, providing
a therapeutic window. Additionally, as the AR is heavily involved in prostate cancer
progression and survival due to its function as a transcription factor regulating expression
of pro-survival genes (Lu et al. 1997; Xu et al. 2006), we propose that its titration away
from normal targets to sites of DNA damage will increase toxicity-a mechanism we
term transcription factor hijacking. Together, we believe the mechanisms of repair
shielding and transcription factor hijacking can allow 1113 to achieve similar efficacy in
the treatment of prostate cancer as cisplatin has toward testicular cancer.
The previous work on 11 3 has demonstrated its efficacy in eliciting apoptosis in
the AR (+) prostate cancer cell line LNCaP (Marquis et al. 2005). Furthermore, 11 3 has
high affinity for AR (-20% of the affinity of dihydrotestosterone (DHT)), and adducted
16-mer oligonucleotides maintain significant affinity to the AR. Of utmost importance, it
is effective in preventing the growth of LNCaP xenograft tumors in NIH Swiss (nu/nu)
mice, while displaying low systemic toxicity (Marquis et al. 2005; Hillier et al. 2006).
11 forms similar levels of adducted DNA in LNCaP xenograft tumors as in the same
cells grown in culture dishes at respective therapeutically relevant doses and
concentrations (Hillier et al. 2006). As such, 1113 has proven efficacy as a potential
prostate cancer therapeutic agent, and further studies are warranted to understand the role
of AR in this toxicity. Additionally, the non-DNA damaging version of this compound,
1 1p-dimethoxy, does not cause apoptosis in LNCaP cells at equivalent concentrations,
but does display the interesting characteristic of arresting cells in G1 phase of the cell
cycle. As such, it is likely that DNA damage is necessary for greatest toxicity, but
potentially the AR-interacting and linker portions of the compounds have significant
effects on their own.
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The primary treatment for metastatic prostate cancer is anti-hormonal therapy,
achieved by minimization of AR activity through removal of circulating androgens and
use of AR antagonists. AR antagonists function by competing with natural androgens
testosterone and DHT for binding in the ligand binding pocket of AR, while failing to
induce the AR to undergo conformational changes necessary to appropriately drive
transcription of target genes. On a detailed molecular level, these conformational
changes are still not completely understood, because the structure of AR has not been
solved in an antagonist conformation. Limited proteolysis studies provide some clues as
to how AR agonists and antagonists affect the structural conformation of the AR and
affect its ability to act as a transcription factor. These experiments show that the AR is
sensitive to complete proteolysis by trypsin in the absence of any androgen. Addition of
androgens, however, causes a conformational change to the receptor that immediately
results in protection of a 35 kDa fragment. This 35 kDa receptor fragment is then
converted to a trypsin-resistant 29 kDa fragment within one hour of androgen stimulation
(Kuil et al., 1995). These fragments each correspond to the very C-terminus of AR, with
the 35 kDa form containing further extension into the hinge region. Several AR
antagonists also allowed for immediate protection of the 35 kDa fragment, but did not
allow formation of the 29 kDa form. As such, it seems that these AR antagonists
(cyproterone acetate, hydroxyflutamide, bicalutamide, nilutamide) function in part by not
allowing the conformational changes that result in protection of a 29 kDa region of the
ligand binding domain (LBD). Interestingly, RU486 initially protects the 35 kDa
fragment before allowing conversion to the smaller 29 kDa form and a unique 25 kDa
form (Kuil et al., 1995). This unique 25 kDa fragment corresponds to deletion of the
most C-terminal amino acids, likely due to displacement of helix 12 as seen in the crystal
structure of RU486 complexed with glucocorticoid receptor (GR) (Kauppi et al., 2003),
toward which RU486 also acts antagonistically. Furthermore, the estrogen receptor (ER)
LBD has been solved in both agonist and antagonist conformations. The most striking
difference between these conformations is the inability for helix 12 to close over the
ligand binding pocket in the antagonist conformation (Brzozowski et al., 1997). By
limiting helix 12 closure in the AR, it is presumed that AF2 formation does not occur as
- Chapter 2 -
favorably, and coactivator binding gives way to corepressor binding, limiting AR
transcriptional activity (Hodgson et al., 2008).
Several steps are involved in the progression of AR from a cytoplasmic
unliganded receptor into its trans-active conformation, all caused by changes induced by
initial ligand binding. The receptor must dissociate from a complex with heat shock
proteins, relocalize to the nucleus, become phosphorylated, self-dimerize, bind at
androgen response elements in gene promoters and enhancers, and recruit appropriate
coactivator proteins, chromatin remodeling machinery and associated general
transcriptional elements in order to successfully drive transcription (Brinkmann et al.
1999). Theoretically, an AR antagonist could function by limiting the ability of AR to
carry out any of these steps.
Mutation of AR is a common occurrence during antiandrogen treatment of
advanced prostate cancer, often allowing cells to resume growth in the presence of
antiandrogens. The LNCaP AR serves as an example, as a threonine at position 877
within the ligand binding pocket is mutated to alanine. This mutation allows for a switch
for the antiandrogen hydroxyflutamide from an antagonist to an agonist (Veldscholte et
al., 1992). Bicalutamide still functions as an antagonist toward this mutated receptor, but
other mutations within the ligand binding pocket can occur in order to allow it to also
activate the AR (Culig et al., 1999).
Despite mutations allowing prostate cancers to progress with less androgens or
with antiandrogens, the AR remains a viable target because of its continued expression in
most hormone refractory prostate cancers (van der Kwast et al. 1991; Visakorpi et al.
1995; Gregory et al. 1998; Holzbeierlein et al. 2004; Mohler et al. 2004). Thus, our
strategy represents a novel method which could prove successful in treatment of all
stages of prostate cancer progression. The work here has addressed the effects of 1113
treatment on AR expression, phosphorylation, nuclear localization, association with DNA
androgen response elements (AREs), and ultimate transcriptional activity.
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Materials and Methods
Chemicals: Flutamide, 5c-dihydrotestosterone (DHT), Z-Leu-Leu-Leu-al (MG-132),
and cycloheximide were acquired from Sigma-Aldrich (St Louis, MO). Bicalutamide
was from LKT Laboratories, Inc. (St. Paul, MN) and R1881 from Perkin-Elmer Life
Science (Waltham, MA). Synthesis of 11 -dichloro (referred to herein as 11P3) and 11 3-
dimethoxy were performed in our laboratory and have previously been described
(Marquis et al. 2005).
Cell Culture: LNCaP cells (ATCC, Rockville, MD) were maintained in RPMI 1640
media supplemented with glucose (2.5 g/L), 1 mM sodium pyruvate, 10 mM HEPES, and
10% fetal bovine serum. Media and supplements were obtained from Invitrogen
(Carlsbad, CA), except for fetal bovine serum (Hyclone, Salt Lake City, UT). COS7
cells (ATCC) were grown in DMEM (Invitrogen) supplemented with 10% fetal bovine
serum. CWR22Rvl and C4-2B cells (ATCC) were grown in RPMI 1640 with 10% fetal
bovine serum. MDA-MB-453 cells (ATCC) were grown in MEM-a media
supplemented with 1 ng/mL EGF, 2 pg/mL human recombinant insulin, 100 mM non-
essential amino acids, 10 mM HEPES (all Invitrogen), and 10% fetal bovine serum
(Hyclone). All cells were grown in a humidified 5% CO 2/air atmosphere at 370 C. For
transcriptional reporter assays and where otherwise indicated, media formulations were
the same except for use of phenol red free versions supplemented with 10% charcoal
dextran treated FBS (CDTFBS) (Hyclone) in order to remove all androgens.
Western blots: Cells were harvested by scraping into media, washing with PBS, and
subsequently lysing in RIPA buffer (Santa Cruz Biotechnology, Santa Cruz, CA)
containing PMSF, sodium orthovanadate, and protease inhibitor cocktail at O0C. Cellular
debris was pelleted by centrifugation at 14,000 RPM in a bench top microcentrifuge,
supernatants were collected, and protein quantified by Bradford dye binding assay (Bio-
Rad Laboratories, Hercules, CA). For cellular fractionation, NE-PER nuclear and
cytoplasmic extraction reagents kit (Pierce, Rockford, IL) was used according to
instructions. Equal quantities of protein were electrophoretically separated on a bis-tris
precast polyacrylamide gel (Invitrogen) and transferred to Immobilon-P PVDF
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membrane (Millipore, Billerica, MA). Non-specific protein binding was blocked with
5% milk in Tris-buffered saline (0.1% Tween 20, 10 mM Tris [pH 7.4], 150 mM NaCI)
and proteins were detected by primary antibodies followed by horseradish peroxidase
(HRP) conjugated secondary antibodies and chemiluminescent HRP substrate
(Supersignal West; Pierce, Rockford, IL). Antibodies used were as follows: AR (SC-
7305, Santa Cruz), Phospho-AR (Ser81) (#07-1375; Millipore), P-actin (SC-1615R;
Santa Cruz), PARP (06-557; Upstate Biotechnology, Lake Placid, NY; now Millipore),
ct-tubulin (CP06, Calbiochem, San Diego, CA), and HRP-conjugated secondary
antibodies (#7076, anti-mouse IgG; #7074 anti-rabbit IgG; Cell Signaling Technology,
Danvers, MA).
Expression Vectors: The vectors pGL4.10 (promoterless firefly luciferase) and
pGL4.74 (renilla luciferase driven by thymidylate kinase promoter) were acquired from
Promega (Madison, WI). We prepared pGL4PSA containing promoter and enhancer
regions of the KLK3 (PSA) gene. A 662 base pair segment of the PSA promoter (-631 to
+31), containing AREI and AREII was obtained by PCR amplification from MDA-
MB231 genomic DNA using forward primer (5'-GCG GAG CTC AAT TCC ACA TTG
TTT GCT GCA C-3') and reverse primer (5'-ATA CTC GAG ACT CTC CGG GTG
CAG GTG GTA A-3'), containing SacI and XhoI restriction sites, respectively. The
reverse primer also contains an additional A between the Xhol restriction site and the
PSA promoter sequence in order to prevent creation of a second SacI restriction site
following ligation. An additional 1446 base pair segment of the PSA enhancer (-5321 to
-3877, containing AREIII) was amplified from LNCaP genomic DNA using forward
primer GCG TAT GGT ACC AGA GAT TTT TTG GGG G and reverse primer TAT
GCG GAG CTC GTA TCT GTG TGT CTT CT, containing KpnI and SacI restriction
sites, respectively. The amplified PSA promoter and enhancer regions were ligated in
tandem upstream of the luciferase gene in pGL4.10. This completed vector was
sequenced at the MIT CCR Biopolymers Laboratory and found to match published
human genome sequence AC011523 except for two substitutions (-4363 G->T, -4264 C-
>A), both outside of known ARE's. Vectors pCINeo, pCINeoAR, VP16-AR, VP16-AR
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NTD (1-538), pm-AR LBD (644-919), and pG5-Luc were all generous gifts from the
laboratory of Steven Balk (Beth-Israel Deaconess Medical Center, Boston, MA).
Luciferase Transcriptional Reporter Assays: For testing of AR transcriptional activity
in LNCaP or MDA-MB-453 cells, 24-well tissue culture plates were used and cells were
cotransfected with pGL4PSA and pGL4.74 in a 24:1 ratio using lipofectamine and PLUS
reagent in Opti-MEM media according to manufacturer's instructions (Invitrogen). After
3 hrs, media was supplemented to 10% FBS, and after 24 hrs replaced with fresh phenol
red free media containing 10% CDTFBS. Following a further 24 hr incubation, test
compounds were diluted 1,000-fold into CDTFBS containing media and cells incubated
24 hrs prior to cell lysis and luciferase detection using dual-luciferase reporter assay
system (Promega) with TD 20/20 luminometer (Turner Biosystems, Sunnyvale, CA). All
samples were performed in at least quadruplicate and firefly luciferase measurements
were normalized to renilla luciferase readings. To test activity in COS7 cells,
transfection was performed with lipofectamine 2000 reagent according to manufacturer
instructions (Invitrogen) and included pCINeo (negative control), pCINeoAR (AR
expression plasmid), or VP16-AR (VP16 activation domain fused to N-terminus of full
length AR). The procedure was otherwise identical.
N/C Terminal AR Interaction Assay: In order to test interaction of N and C termini of
AR, COS7 cells were co-tranfected with VP16-AR NTD (1-538) (herpes simplex virus
VP16 activation domain fused to NTD of AR), pm-AR LBD (644-919) (S. cerevisiae
Gal4 DNA binding domain fused to AR ligand binding domain), pG5-Luc (five Gal4
response elements upstream of firefly luciferase), and pGL4.74 using lipofectamine 2000.
Assay was otherwise performed as with luciferase transcriptional reporter assays.
PSA Media Assay. PSA secretion into culture media was detected by ELISA (Bio-
Quant, Inc., San Diego, CA). LNCaP cells were cultured for 48 hrs in CDTFBS media
prior to addition of test compounds for 24 hrs. Aliquots of media were collected and
used to detect PSA secretion, while cells were isolated and used for RT-PCR analysis of
androgen-regulated genes.
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RT-PCR: RNA was isolated from cells using RNEasy kit with optional on-column
DNAse digestion (Qiagen, Valencia, CA) and quantified by UV absorbance. RT-PCR
was performed with Quantitect SYBR Green RT-PCR kit (Qiagen) at MIT BioMicro
Center on MJ Research Real-Time PCR Machine with GAPDH as control. Primers were
designed using Primer3 software (Rozen and Skaletsky, 2000) and are as follows: AR
(based on accession NM_00044) Forward: GCA GGA AGC AGT ATC CGA AG,
Reverse: TGG CGT TGT CAG AAA TGG T; GAPDH (based on accession NM_002046)
Forward: ACA GTC AGC CGC ATC TTC TT, Reverse: GCC CAA TAC GAC CAA
ATC C; KLK3 (PSA) (based on accession BC_005307) Forward: AAC GCA CCA GAC
ACT CAC AG, Reverse: TCC TTA CTT CAT CCC CAT CC; KLK2 (based on accession
NM_001002231) Forward: AGG ATA AGC TGG AGC CAC AA, Reverse: GGA TCC
TCC CCT TCT TTC TG. For analysis of KLK2 and KLK3 mRNA, cells were cultured
for 48 hrs in CDTFBS media prior to addition of test compounds for 24 hrs and
subsequent transcript detection.
Statistics: Significance tests were performed with unpaired 2-tailed student's t-test as
implemented in Excel 2002 (Microsoft, Redmond, WA).
Results
AR Steady-State Levels are Reduced by 11J3 Treatment
11 was designed to kill cancer cells selectively by creating sites of damage that
would recruit the AR and result in enhanced toxicity. As such, it is prudent to determine
the effects of treatment on expression and turnover of this protein target. LNCaP cells
are the AR positive cell line of choice used in most of the following studies. Thus, these
cells were treated with 11 at different concentrations and durations to determine effects
on AR protein expression, revealing a dose and time-dependent decrease in AR protein
upon treatment. However, previous reports (Marquis et al. 2005; Hillier et al. 2006) have
demonstrated that 11 P is highly toxic to LNCaP cells at concentrations greater than 5 gM,
confounding the interpretation and meaning of biochemical analysis at these higher doses.
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As such, 5 pM 11 was chosen as an optimal concentration to test effects of treatment on
AR protein expression and turnover. At this concentration, it is evident that 11[3 causes a
significant decrease in the steady state level of AR protein, lowering it by as much as
-80% following 15 hrs of treatment (Figure 2.2). Furthermore, it was demonstrated that
this same concentration of 11 could cause a reduction in AR protein levels in two other
androgen-insensitive prostate cancer cell lines, C4-2B and CWR22Rvl (Figure 2.3),
demonstrating that this may be a general effect.
Protein Level Decrease is Due to Enhanced Proteasomal Degradation
The reduction in steady-state levels of AR protein could be the result of either
decreased expression or increased turnover (degradation). One possibility is that 11 3
causes transcription of the AR gene to be reduced, resulting in less protein expression
from a smaller pool of mRNA. However, Figure 2.4 demonstrates that 11[3 does not have
a significant effect on AR mRNA expression at this concentration within 24 hrs.
Alternatively, 11 3, by interacting with the AR and inducing a receptor conformation
distinct from a stabilizing conformation, may increase receptor turnover and result in
lower steady-state levels. This possibility was first addressed by testing the effects of
treatment with the non-DNA damaging compound 11 3-dimethoxy on AR protein levels.
11 3-dimethoxy also results in reduced steady-state AR protein, increasing the likelihood
that direct interaction of these compounds with AR is responsible for its reduced levels
(Figure 2.5).
The AR is known to be degraded through the ubiquitin-proteasome system
(Sheflin et al. 2000; Lin, Wang et al. 2002). Thus, 11[3 may function in part by
enhancing ubiquitylation of AR leading to subsequent proteasomal degradation. To
address this possibility, cells were co-treated with 11 3 and the proteasome inhibitor MG-
132, before monitoring AR expression over time and comparing to levels in untreated
cells or individual 11 3 or MG-132 treatment (Figure 2.6). As can be seen, addition of
MG-132 increases steady-state protein levels. Notably, MG-132 has an effect of also
hindering AR transcription (Lin, Altuwaijri et al. 2002). Thus, after -3 hrs of treatment,
AR levels begin to fall, returning to previous untreated levels within 15 hrs. As already
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demonstrated, 1113 treatment alone results in immediate reduction of AR levels.
However, in the presence of proteasomal inhibition, 1113 is unable to cause this
immediate reduction in AR levels, instead increasing in expression just like with MG-132
treatment alone. Furthermore, AR levels in co-treated cells continue to match the levels
seen in MG-132 treated cells after longer treatment, increasing support for the view that
the decrease in AR protein caused by 1113 is due to proteasomal degradation.
Protein Turnover is not Significantly Increased in Absence of Protein Synthesis
To substantiate the finding that 1113 increases receptor turnover, LNCaP cells
were treated with the translational inhibitor cycloheximide in the presence or absence of
1113 to determine whether AR half-life was decreased in the presence of 11 3. Figure 2.7
demonstrates that cycloheximide treatment results in a time-dependent reduction in AR
levels, as less protein is being synthesized, while receptor degradation continues.
Comparing protein levels between 1113 treated and cycloheximide treated cells shows a
slightly faster rate of decrease in cells treated with 113, supporting the hypothesis that
1113 enhances receptor turnover (AR tl/2 = 6.5 hrs in 1113 treated cells, 9.6 hrs in
cycloheximide treated cells). However, when 1113 and cycloheximide are co-
administered to LNCaP cells, 1113 does not enhance the rate of receptor turnover above
that seen with cycloheximide.
Reduction in AR Levels is Hindered by Competition with Ligand for AR
An additional experiment involved testing effects of 1113 on AR levels in LNCaP
cells grown in androgen-depleted CDTFBS media, with and without addition of 1 nM
synthetic androgen R1881 as competitor. Under these conditions, AR protein levels are
-30% lower than in cells grown in full media, presumably due to increased receptor
turnover in absence of stabilizing hormone. Addition of 1113 causes reduction in AR
protein levels, but to a lesser extent than in cells grown in normal growth media
containing androgens (Figure 2.8, compare with Figure 2.2). Addition of 1 nM R1881 to
these androgen-deprived cells allows AR to recover to levels seen in normal media.
Concurrent addition of R1881 with 1113 limits the ability of 113 to elicit decreased AR
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levels. Based on this finding, it is likely that interaction of 1113 with the AR is necessary
to increase receptor turnover. The results are consistent with the view that 11 3 increases
receptor turnover by interfering with natural androgen binding and promoting
proteasomal degradation.
The Androgen Receptor Is Phosphorylated and Transported to the Nucleus Upon
110 and 111-Dimethoxy Treatment
We next sought to determine whether 11 3 could affect the ability of AR to act as
a transcription factor. As a first step toward understanding this possibility,
phosphorylation of AR at Ser81 was measured. This site was previously demonstrated to
display the highest stoichiometric increase in phosphorylation upon addition of androgen
to androgen-deprived cells (Gioeli et al., 2002). First, it was demonstrated that 1 nM
R1881 results in a robust increase in Ser81 phosphorylation (Figure 2.9). Somewhat
surprisingly, 5 p~M 11 3 was also able to elicit a similar increase in AR phosphorylation
after 3 hrs treatment. At later time points, R1881 appears to maintain greater AR
phosphorylation. However, it is important to recall that 1113 at this concentration
ultimately results in a decrease in total receptor levels. The ability of 11 3 to interfere
with RI881-induced AR phosphorylation was also tested, but 11 3 appears to have little to
no effect on the phosphorylation elicited by R1881.
Since 11 3 is designed to form a nuclear complex sandwiched in between DNA
and AR, an additional important experiment involved monitoring AR subcellular location
following 11 3 treatment. The AR is a cytoplasmic protein in absence of ligand, and as
such, if free 11 compound interacts with unliganded AR in the cytoplasm, its capacity to
damage DNA and form a complex would be minimized if the receptor remained
cytoplasmic. LNCaP cells grown in CDTFBS media were treated as above with 1 nM
R1881, 1 .tM 1113, or the combination for 24 hrs prior to isolation and separation into
cytoplasmic and nuclear extracts. These were individually probed for AR expression, as
well as for markers of nuclear (PARP) and cytoplasmic (P-tubulin) compartments. While
R1881 elicited relocalization of AR from cytoplasmic into a nuclear compartment as
expected, it was quite interesting that 1113 effectively recruited AR into the nuclear
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compartment as well (Figure 2.10). Since 113 was activating toward the AR re-
localization on its own, it did not hinder the ability of R1881 to effect AR re-localization
to the nucleus.
11D and 11 0-Dimethoxy Potently Inhibit Interaction of N and C termini of AR
An additional effect of androgen binding to AR is a conformational change that
allows interaction between the N and C termini of the receptor. Generally speaking, this
N/C interaction is prompted by low concentrations of potent androgens, whereas it is
inhibited by AR antagonists (Langley et al. 1995; Kemppainen et al. 1999). A
mammalian two-hybrid assay was used to monitor this interaction. The N-terminus of
AR (1-538) was fused to the herpes simplex virus VP16 transactivation domain, while a
separate vector contained a fusion between the AR LBD (644-919) and the S. cerevisiae
Gal4 DBD. A Gal4 responsive reporter was co-transfected to measure interaction
between the N and C terminal halves of AR, while a renilla luciferase plasmid was used
to control for transfection efficiency. The AR LBD and Gal4 DBD are unable to drive
transcription from this promoter effectively without also recruiting the strong activation
domain present in VP 16, which will only be recruited by interaction between the N and C
termini of the AR. As anticipated, DHT is able to enhance the N/C interaction of the AR
quite robustly (Figure 2.11B). 1113 or l11p-dimethoxy are unable to cause this N/C
interaction (no increase in reporter activity over vehicle treatment, data not shown), but
are both quite effective at inhibiting the interaction. In fact, at concentrations of 113-
compounds as low as 10 nM, inhibition is evident and becomes quite potent at higher
concentrations (Figure 2.11B).
110 and 11-Dimethoxy are Weak AR Agonists, but 110 Efficiently Promotes AR
Binding to Androgen Response Elements
The findings that 11 3 could induce AR phosphorylation and nuclear localization
prompted us to study this interaction further and determine whether 1103 could act as a
normal androgen and enhance transcriptional activity of AR. To study this possibility, a
luciferase reporter system was designed by cloning promoter and enhancer elements of
the androgen-responsive KLK3 (PSA) gene upstream of firefly luciferase, as has been
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performed elsewhere (Latham et al., 2000; Jia et al., 2003). Figure 2.12A demonstrates
that this system responds appropriately by increasing firefly luciferase expression in the
presence of DHT (R1881 is also effective, Figure 2.14C). Figure 2.12B shows that the
11 3-compounds are able to increase transcription of this reporter significantly, but to
much less extent than that induced by DHT. 11 1-Dimethoxy is slightly more effective as
an androgen than 1113, but both compounds are relatively weak AR agonists.
Concentrations greater than 1 gM were not tested in these reporter assays due to
enhanced cellular toxicity related to transfection conditions. Additionally, competition
for binding to AR with 10 ptM of the AR antagonist flutamide is able to inhibit the
activation caused by 1 tM 11 3, demonstrating that the enhanced transcription is likely
due to direct interaction between 11 3 and the AR (Figure 2.12C).
To test whether 1113 could efficiently promote AR binding to response elements in
the promoters of androgen-regulated genes, the same PSA promoter/enhancer driven
reporter system was used, but now with a fusion of AR to the VP16 activation domain in
otherwise AR negative COS7 cells. By creating a fusion of the strong activation domain
of VP 16 to AR, the AR gains the ability to increase transcription from a promoter as long
as it is recruited effectively. While 1113 may cause effective recruitment of the AR to
androgen response elements within gene promoter elements, if the receptor does not
undergo conformational changes allowing for additional recruitment of specific co-
activator proteins, it will not effectively drive transcription. By using this VP16-AR
fusion, however, it is easily demonstrated that 11 3 is quite effective at recruiting AR to
the promoter/enhancer regions of PSA within a reporter plasmid (Figure 2.13). While
DHT enhances transcriptional activity through VP 16-AR at 1 nM, 100-fold more 11 3 is
necessary in order to enhance this transcription. It is clear, however, that 100 nM 11 3 is
similarly effective as an equivalent concentration of DHT at promoting this interaction.
Thus, 1113 efficiently promotes AR binding to androgen response elements (AREs) at
concentrations typically used for treatment of LNCaP cells.
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110 Compounds are Moderate AR Antagonists
Despite effectively relocalizing the AR into the nucleus and even to AREs in
androgen-responsive gene promoters, 11 p is not a very effective agonist to a normal AR,
increasing luciferase reporter expression -4-fold (Figure 2.12B). As such, and especially
considering its robust ability to inhibit the N/C terminal interaction, it seemed likely that
11 3 could act as a potent antagonist of AR activation by DHT. To test this possibility,
the same PSA promoter/enhancer reporter system was used in LNCaP cells, but
increasing concentrations of 113 were co-administered with 1 nM DHT. Figure 2.14A
shows that both 110 compounds are moderate antagonists of AR transcriptional activity,
reducing DHT-induced activation by as much as -60%. However, while the N/C
terminal interaction was inhibited by concentrations of 11 3 compounds as low as 10 nM,
antagonism of receptor activity requires concentrations > 100 nM. Figure 2.14B
demonstrates that the AR antagonist bicalutamide, at an equivalent 1 p.M concentration,
is more effective than 110 compounds at interfering with AR activity. Furthermore,
Figure 2.14C shows that both 113 compounds are also able to antagonize AR activity
driven by the more robust AR agonist, R1881. While both 113 and 1 lp-dimethoxy
appear equivalent in their ability to antagonize transcription induced by DHT, 1 3-
dimethoxy is slightly more effective in competition with R1881.
As shown here, 110 is able to bring about a reduction in total steady-state AR
protein levels. As such, it might be assumed that androgen regulated gene transcription
would be decreased as a result of less available transcription factor. While this is likely
to be true, 11 p does not significantly decrease AR protein levels at concentrations < 1 p.M
(the maximum concentration used in transcriptional reporter assays), making it very
likely that 11(3 has a true antagonistic interaction with AR in addition to causing its
eventual degradation (Figure 2.15).
113 is a Mild Agonist and Moderate Antagonist of AR Transcriptional Activity with
Wild-Type AR
The AR expressed in LNCaP cells has a mutation from threonine to alanine at
amino acid 877, which allows for more promiscuous binding of ligands and even for
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certain molecules to switch from antagonists to agonists (Veldscholte et al., 1992).
Additionally, performing reporter assays in LNCaP cells does not allow for assurance
that observed effects depend on AR, because it is impossible to perform a control
experiment in the absence of AR. To address these two concerns, COS7 cells were also
used with transfected wild-type AR (pCINeoAR) or an empty vector (pCINeo) that lacks
AR. These cells are unable to increase firefly luciferase transcription driven by DHT
when transfected with empty vector (Figure 2.16A), demonstrating that the PSA
promoter/enhancer driven reporter plasmid is not functional in these cells in absence of
AR. After transfection of wild-type AR vector, however, the COS7 cells become very
responsive to DHT stimulation (Figure 2.16B). Furthermore, 11 3 acts as a weak agonist
and an effective antagonist just as seen in LNCaP cells with the mutant AR in that
scenario. The assay was also performed in MDA-MB-453 cells (also WT-AR) (Hall et al.
1994) with the same general results (Figure 2.17). Interestingly, in these cells, 11 3-
dimethoxy is a more effective antagonist than 11 3, as was seen in LNCaP cells when
competition was against R1881.
Effects of 110 Treatment on AR Transcriptional Activity are Seen with Endogenous
Androgen-Regulated Genes at mRNA and Protein Levels
Reporter assays are very useful for rapid identification of potential AR
antagonists, but being synthetic, may not accurately reflect transcriptional events
occurring on native chromatin. Another way to assess AR agonist/antagonist activity is
to measure expression of endogenous androgen-regulated genes and protein products.
Measurement of endogenous androgen-regulated genes was performed with LNCaP cells,
analyzing expression of KLK2 and KLK3 (PSA) genes by RT-PCR. The assay format is
slightly different than used for reporter assays-cells are cultured for 48 hrs in CDTFBS
media prior to incubation with test compounds for 24 hrs, whereas reporter assays were
conducted after only 24 hrs in CDTFBS media. This extended duration in androgen-
deprived media made cells more responsive to addition of androgens, increasing the
reliability of results. Analysis of KLK2 and KLK3 transcript levels confirmed 1113
compounds as AR agonists (Figure 2.18). KLK2 was found to be more responsive to
addition of androgen than KLK3, increasing by -100 fold with addition of 1 nM DHT,
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and by -50-fold by addition of 1 p.M 1113. Both 1113 compounds also remain weakly
acting antagonists of AR activation by DHT. They appear to be less effective at
antagonizing transcription of native genes than in the PSA promoter/enhancer reporter
system, but this may reflect the heightened androgen-responsive nature of cells cultured
for an extra day without androgen. Finally, PSA protein (KLK3 gene product) secretion
into culture media was measured in order to determine whether the effects of 111 on AR-
mediated transcription are carried through the steps of protein translation. The 1113
compounds act similarly in affecting secretion of PSA protein into cell culture media-
driving its expression in absence of androgen, but interfering with the ability of DHT to
drive its expression (Figure 2.19).
Discussion
We designed 1113 so that it will form sites of DNA damage that specifically
recruit the AR with the purpose of limiting both adduct repair as well as AR-mediated
transcription. In order for AR to bind to sites of 1113-damaged DNA, it is necessary that
its expression is maintained at a certain level and that it exists in a nuclear location.
Alternatively, free 1113 may interact with the AR first and subsequently form a site of
DNA damage, but will likely be most effective if it is able to enhance AR nuclear import
and DNA binding.
The results shown here demonstrate that 1113 causes a decrease in AR steady-state
protein levels, and are suggestive that this decrease is due to enhanced protein turnover,
rather than decreased protein synthesis. It is well established that the AR is stabilized by
the binding of androgens, but not by AR antagonists, even at much higher concentrations
(Kemppainen et al. 1992). Furthermore, it has been shown that this stabilization requires
interaction of the N and C termini, which also enhances ligand retention (Zhou et al.
1995). As such, the enhanced receptor turnover caused by 1113 is potentially due to its
ability to compete away androgen binding, inhibit N/C interaction, and thereby increase
protein unfolding, leading to its ubiquitylation and proteasomal degradation. AR has
been shown to interact with several E3 ubiquitin ligases, including Mdm2 (Lin, Wang et
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al. 2002), CHIP (Cardozo et al., 2003), and SNURF (Poukka et al., 2000). Further
studies will be necessary to identify whether 113 increases receptor turnover by
increasing association with any of these ubiquitin ligases. Studies can also address
whether AR ubiquitylation is enhanced by 1113 treatment.
While the ability of 1113 to increase receptor turnover may in turn limit the
quantity of complexed DNA adducts, the existence of these complexes remains to be
demonstrated, and it is unclear what quantity would be necessary in order to enhance
toxicity. Potentially, even a small number of complexed adducts could create a
significant burden if proven more difficult to repair. Additionally, most prostate cancers
depend on the presence of AR to proliferate. Therefore, 1113-mediated AR degradation
could enhance toxicity by physically removing the transcription factor crucial for survival.
Even in advanced disease, prostate cancers generally maintain AR expression,
often continuing to rely on androgenic signaling while having evolved the means to
proliferate with either much lower androgen concentrations or by feeding on antagonists.
This perpetual presence of AR allows for continued strategies of targeting AR and its
signaling mechanisms such as the one reported here. One strategy of killing these
cancers that is increasingly attempted involves the physical removal of AR by various
means, including siRNA or use of small molecules modulating receptor expression (Zhu
et al., 1999; Xing et al., 2001; Cha et al., 2005; Liao et al., 2005; Burnstein, 2005;
Bhattacharyya et al., 2006; Compagno et al., 2007; Eder et al., 2000). The advantage of
removing AR from the picture is that such a mechanism could be effective against
hormone refractory prostate cancers, and it is unlikely to lead to resistance mechanisms
such as those that switch former AR antagonists into AR agonists. 1113 may work, in part,
by causing increased AR turnover in the same manner as some of these other strategies,
thus increasing toxicity to cells that require AR for survival.
Likewise, the ability of 1113 to interfere with AR transcriptional activity may
enhance toxicity. One hypothesis is that sites of DNA damaged by 1113 would recruit the
AR away from its natural response elements in promoters of androgen-regulated genes
and thereby antagonize transcription in a novel way. However, the data shown here do
not provide support for this hypothesis, since the non-DNA damaging compound, 1113-
dimethoxy, has an equal or greater capacity to disrupt signaling by the AR. The data do
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not definitively rule out the possibility that adducts can recruit the AR, or even that these
adduct complexes would be more effective in antagonizing AR signaling than free
compound. However, a hypothesis that proposes that ligand localized to DNA is more
accessible by AR than ligand that does not bind DNA is unsupported. Simply put, having
the ability to damage DNA has not improved the antagonistic nature of these compounds.
11i was shown to induce phosphorylation of AR at Ser81 to a similar extent as
the natural androgen DHT. A detailed understanding of AR phosphorylation and how it
influences AR transcriptional activity is not completely known. Studies have shown that
AR transcriptional activity is positively correlated with phosphorylation at this site
(Mellinghoff et al., 2004), and also that a mutant AR defective in DNA binding arrests in
subnuclear foci and is hypophosphorylated at Ser81 (Black et al., 2004). Finally, cyclin-
dependent kinase 1 (Cdkl) was shown to have the ability to phosphorylate AR at this site
in response to addition of androgens (Chen et al. 2006). However, this same study also
showed that AR transcriptional activity does not depend on phosphorylation at this site.
Based on these data, it seems that AR phosphorylation is more of an effect of AR
transcriptional activation than a requisite cause. It was likely, based on AR
phosphorylation at this site, that 11 P could also induce nuclear localization and binding to
AREs.
A very important finding is that 11 p causes redistribution of AR from cytoplasm
into the nucleus, and even enhances binding of the AR at the synthetic PSA
promoter/enhancer. If 11 did not promote this nuclear localization, it is likely that DNA
damage would be minimized because the compound would become trapped in the
cytoplasm in a complex with cytoplasmic receptor and fail to access DNA. This is not to
suggest that a hypothetical analogue of 11i that did not promote AR re-localization
would not be able to form sites of DNA damage, but that it may have reduced ability to
do so compared to the compound which does re-localize AR directly to DNA. The
ability of 11i to cause AR redistribution into the nucleus is not altogether surprising, as
several AR antagonists including hydroxyflutamide, bicalutamide, and RU486 also elicit
the same nuclear transport (Kemppainen et al. 1992; Masiello et al. 2002). RU486 shares
the same steroidal framework of 1103, and has similar effects on AR transcription, acting
as a partial agonist. It is thought that the ability of RU486 to abrogate AR N/C
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interaction and antagonize activity (Song et al., 2004) is due to the bulky dimethyl-
amino-phenyl group appended at its position 11 3 preventing closure of helix 12, as
demonstrated in the crystal structure of RU486 complexed to the highly structurally
similar GR-LBD (Kauppi et al., 2003). As such, we deem it likely that 113 limits N/C
interaction in AR by a similar displacement of helix 12. Inhibition of the N/C interaction
does not always correlate with pure antagonism, and this is true in the case of both
RU486 and 113, as higher concentrations of each permit minimal AR transactivation.
While this can be viewed as a limitation of standard AR antagonist therapies, we consider
it advantageous that 11 3 successfully relocalizes the AR to AREs within androgen-
responsive gene promoters, as this likely assists in formation of DNA adducts. Inhibiting
the N/C interaction that occurs in the AR may also help explain increased receptor
turnover.
While 11 3 is not an exceptional antagonist of AR activity, it remains effective in
preventing growth of LNCaP xenograft tumors while sparing the mice bearing them.
Further studies have been performed to determine more definitively whether the AR has a
role in this mechanism of tumor-specific toxicity.
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A Novel Agent Designed to Inhibit Repair
Processes in a Cancer Cell
Compound reactsProtein Iwith DNARecognition
Warhead Domain H >
Warhead
NON-CANCEROUS CELL
Adduct is Repaired and
Rendered Non-Toxic
I
Repair
Enzyme
,/ I
CANCER CELL
Complex is
Toxic to Cell
Fig 2.1 Rationale for drug design. Molecules are designed such that they have dual
functionality- ability to damage DNA while maintaining affinity for a cancer-specific
protein. As shown here, the molecule would enter cells and damage DNA. Then, in
normal cells where this protein is expressed at lower levels, repair would occur, while
in a cancer cell expressing the protein (steroid receptor in this example), the protein
would bind to an adduct and physically shield it from repair enzymes. Additionally,
where this cancer-specific protein is a transcription factor involved in survival, it is
thought that titration away from response elements would enhance toxicity.
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11 P Causes Reduction in Steady-State
Level of AR Protein in LNCaP Cells
0 3 6 9 15 24 24 48
70 49 27 17 24 21
Fig 2.2 Measurement of AR protein levels in LNCaP cells.
LNCaP cells were treated for times shown with 5 M 113, before
isolation and measurement of protein levels by Western blot as
discussed in Materials and Methods.
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1103 Causes Reduction in Steady-State
Level of AR Protein in C4-2B and
CWR22RvI Cells
A.
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t (hr) 0 3 6 9 18 24
Fig 2.3 Measurement of AR protein levels in C4-2B (A) and
CWR22Rv1 (B) cells. Cells were treated for times shown with 5
1iM 1113, before isolation and measurement of protein levels by
Western blot as discussed in Materials and Methods.
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1103 Does Not Significantly Affect AR
mRNA Expression in LNCaP Cells
0 2 4 6 8 16 24
Time (hr)
Fig 2.4 AR mRNA levels following 110 treatment. Cells were
treated with 5 pM 110 for times shown prior to harvesting cells
and isolating total mRNA. AR mRNA was measured by
quantitative RT-PCR and normalized to GAPDH as discussed in
Materials and Methods.
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11P3-Dimethoxy Also Causes Reduction
in AR Protein Levels
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Fig 2.5 Analysis of AR protein levels after treatment with 5 iM
110-dimethoxy for times shown, before isolation and
measurement of protein levels by Western blot as discussed in
Materials and Methods. Spot densitometry is shown below.
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Proteasome Inhibition Hinders 111-
Mediated AR Down Regulation
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Fig 2.6 Analysis of AR protein levels after treatment with 110 in
the presence of the proteasome inhibitor MG-132 (5 gM). Spot
densitometry is shown below.
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AR Degradation Is not Enhanced by
113 in Absence of New Protein
Synthesis
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Fig 2.7 Analysis of AR protein levels after treatment with 11 3 in
the presence of translational inhibitor cycloheximide (10 gM) for
times shown. Spot densitometry is shown below.
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Competition with Ligand for AR Limits
11 O-Mediated AR Degradation
AR
Actin
Time (h)
R1881 inM
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Fig 2.8 Analysis of AR protein levels after treatment with 110 in
the presence of synthetic AR ligand R1881. First lane is from
cells grown in media containing 10% FBS for comparison, while
all other lanes are grown in media containing CDTFBS
(androgen free). Spot densitometry is shown in graph below,
relative to AR level in untreated cells (CDTFBS media).
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AR Phosphorylation (Ser81) is
Induced by 113
p-AR
Time (h)
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Fig 2.9 Analysis of AR protein phosphorylation by Western blot.
LNCaP cells, growing in CDTFBS containing media, were
treated as indicated before isolating proteins and
immunoblotting for AR Ser81 phosphorylation.
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11i Induces AR Nuclear Localization
Cyt Nuc Cyt Nuc Cyt Nuc Cyt Nuc
AR
PARP
Tubulin 4$ am -p
Untreated 110 1IpM R1881
lnM
R1881 1nM
+ 113 1pM
Fig 2.10 Analysis of AR location by Western blotting. LNCaP
cells were treated for 24 hrs in CDTFBS containing media as
indicated before separation of nuclear and cytoplasmic
fractions. These extracts were then probed for expression of
AR, PARP (nuclear protein), and 3-tubulin (cytoplasmic protein).
Cytoplasmic fractions = 20 jLg total protein, nuclear fractions =
10 gg.
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113 Compounds Inhibit NIC Terminal
Interaction of the AR Induced by DHT
A.
Gal4 sites
M11 -dimethoxy
DMSO DHTInM 0.1
Treatment
1 10 100
Competitor Concentration (nM)
Fig 2.11 Measurement of N/C terminal interaction within the AR by
mammalian two-hybrid assay. A. Schematic diagram of assay. B. COS7
cells were transfected with plasmids pmARLBD-649-919, VP16ARNTD1-
538, pG51uc, and pgL4.74, then later treated with compounds shown in
CDTFBS containing media for 24 hrs before isolation and measurement
of firefly and renilla luciferase. Right graph contains 1 nM DHT in all
samples. Error bars are +/- SEM. *p-val < 0.05, **p-val < 0.01
(significance of differential expression is in comparison to 1 nM DHT in
graph on right).
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11p3 Compounds Are Weak AR
Agonists
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Fig 2.12 Measurement of AR Activation by luciferase reporter assay.
LNCaP cells were transfected with plasmids pGL4PSA and pGL4.74
before treatment for 24 hrs in CDTFBS containing media with
compounds indicated. A. 1 nM DHT induces ~27-fold activity over
background, B. 1 CpM 110 and 113-dimethoxy induce -4 and 7-fold
enhanced transcription over background, respectively. C. Enhanced
activation of AR is dependent on interaction between 11 p and AR, as 10
giM flutamide (Flut) prevents 1 jM 11p activation. Error bars are +/-
SEM. *p-val < 0.05, **p-val < 0.01.
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111p Promotes Efficient Association of
AR with the PSA Promoter
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Fig 2.13 Measurement of AR activation by luciferase reporter
assay. COS7 cells were transfected with plasmids VP16-AR,
pGL4PSA, and pGL4.74 before treatment for 24 hrs in CDTFBS
containing media with compounds indicated. Error bars are +/-
SEM. *p-val < 0.05, **p-val < 0.01.
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1113 Compounds are Moderate AR
Antagonists
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Fig 2.14 Measurement of AR activation by luciferase reporter assay. LNCaP cells
were transfected with plasmids pGL4PSA and pGL4.74 before treatment for 24 hrs
with compounds and concentrations indicated, in CDTFBS containing media. A. 11
compounds are able to antagonize DHT-enhanced AR activity by as much as -60%
B. DHT activation of AR transcription is -27-fold greater than background, while 1 jgM
bicalutamide (bic) effectively antagonizes most of this activity. C. 11 3 (1 1 M) is able to
antagonize AR activity driven by DHT or R1881; 11 -dimethoxy (Di) is slightly more
effective than 1 against R1 881-driven AR transcriptional activity. Error bars are +/-
SEM. *p-val < 0.05, **p-val < 0.01.
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113p Does Not Significantly Reduce AR
Levels at Concentrations < 1 pM
AR
0 1 10 100 1000 10000
11ip Concentration (nM)
Fig 2.15 Western blot of AR level in LNCaP cells treated with
11P. Cells were treated as indicated prior to analysis of AR
protein levels by immunoblot. Concentrations up to 1 CtM do not
significantly affect AR protein levels.
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113 Acts as Mild Agonist and Moderate
Antagonist Toward Wild-Type AR
(COS7 cells)
A. B.
20-**
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Fig 2.16 Measurement of AR activation by luciferase reporter
assay. COS7 cells were transfected with plasmids pGL4PSA,
pGL4.74, and pCINeo (A) or pCINeoAR (B) before treatment for
24 hrs with compounds indicated in CDTFBS containing media.
A. There is no enhanced firefly luciferase expression in absence
of AR. B. When wild-type AR is transfected, 110 is a weak
agonist and a moderate antagonist of AR activity. Bic =
bicalutamide, 1 [M. Error bars are +/- SEM. **p-val < 0.01;
DHT, 110 are with reference to DMSO, DHT + 110 or
bicalutamide are with reference to 1 nM DHT.
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113 Acts as Mild Agonist and Moderate
Antagonist Toward Wild-Type AR
(MDA-MB-453 Cells)
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Fig 2.17 Measurement of AR transcriptional activity in MDA-MB-453
cells. Cells were transfected with pGL4PSA and pGL4.74 vectors prior to
indicated treatments for 24 hrs in CDTFBS containing media. Extracts
were then prepared and assayed for firefly and renilla luciferase. 113
acts as a weak agonist, and also as a moderate antagonist towards the
wild-type AR expressed in these breast cancer cells. Error bars are +/-
SEM. **p-val < 0.01; for DHT, 11P and 11J-dimethoxy (di), comparison is
to untreated. For DHT + 11P or 11p-dimethoxy, comparison is to 1 nM
DHT.
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Identification of 11 Compounds as
Partial AR Agonists is Supported by
RT-PCR of Androgen-Regulated Genes
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Fig 2.18 Measurement of KLK2 and KLK3 (PSA) mRNA levels by RT-PCR. LNCaP
cells, previously grown in hormone-depleted media for 48 hrs, were treated with
compounds shown (DHT, 1 nM; 1103, 1 pVM; Di = 1113-dimethoxy, 1 iM; flut = flutamide,
10 ptM) for 24 hrs prior to isolation of RNA and analysis as described in materials and
methods. Error bars are +/- SEM. *p-val < 0.1, **p-val < 0.05, ***p-val < 0.01; For
11, 1130-dimethoxy (di), and DHT, comparison is to untreated, for DHT + 113 or 1103-
dimethoxy, comparison is to DHT, for 1113 + flutamide, comparison is to 1113.
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113 Increases Secretion of PSA into
Culture Media and is Weakly
Antagonistic toward DHT-induced PSA
Secretion
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Fig 2.19 Measurement of PSA secretion into media of growing LNCaP
cells, previously cultured in hormone-depleted media for 48 hrs before
treatment with compounds shown (DHT, 1 nM; 110, 1 iM; Di = 1103-
dimethoxy, 1 gM; flut = flutamide, 10 iM) for 24 hrs prior to isolation of
RNA and analysis as described in materials and methods. Error bars are
+/- SEM. *p-val < 0.05, **p-val < 0.01; For 110, 1130-dimethoxy, and DHT,
comparison is to untreated, For DHT + 11 p or 11 p-dimethoxy, comparison
is to DHT. For 11P + flutamide, comparison is to 11P.
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Introduction
Prostate cancer remains a leading killer of males in developed countries, despite
continuing medical advances in detection and treatment of this disease (Jemal et al.,
2008). Especially in late-stage, hormone-refractory prostate cancer, there is little help
offered by chemotherapeutic treatment, and new therapies that continue to treat the
disease are much needed. Treatment of metastatic prostate cancer consists of minimizing
AR activity through chemical castration methods and use of AR antagonists. However,
antagonistic therapies eventually fail as the tumor develops mechanisms to grow with
lower androgen levels or acquires mutations allowing former antagonists to function as
AR agonists. Nevertheless, the AR remains a tractable target because it continues to be
expressed in a majority of cases (van der Kwast et al. 1991; Visakorpi et al. 1995;
Holzbeierlein et al. 2004; Mohler et al. 2004), and usually continues to function in
promoting expression of pro-growth and pro-survival genes (Gregory et al. 1998;
Zegarra-Moro et al. 2002). As an example of a way to continue employing AR as a
target, therapies that can eradicate AR have been proposed and attempted with some
success in pre-clinical scenarios (Zhu et al. 1999; Xing et al. 2001; Cha et al. 2005; Liao
et al. 2005; Burnstein 2005; Bhattacharyya et al. 2006; Eder et al. 2000; Eder et al. 2002).
Our proposed strategy for achieving selective toxicity toward prostate cancer cells
involves the chemical tethering of a DNA damaging agent to a ligand for the AR within a
single compound, 1131. Together, the ligand and damaging agent will form sites of DNA
damage that go on to recruit AR association, resulting in two potential means for
enhanced toxicity to cells expressing AR: 1) AR could physically block the access of
DNA repair enzymes, leading to adduct persistence, and 2) the AR may be titrated away
from its normal sites of transcriptional activity in the promoters of genes related to
growth and survival, leading to reduced expression. Either separately or in combination,
these two proposed mechanisms would increase the toxicity of compounds toward AR
positive prostate cancer cells. Importantly, if these mechanisms of toxicity are achievable,
the only crucial factor is AR expression. Advanced disease stage that may have acquired
2-(6-((8S, 11S,13S,14S,17S)- 17-hydroxy-13-methyl-3-oxo-
2,3,6,7,8,11,12,13,14,15,16,17 dodecahydro- 1H-cyclopenta[a]phenanthren- 11-
yl)hexylamino)ethyl 3-(4-(bis(2-chloroethyl)amino)phenyl)propylcarbamate
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independence from androgen signaling either by mutation within the AR ligand binding
pocket allowing promiscuity for different ligands, or activation independent of androgen
binding would still be treatable by creating persistent sites of DNA damage and
physically removing AR from sites of gene activation.
To address whether AR enhances the toxicity of 110 toward prostate cancer cells,
we have employed three primary strategies: 1) interference with 11p binding to AR by
free steroid ligand, 2) use of isogenic cell lines differing, presumably, only in AR
expression status, and 3) synthesis of an Il variant compound, 17-OH-113, with
reduced affinity to AR. Since the mechanisms proposed depend on a persistent
interaction of 11 3 with the AR, it is thought that addition of a large quantity of free AR
ligand will disrupt their association and reduce toxicity. A previous report demonstrated
that 11p has approximately 10% of the affinity to AR as the synthetic androgen RI 881
(Marquis et al., 2005). Thus, addition of 1 p.M R1881 to cells undergoing treatment with
toxic micromolar concentrations of 113 should be able to disrupt association and inhibit
toxic effects. Isogenic cell lines allow for testing the effects of changing a single variable,
rather than testing cell lines that differ in AR expression but are of distinct lineage, which
would confound interpretation of results. The only drawback to isogenic cells in this
specific case is that the cell lines employed do not depend on AR for survival. As such,
they are most useful for testing the hypothesis that AR can hinder repair of 11 -DNA
adducts and increase toxicity. Finally, by synthesizing a control compound with similar
physicochemical parameters but with less affinity for AR, we can address the importance
of the interaction between 11 P and the AR in the mechanism of compound toxicity.
In synthesizing a compound with reduced affinity to AR, we chose to follow a
route that would result in the least modification of our compound. We hoped to avoid
any misinterpretation of results that could occur from altered solubility, cellular uptake
and distribution, metabolism, or loss or gain of interaction with factors other than AR.
Previous studies have shown that the AR prefers an alcohol function at the 17 position of
the steroid, in the p (S) stereoisomer. In fact, it has been shown that inversion of this
alcohol from P to a in some steroids results in a 200 fold reduction in binding affinity to
AR (Fang et al., 2003). Crystal structures of AR complexed with testosterone,
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dihydrotestosterone, or R1881 demonstrate that the alcohol at C-17 forms hydrogen
bonds with Thr-877 and Asn-705 (Matias et al., 2000; Sack et al., 2001; Pereira de Jesus-
Tran et al., 2006), and presumably would be unable to maintain the hydrogen bonding
upon alcohol inversion. As such, our strategy for reducing affinity of 11 3 for AR was
inversion of the alcohol at C-I17, creating 17a-OH-11 3. We were then able to determine
how reducing affinity affected toxicity toward cells expressing AR.
The results shown here demonstrate that AR is not, in fact, a requirement for
toxicity of our compound. Competition with AR ligand was unable to interfere with
toxicity toward LNCaP or PC3-AR cell lines. Moreover, an isogenic pair of cell lines
differing only in AR status proved to be equally sensitive to 11 3, and the 17a-OH-1 3
compound proved to have only slightly lower toxicity than 113 to several cell lines,
which was most likely due to an unforeseen reduced ability to form DNA damage.
Materials and Methods
Chemicals: 5c-Dihydrotestosterone (DHT) was acquired from Sigma-Aldrich.
Bicalutamide was from LKT Laboratories, Inc. (St. Paul, MN). [3H]-R1881 and R1881
were from Perkin-Elmer Life Science (Waltham, MA). Synthesis of 11 p-dichloro
(referred to herein as 11 P3) and 11 -dimethoxy were performed in our laboratory and have
previously been described (Marquis et al. 2005). Synthesis of [14C]-113 (25mCi/mmol)
was also conducted in house and described previously (Hillier et al., 2006).
Chemical Synthesis of 17a-OH-110
17P-OH(estra-A4 9(10)-dien-3-one), otherwise known as 9(10)nandrolone, was acquired
from Brighton Co., LTD (Changsha, Hunan, China). All other chemicals and reagents
for synthesis were obtained from Sigma-Aldrich, EMD Biosciences, or Mallinckrodt.
Please refer to Scheme 3.1 for synthetic route.
Mitsunobu Inversion of 17-OH of Starting Material 17I3-OH(estra-A4' 90o)-dien-3-one)
to Form (8S,13S,14S,17R)-17-hydroxy-13-methyl-6,7,8,11,12,13,14,15,16,17-
decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
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To 4.89 g (17.9 mmol) of the starting dienone was added 6.11 g (23.3 mmol, 1.3 eq) PPh3
and 4.04 g (24.2 mmol, 1.35 eq) 4-nitrobenzoic acid in a flame-dried round bottom flask
under argon. 40 mL anhydrous THF was added and reaction mixture was heated to 700C
to dissolve. 4.9 g (24.2 mmol, 1.35 eq) DIAD was added dropwise over 5 minutes with
stirring. Reaction was maintained at 700C for 2 hrs, then allowed to cool to RT. 100 mL
sat. NaHCO 3 was added and product extracted with EtOAc, dried over MgSO4, and
concentrated under reduced pressure. Product was purified by flash chromatography on
silica gel (15% - 25% EtOAc in hexanes) and used directly in the following reaction.
Ester hydrolysis to form 17a-hydroxy-4,9-estradien-3-one
The resulting 4-nitrobenzoate was dissolved in 40 mL anhydrous MeOH and 38 mg
K2CO 3 (0.36 mmol, 0.02 eq) was added. Reaction was heated to 600 C with vigorous
stirring for 14 hrs, then concentrated. Product was partitioned between water and EtOAc
and dried over MgSO 4. Product (1) was purified by flash chromatography on silica gel
(15% -- 25% - 50% EtOAc in hexanes) to produce a white powder (3.08 g, 63.2% yield
over 2 steps).
Two-dimensional gradient-selected correlation spectroscopy (gCOSY),
heteronuclear single quantum coherence (HSQC), and gradient-selected heteronuclear
multiple bond correlation (gHMBC) NMR experiments were performed to completely
assign all spectra and identify successful epimerization of the 2' alcohol at C-17.
'H NMR (CDC13): 6 5.68 (s, 1H), 6 3.83 (dd, 1H), 6 2.86 (ddd, 1H), 6 2.91 (dyt, 1H), 6
2.55 (m, 1H), 6 2.48, 6 2.45 (m, 2H), 6 2.42 (yt, 1H), 6 2.36 (qt, 1H), 6 2.13- 6 2.28 (m,
3H), 6 1.95 (dyq, 1H), 6 1.83 (dddd, 1H), 6 1.72 (ytd, 1H), 6 1.61 (m, 2H), 6 1.54 (dddd,
1H), 6 1.45 (d, 1H), 6 1.36 (ptdd,1H), 8 1.30 (yqdd, 2H), 6 0.83 (s, 3H)
13C NMR (CDCI3): 8 16.392, 24.683, 25.497, 25.909, 27.800, 30.858, 31.307, 32.620,
37.166, 39.492, 45.164, 49.078, 79.424, 122.052, 125.348, 146.424, 157.489, 199.925
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Complete synthesis of 1113 has been described previously (Marquis et al., 2005). We
have slightly modified the literature procedure as described here for synthesis of 17a-
OH-11P3.
Synthesis of 3,3-Ethylenedioxy-173-hydroxy-5(10)9(11)-estradiene
To 3.06 g (11.2 mmol) (1) dissolved in 100 mL anhydrous benzene was added 6.97 g
(112 mmol, 10 eq) ethylene glycol, followed by 209 mg (1.1 mmol, 0.1 eq) p-
toluenesulfonic acid. Flask was fitted with a Dean-Stark apparatus and condenser
column, heated to reflux 1 hr. Reaction was cooled and poured into a separatory funnel.
Flask was washed with hexanes. Benzene/hexane layer collected and concentrated.
Product was purified by flash chromatography on silica gel (50% EtOAc/hexanes),
concentrated and used immediately in following reaction.
Silylation of 20 Alcohol
Steroid was dissolved in 50 mL anhydrous CH2C12. 2.29 g (33.6 mmol, 3 eq) imidazole,
134 mg (1.1 mmol, 0.1 eq) 4-dimethylaminopyridine, and then 3.38 g (22.4 mmol, 2 eq)
TBS-C1 was added. Reaction was stirred RT lhr, concentrated, washed with brine and
extracted with EtOAc. Product was purified by flash chromatography on silica gel (5%
EtOAc/hexanes) and used immediately in the following reaction.
Epoxidation to form 3,3-Ethylenedioxy-17f3-tert-butyldimethylsilyloxy-5a,lOz-
oxido-9(11)-estrene (2)
Steroid was dissolved in 50 mL anhydrous CH2C 2 and cooled to OoC. 0.74 mL (5.31
mmol, 0.5 eq) hexafluoroacetone trihydrate added, followed by 0.74 mL pyridine. 3.6
mL (31.83 mmol, 3 eq) 30% H20 2 added dropwise and reaction was allowed to warm to
RT gradually with vigorous stirring over 13 hrs. 5% Sodium thiosulfate and CH2C12
were added and the organic phase was separated and dried over MgSO 4. Product (2) was
purified by flash chromatography on silica gel (10% EtOAc/hexanes) (3.84 g, 76.8%
yield from (1)).
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Preparation of the Grignard and alkylation of (2) to form (5R,8S,11S,13S,14S,17R)-
17-(tert-butyldimethylsilyloxy)- 11-(6-(tert-butyldimethylsilyloxy)hexyl)-13-methyl-
1,2,4,5,6,7,8,1 1,12,13,14,15,16,17-tetradecahydrospiro[cyclopenta[a] phenanthrene-
3,2'-[1,3]dioxolan]-5-ol
Grignard reagent was prepared in situ from (6-bromohexyloxy)tert-butyl-dimethyl-silane.
Briefly, 1.25 g (51.6 mmol, 6 eq) flaked magnesium was added to a flame dried 3-neck
round bottom flask and dried with heat gun 15 minutes. 40 mL anhydrous THF was
added, followed by 15.23 g (51.6 mmol, 6 eq) of (6-bromohexyloxy)tert-butyl-dimethyl-
silane, and reaction was heated to reflux 2.5 hrs to form Grignard. At this time, the
reaction was cooled to -200C, and 1.06 g (5.16 mmol, 0.6 eq) copper(I)bromide-
dimethylsulfide complex was added. 3.84 g (8.60 mmol) epoxide (2) was dissolved in 10
mL anhydrous THF and added. Reaction was maintained at -200 C for 1.5 hrs with
stirring. 50 mL ice-cold sat. NH 4C1 was added and reaction was filtered through celite
and concentrated. Product (3) was purified by flash chromatography on silica gel (10%
EtOAc/hexanes) (4.57 g, 80.2%).
Deprotection of Primary Alcohol
4.57 g (6.89 mmol) (3) was dissolved in 20 mL anhydrous THF. 10.3 mL (10.3 mmol)
tetrabutylammonium fluoride (IM in THF) was added and reaction was stirred RT 4 hrs.
Product was purified by flash chromatography on silica gel (50% EtOAc/hexanes) (2.74
g, 72.5%).
Iodination to Synthesize (5R,8S,11S,13S,14S,17R)-17-(tert-butyldimethylsilyloxy)-
11-(6-iodohexyl)-13-methyl-1,2,4,5,6,7,8,11,12,13,14,15,16,17-
tetradecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-5-ol (4)
To a 3-necked flame-dried round bottom flask, 1.39 g (5.49 mmol, 1.1 eq) finely crushed
12 was added. 40 mL anhydrous CH 2Cl2 was added and mixture was stirred 15 minutes
to dissolve. In separate flask, 2.74 g steroid (4.99 mmol) was dissolved in 10 mL
anhydrous CH 2Cl 2 and cooled to OoC. 1.44 g (5.49 mmol, 1.1 eq) triphenylphosphine and
679 mg (9.98 mmol, 2 eq) imidazole was added. 12 solution was then added dropwise to
the mixture over 20 minutes. Reaction turns from clear to yellow toward end of addition.
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The reaction was allowed to proceed 4 hrs, gradually reaching RT. 25 mL 20% sodium
bisulfite was added to quench reaction, causing clearing, followed by 50 mL CH2C 2.
The organic layer was collected, filtered over celite, concentrated, and purified by flash
chromatography on silica gel (50% EtOAc/hexanes) to yield 2.85 g (4) (86.6%).
Reaction of (4) with N-(2-(tert-butyldimethylsilyl)oxyethyl)-2-nitrobenzene
sulfonamide
To a flame-dried 3 neck round bottom flask, 1.63 g (4.51 mmol, 1.1 eq) N-(2-(tert-
butyldimethylsilyl)oxyethyl)-2-nitrobenzene sulfonamide was dissolved in 20 mL
anhydrous CH3CN. 30.3 mg (82 jtmol, 0.02 eq) tetrabutylammonium iodide was added,
followed by 1.47 g (4.51 mmol, 1.1 eq) Cs 2CO 3, turning the reaction bright yellow.
Steroid (4) was dissolved in 5 mL anhydrous THF and added. Vessel was fitted with an
oven-dried condenser column and heated to reflux for 2 hrs. The reaction was then
cooled, filtered twice through celite, concentrated, and purified by flash chromatography
on silica gel (20% EtOAc/hexanes), yielding 3.23 g (5), 88.5%.
Deprotection of 20 Amine
To a flame-dried round bottom flask, 2.73 g (3.06 mmol) of steroid (5) was added and
dissolved in 30 mL anhydrous CH 3CN. 1.95 g (14.1 mmol, 4.6 eq) K2CO3 added,
followed by 626 pL (6.13 mmol, 2 eq) thiophenol. Reaction was heated to 370 C, allowed
to proceed 30 minutes, then filtered and concentrated. Product (6) was purified by flash
chromatography on silica gel (50% EtOAc/hexanes -- 5% MeOH/CH 2C12), yielding 1.96
g (90.7%) (structure not shown in Scheme 3.1).
Reprotection of 20 Amine with diphenylphosphine
970 mg (1.37 mmol) steroid (6) was dissolved in 25 mL CH2C12 and cooled to 00 C. 382
pL (2.74 mmol, 2 eq) Et3N added. 284 pL (1.51 mmol, 1.1 eq) diphenylphosphinic
chloride was dissolved in 5 mL CH 2C12 and added dropwise over 30 minutes. Reaction
was allowed to proceed at RT for 3 hrs with vigorous stirring, then extracted with H20
and CH 2Cl 2 and dried over MgSO4. Product (7) was purified by flash chromatography on
silica gel (100% EtOAc), giving 1.01 g (81.5%) (structure not shown in Scheme 3.1).
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Deprotection of 10 Alcohol to Form N-(6-((5R,8S,11S,13S,14S,17R)-17-(tert-
butyldimethylsilyloxy)-5-hydroxy-13-methyl-1, 2 ,4,5 ,6 ,7 ,8 ,11,12,13,14,15,16,17-
tetradecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolane]- 11-yl)hexyl)-
N-(2-hydroxyethyl)-P,P-diphenylphosphinic amide (8)
1.51 g (1.67 mmol) steroid (7) was dissolved in 10 mL anhydrous THF. 1.83 mL (1.83
mmol, 1.1 eq) tetrabutylammonium fluoride was added and reaction was stirred
vigorously for 30 minutes. Reaction was concentrated, and product (8) was purified by
flash chromatography on silica gel (100% EtOAc 4 5% MeOH/CH 2CI2), giving 1.24 g
(93.9%).
Synthesis of 2-((6-((5R,8S,11S,13S,14S,17R)-17-(tert-butyldimethylsilyloxy)-5-
hydroxy-13-methyl-1,2,4,5,6,7,8,11,12,13,14,15,16,17-
tetradecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolane]-11-
yl)hexyl)(diphenylphosphoryl)amino)ethyl 4-nitrophenyl carbonate (9)
1.24 g (1.56 mmol) steroid (8) was dissolved in 10 mL anhydrous THF. 654 p~L (4.70
mmol, 3 eq) Et3N was added, followed by 947 mg (4.70 mmol, 3 eq) 4-nitrophenyl
chloroformate. Some precipitation occurred and reaction became cloudy yellow.
Reaction was allowed to proceed 3hrs at RT. 100 mL EtOAc and 50 mL sat. NaHCO 3
was added. The organic layer was collected, washed three times with sat. NaHCO 3 and
once with H20, dried over MgSO4, and concentrated. Product (9) was purified by flash
chromatography on silica gel (50% EtOAc/hexanes - 100% EtOAc), giving 1.28 g
(85.3%).
Reaction of 4-(3-aminopropyl)-N,N-bis(2-chloroethyl)aniline with p-nitrophenyl
carbonate
640 mg (669 jtmol) carbonate (9) was dissolved in 4 mL anhydrous THF. 4-(3-
aminopropyl)-N,N-bis(2-chloroethyl)aniline was dissolved in 4 mL anhydrous THF and
added dropwise to reaction, turning it bright yellow. Reaction was allowed to proceed
with stirring 1 hr. 150 mL EtOAc and 50 mL sat. NaHCO 3 added, organic layer collected
and washed twice with NaHCO 3 and once with H20, dried over MgSO4, filtered, and
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concentrated. Product (10) was purified by flash chromatography on silica gel (75%
EtOAc/hexanes 
- 100% EtOAc), yielding 616 mg of a white foamy solid (84.3%).
Removal of tert-butyldimethylsilanoxy- and phosphinamido- groups from
compound (10) to form 2-(6-((8S,11S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-
2,3,6,7,8,11,1 2 ,13 ,14 ,15 ,16 ,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-
yl)hexylamino)ethyl 3 -(4-(bis( 2-chloroethyl)amino)phenyl)propylcarbamate (11),
17a-OH-1113
616 mg (563 limol) steroid (10) was dissolved in 1 mL dioxane. 1.13 mL (4.5 mmol, 8
eq) 4M HCl in dioxane was added dropwise and reaction was allowed to proceed 2 hrs,
turning deep purple. 500 mg NaHCO 3 was added to quench HCI. Reaction was filtered
through glass pipette stuffed with kimwipe, concentrated, and purified by flash
chromatography on silica gel (5% - 10% MeOH/CH 2CI2), then re-purified by flash
chromatography on alumina (2% MeOH/CH 2CI2), giving 308 mg final product (11)
(76.3%).
'H NMR (CDC13): 8 7.05 (d, 2H), 6 6.62 (d, 2H), 6 5.64 (s, 1H), 6 4.81, (s broad, 1H), 6
4.18, (t, 2H), 6 3.7 (m, 5H), 8 3.62 (m, 4H), 8 3.19-3.09 (m, 2H), 6 3.07 (m, 1H), 2.85 (m,
3H), 6 2.59 (dt, 5H), 6 2.44-2.20 (m, 6H), 6 1.96 (m, 1H), 6 1.88 (m, 1H), 6 1.78 (m, 3H)
5 1.64-1.22 (m, 17H), 5 0.83 (s, 3H).
HRMS (ESI): calculated for C40H590 4NC12 [M + H]: 716.3955, found: 716.3922
Purity by HPLC > 94%.
Preparation of N-(2-(tert-butyldimethylsilyl)oxyethyl)-2-nitrobenzene sulfonamide
1.98 mL (32.7 mmol, 1.1 eq) ethanolamine and 4.56 mL (32.7 mmol, 1.1 eq) Et3N were
dissolved in 100 mL CH2C12 and cooled to 00 C. 6.6 g (29.8 mmol) 2-nitrobenzene
sulfonyl chloride was added, causing some precipitation. Reaction proceeded for 20
minutes. Product was partitioned between CH 2Cl 2 and H20. Organic layer concentrated
and used immediately in subsequent reaction.
Crude sulfonamide was dissolved in 60 mL CH2Cl 2 and cooled to OoC. 2.23 g (32.7
mmol, 1.1 eq) imidazole, 364 mg (2.9 mmol ,0.1 eq)) 4-dimethylaminopyridine, and
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finally 4.94 g (32.7 mmol, 1.1 eq) TBS-Cl were added. Reaction was removed from ice,
allowed to proceed 1 hour. Product was partitioned between CH2C 2 and H20,
concentrated, and purified by flash chromatography on silica gel (20% EtOAc/hexanes),
giving 10.02 g (93.4% over 2 steps).
Preparation of 4-(3-aminopropyl)-N,N-bis(2-chloroethyl)aniline
To a flame-dried round bottom flask, 2.00 g (6.57 mmol) chlorambucil was added and
dissolved in 20 mL anhydrous THF. This was cooled to -780 C, and 0.87 mL (7.89 mmol,
1.2 eq) N-methylmorpholine was added, followed by 0.75 mL (7.89 mmol, 1.2 eq) ethyl
chloroformate. Allowed to proceed 5 minutes, checked by TLC, and then moved
to -10C bath before adding 854 mg (13.15 mmol, 2 eq) sodium azide dissolved in 3 mL
H20. Reaction allowed to proceed 20 minutes, then partitioned between brine and
EtOAc. Organic layer was collected and dried over MgSO4. Product 4-(4-(bis(2-
chloroethyl)amino)phenyl)butanoyl azide used immediately in subsequent reaction.
Crude acyl azide was dissolved in 13mL anhydrous CHCl3. 1.36 mL (13.15 mmol, 2 eq)
benzyl alcohol added and reaction was warmed to reflux overnight. Reaction
concentrated and purified by flash chromatography on silica gel (15% - 25%
EtOAc/hexanes), giving 2.51 g benzyl 4-(4-(bis(2-chloroethyl)amino)phenyl)
butanoylcarbamate (93.3%).
Immediately prior to use, Cbz protecting group was removed from aniline
mustard. To a flame-dried round bottom flask, 411 mg (1 mmol) Cbz-protected aniline
mustard was added, along with 106 mg (100 gtmol) Pd on carbon. 5 mL MeOH was
added, the reaction was purged with argon, and an H2-filled balloon was attached.
Reaction was allowed to proceed 1 hr, filtered over celite, concentrated, and used
immediately in subsequent reaction.
Analytical Techniques: NMR data was collected at MIT Department of Chemistry
Instrumentation Facility under the expert guidance of Dr. Jeff Simpson, using a Varian
Inova 500 Mhz NMR spectrometer, which was equipped with a 5 mm inverse broadband
z-axis gradient probe for use in 2D experiments.
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13C NMR experiments were performed using a Varian Inova 500 Mhz NMR spectrometer
fitted with a 5 mm broadband probe. Samples were dissolved in CDCl 3 and referenced to
TMS. All data was acquired and processed using Varian's VNMR 6.1C software running
on a Sun microcomputer. Methods used included 1H, 13C, dimensional gradient-selected
correlation spectroscopy (gCOSY), heteronuclear single quantum coherence (HSQC),
and gradient-selected heteronuclear multiple bond correlation (gHMBC) experiments.
Reversed-phase HPLC analysis was performed using a Varian C18 Ultrasorb 5 ptm 4.6 x
250mm column with a UV diode array detector (Varian ProStar 330 PDA). Compounds
were separated using a 50% to 100% MeOH gradient over 20 minutes with a flow rate of
ImL/min. The aqueous phase used was 0.05 M sodium acetate and 10% CH 3CN in H20.
High resolution mass spectrometry was performed on an Agilent ESI-TOF spectrometer.
Cell Culture: LNCaP cells (ATCC, Rockville, MD) were maintained in RPMI 1640
media supplemented with glucose (2.5 g/L), 1 mM sodium pyruvate, 10 mM HEPES (all
Invitrogen, Carlsbad, CA), and 10% fetal bovine serum (Hyclone, Salt Lake City, UT).
MDA-MB-453 cells (ATCC) were grown in MEM-ac media supplemented with 1 ng/mL
EGF, 2 ptg/mL human recombinant insulin, 100 mM non-essential amino acids, 10 mM
HEPES (all Invitrogen), and 10% fetal bovine serum (Hyclone). All cells were grown in
a humidified 5% CO2/air atmosphere at 37C. For transcriptional reporter assays and
where otherwise indicated, media formulations were the same except for use of phenol
red free versions supplemented with 10% charcoal dextran treated FBS (CDTFBS)
(Hyclone) in order to remove all androgens. PC3-AR cells are a clonal cell line derived
from PC3 cells stably transfected with a plasmid containing the coding region for the
human androgen receptor. PC3-Neo cells were transfected with this same vector lacking
the AR sequence. Both were generous gifts from Mien-Chie Hung (University of Texas
M.D. Anderson Cancer Center). PC3-AR and PC3-Neo cells were grown in the same
media as LNCaP with the addition of 400 jtg/mL geneticin. PC3-AR1 and PC3-AR9 are
also isogenic clonal sublines of PC3 made by transfection of AR, though PC3-AR1 do
not express detectable AR and are unresponsive in an AR reporter assay, while PC3-AR9
cells express a functional AR for reporter assays (Shaoyong Chen, personal
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communication). These were a kind gift from the laboratory of Steven Balk (Beth-Israel
Deaconess Medical Center, Boston, MA). An additional PC3 subline expressing AR
protein, A103, was also acquired from the Balk lab. PC3-AR1, PC3-AR9, and A103
cells were grown in RPMI 1640 with 10% fetal bovine serum and 400 lpg/mL geneticin.
Western Blots: Cells were harvested by scraping into media, washing with PBS, and
subsequently lysing in RIPA buffer (Santa Cruz Biotechnology, Santa Cruz, CA)
containing PMSF, sodium orthovanadate, and protease inhibitor cocktail at OoC. Cellular
debris was pelleted by centrifugation at 14,000 RPM in a bench top microcentrifuge,
supernatants were collected, and protein quantified by Bradford dye binding assay (Bio-
Rad Laboratories, Hercules, CA). Equal quantities of protein were electrophoretically
separated on a bis-tris precast polyacrylamide gel (Invitrogen) and transferred to
Immobilon-P PVDF membrane (Millipore, Billerica, MA). Non-specific protein binding
was blocked with 5% milk in Tris-buffered saline (0.1% Tween 20, 10 mM Tris [pH 7.4],
150 mM NaCI) and proteins were detected by primary antibodies followed by horseradish
peroxidase (HRP) conjugated secondary antibodies and chemiluminescent HRP substrate
(Supersignal West; Pierce, Rockford, IL). Antibodies used were as follows: AR (SC-
7305, SC-816, Santa Cruz), p-actin (SC-1615R; Santa Cruz), and HRP-conjugated
secondary antibodies (#7076, anti-mouse IgG; #7074 anti-rabbit IgG; Cell Signaling
Technology, Danvers, MA).
Luciferase Transcriptional Reporter Assays: For testing of AR transcriptional activity
in LNCaP cells, 24-well tissue culture plates were used and cells were co-transfected with
pGL4PSA and pGL4.74 in a 24:1 ratio using lipofectamine and PLUS reagent in Opti-
MEM media according to manufacturer's instructions (Invitrogen). After 3 hrs, media
was supplemented to 10% FBS, and after 24 hrs replaced with fresh phenol red free
media containing 10% CDTFBS. Following a further 24 hrs incubation, test compounds
were diluted 1,000-fold into CDTFBS containing media and cells incubated 24 hrs prior
to cell lysis and luciferase detection using dual-luciferase reporter assay system (Promega,
Madison, WI) with TD 20/20 luminometer (Turner Biosystems, Sunnyvale, CA). All
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samples were performed in at least quadruplicate and firefly luciferase measurements
were normalized to renilla luciferase readings.
Expression Vectors: The vectors pGL4.10 (promoterless firefly luciferase) and
pGL4.74 (renilla luciferase driven by thymidylate kinase promoter) were acquired from
Promega. We prepared pGL4PSA containing promoter and enhancer regions of the
KLK3 (PSA) gene. A 662 base pair segment of the PSA promoter (-631 to +31),
containing AREI and AREII was obtained by PCR amplification from MDA-MB231
genomic DNA using forward primer (5'-GCG GAG CTC AAT TCC ACA TTG TTT
GCT GCA C-3') and reverse primer (5'-ATA CTC GAG ACT CTC CGG GTG CAG
GTG GTA A-3'), containing SacI and Xhol restriction sites, respectively. The reverse
primer also contains an additional A between the Xhol restriction site and the PSA
promoter sequence in order to prevent creation of a second SacI restriction site following
ligation. An additional 1446 base pair segment of the PSA enhancer (-5321 to -3877,
containing AREIII) was amplified from LNCaP genomic DNA using forward primer
GCG TAT GGT ACC AGA GAT TTT TTG GGG G and reverse primer TAT GCG
GAG CTC GTA TCT GTG TGT CTT CT, containing KpnI and SacI restriction sites,
respectively. The amplified PSA promoter and enhancer regions were ligated in tandem
upstream of the luciferase gene in pGL4. 10. This completed vector was sequenced at the
MIT CCR Biopolymers Laboratory and found to match published human genome
sequence AC011523 except for two substitutions (-4363 G->T, -4264 C->A), both
outside of known ARE's.
AR siRNA: StealthTM Select 3 RNAi against AR was acquired from Invitrogen.
Transfection was performed in PC3-AR cells with Lipofectamine 2000 (Invitrogen)
according to manufacturer protocols. Cells were allowed 24 hrs to efficiently reduce AR
expression prior to adding test compounds, which were left on an additional 24 hrs prior
to counting attached cells. Negative control siRNA used was StealthTM RNAi negative
control Med GC content duplex #2 (Invitrogen).
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Relative Binding Affinity Experiments: Whole cell extracts for use in relative binding
affinity studies were acquired from LNCaP and MDA-MB-453 cells (Veldscholte et al.,
1990). Competitive binding reactions were performed similarly as previously described
(Fang et al., 2003). Samples in duplicate contained 5 nM [3H]-R1881, from 0.1 nM to 10
jtM unlabeled competitor, 125 jtg whole cell extract, and 5% DMF in binding assay
buffer in a total reaction volume of 100 tL. Reactions were mixed and allowed to
incubate at 40C for 18 hours. At this time, 200 jtL of hydroxyapatite (HAP) slurry (50%
HAP in 50 mM Tris, 1 mM EDTA solution) was added, and each reaction was vortexed
in 5 minute intervals for 20 minutes. Samples were then centrifuged at top speed in a
Beckman-Coulter 18 Microfuge for 10 minutes. Supernatants were aspirated, 1 mL of
TE buffer was added to each, and samples were re-homogenized. This cycle of
centrifugation, aspiration, and washing was repeated once more. Finally, 1.3 mL ethanol
was used (in two 650 tL steps) to transfer pellets into 10 mL Ecoscint H (National
Diagnostics, Atlanta, GA) scintillation fluid and counting was performed. The
concentration of unlabeled competitor that resulted in a 50% decrease in [3H]-R1881
binding (ECso) was estimated by non-linear regression analysis (Prism, GraphPad
Software, La Jolla, CA). Relative Binding Affinity (RBA) of the competitor was
calculated as [EC 5o R1881 /EC 5o Competitor] x 100.
In some experiments covalently modified DNA was used as the unlabeled
competitor. This DNA was prepared by allowing 113 or 17a-OH-113 (50 M) to react
with calf thymus DNA (3 mg/ml) in a solution containing 25% DMSO at 370C overnight.
The DNA was then isolated by ethanol precipitation in the presence of 0.1 M NaOAc,
washed three times with 70% EtOH to remove unreacted compound, redissolved in H20
and sonicated to reduce viscosity. The concentrations of adducts in DNA modified by
either isomeric compound were estimated by performing a parallel reaction in which
[14C]-113 was allowed to react with DNA under identical conditions. The amount of
covalently bound radioactivity in the isolated DNA was determined by liquid scintillation
counting and the number of adducts per ptg DNA was calculated based on the specific
activity of the radiolabeled compound.
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Growth Inhibition Assay: Cells for growth inhibition assays were plated in 6-well
dishes and allowed to adhere for 48 hrs prior to treatment for times indicated. Cells were
washed with PBS, trypsinized, and counted with a ZI Coulter Counter (Beckman Coulter,
Fullerton, CA).
Clonogenic Survival Assay: Cells at clonal density were treated by addition of media
containing test compound. Colonies that developed over the subsequent 7-10 day period
were fixed (methanol:acetic acid; 9:1), stained with crystal violet, and washed with
several changes of DI H20. Colonies were counted manually, and experiments were
conducted in triplicate.
[ 14C]-ll Uptake by Cells and Formation of DNA Adducts: Cells in exponential
growth phase were treated for 2 hrs with [14C]-1lp in complete growth media. Drug
containing media was aspirated and cells were washed once each with fresh media and
PBS and then trypsinized and collected by centrifugation. After an additional suspension
in PBS to remove loosely associated 1 10, cells were collected by centrifugation and lysed
by addition of RIPA detergent solution (Santa Cruz). An aliquot of the lysed cell solution
was used for protein determination by the Bradford assay (Bio-Rad, Hercules, CA). The
14C activity in the remaining cell lysate was assayed by liquid scintillation counting.
To determine the amount of [14C]-llp covalently bound to cellular DNA,
identically treated PC3-AR and PC3-Neo cells were resuspended in 0.5 mL of 50 mM
HEPES, 100 mM NaCl, 10 mM EDTA containing 0.7% SDS. After incubation with
RNase A (0.5 mg, 370 C for 30 min) and proteinase K (0.4 mg, 37C for 2 hrs) the
solution was extracted with phenol/chloroform/isoamyl alcohol (25:24:1) and then with
chloroform/isoamyl alcohol (24:1). DNA was isolated by ethanol precipitation and
dissolved in deionized water. For assay of adduct formation in PC3-AR1 and PC3-AR9
cells, RNase A was omitted from initial lysis buffer. In this case, following proteinase
digestion, DNA was isolated by ethanol precipitation, redissolved in TE buffer, and
treated with RNase A (0.5 mg, 37oC, 30 mins). DNA was isolated by ethanol
precipitation, and redissolved in deionized water. DNA concentration was quantified by
UV absorption at 260 nm using a Beckman-Coulter DU730 spectrophotometer. The
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amount of 14C in the DNA sample was then determined by accelerator mass spectrometry
(AMS) analysis as described previously (Hillier et al 2006).
Tandem Mass Spectrometric Quantification of Specific DNA Adducts of 111 and
17a-OH-1103: To measure the relative amounts of guanine and adenine adducts and
guanine:guanine cross-links of 113 and 17ca-OH-113, compounds were incubated with
calf thymus DNA overnight under identical conditions as for creation of adducts for RBA
assays. The DNA was re-purified by ethanol precipitation and subjected to 0.05 N HCI
hydrolysis for 3 hrs to release adducted bases. Samples were separated on a C18
reversed-phase HPLC column, connected in-line with a tandem quadrupole (QQQ) mass
spectrometer (Agilent, Santa Clara, CA). Fragmentor and collision energy settings for
multiple reaction monitoring (MRM) mode were optimized for detection of 11 1-guanine,
11 1-adenine, and 11 p-guanine-guanine crosslink adducts. Standards were obtained by
reaction of calf thymus DNA with 11 as described above, where the appropriate fraction
of acid-hydrolyzed 11 p-nucleobase adduct was monitored by diode array detector and
collected, followed by verification of exact mass on an Agilent ESI-TOF mass
spectrometer.
17ao-OH- 113 had a slightly longer retention time on a reversed-phase HPLC
column than 113, which was demonstrated by reacting DNA with a 1:1 mixture of 113
and 17a-OH-1113, and seeing 2 chromatographic peaks for each G, A, or GG adduct.
Verification that 17a-OH-1113 was eluted later was obtained by chromatography of the
DNA hydrolysate from incubations using exclusively 1113 or 17c-OH-1113. This finding
was unambiguously confirmed by reacting 1113 with 15N-labeled DNA from E. coli
(grown on 15NH4C1 with 100% isotopic abundance at all nucleobase nitrogens), and
mixing it with 17a-OH-1p1 reacted with normal (14N) calf thymus DNA prior to
LC/MS/MS analysis with the appropriate 14N and '5N detection parameters. As expected,
co-injection of 1113 reacted with 14N and 15N DNA gave identical retention times.
Our ability to resolve the G, A, and GG adducts by not only nucleobase, but also
by the structure of the drug for a specific base (perturbations of which were remarkably
minor in some cases, such as a carbonyl vs. hydroxyl within a relatively large steroidal
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compound), allowed us to perform co-incubations of DNA with two compounds to
guarantee identical reaction conditions for a comparative analysis. For detection of
single guanine adducts in MRM mode, the first quadrupole was set up to discriminate for
the +2 charge state at m/z of 407.3 (free guanine base attached to 1113 or 17aX-OH- 111
with one hydrolyzed chloroethyl arm), the second quadrupole was used for collision-
induced decay, and the third quadrupole selected for a product of the +1 charge state at
m/z of 152.1 (free guanine base). When detecting adenine adducts, Q1 selected for the +2
charge state mass at m/z 399.3, while Q3 selected for the +1 charge state at m/z 136.1
(free adenine base). Finally, for detecting guanine-guanine crosslinks, QI selected for +2
charge state mass 474.1, while Q3 selected for +l charge state 152.1.
Reversed-phase separation of adducts was performed on a C18 column, with a
gradient from 10-100% CH 3CN with 0.25% acetic acid over 140 mins at a flow rate of 6
p per minute. The aqueous phase used was 10% CH3CN, 0.25% acetic acid in H20.
Statistics: Significance tests were performed with unpaired 2-tailed student's t-test as
implemented in Excel 2002 (Microsoft, Redmond, WA).
Results
1113 Toxicity to LNCaP Cells Cannot be Competed Away with Ligand for AR
Experiments were conducted to determine whether AR is involved in the
mechanism of toxicity for 1113 toward prostate cancer cells. As a first test of AR
involvement, we attempted to compete for binding of 1113 to AR with 1 tM R1881 in the
sensitive LNCaP prostate cancer cells. 1113 has -10% relative binding affinity (RBA) for
AR in comparison to R1881 (Marquis et al., 2005), so it is anticipated that over the range
of 1113 concentrations from 2.5 jtM to 7.5 jlM, 1 lM R1881 will be successful in
competing a significant quantity of 1113 out of the ligand binding pocket of AR. However,
over the course of the 24 hr treatment, this concentration of R1881 is unable to reduce
toxicity of 1113 (Figure 3.1).
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1113 Has Selective Toxicity to PC3-AR Cells, but Apparently not Due to AR
As a more rigorous method to address AR involvement in 11 p toxicity, isogenic
cells (PC3-AR and PC3-Neo) that differ only in AR expression status were acquired. A
clonogenic assay demonstrated that AR expression increased sensitivity of these cells to
1113 (Figure 3.2), which would be consistent with our original model of 110 action.
Efforts were then made in an attempt to test this conclusion further. These efforts
resulted in data that, on balance, contradicted our original model. First, competition
experiments were conducted with a 1 CiM concentration of R1881, as was performed in
LNCaP cells. In accord with results from LNCaP cells, 1 JpM R1881 was unable to
compete away any of the toxicity of 111 toward PC3-AR cells, in both a growth
inhibition format (Figure 3.3) and in a clonogenic assay (Figure 3.4). In the clonogenic
assay, significant toxicity was achieved with as little as 1 iM 1113, making it very likely
that 1 CiM R1881 successfully saturates AR binding sites and limits 111-AR interaction.
Finally, siRNA was used to knock down AR expression in PC3-AR cells in an attempt to
revert them to the PC3-Neo phenotype. Despite achieving a successful reduction in
steady-state AR protein levels (Figure 3.5), toxicity of 1113 toward the siRNA treated
cells remained unaffected (Figure 3.6).
The level of full length AR expression in the PC3-AR cells is low-several fold
less than in LNCaP cells (Figure S3.1). It is known that over time, most PC3 cells forced
to express AR will begin to lose AR expression. Furthermore, this cell pair as originally
acquired was based on a pooled population. While full-length AR is clearly expressed to
a greater extent in PC3-AR than PC3-Neo cells, the PC3-AR cells also express an -42
kDa band that is detected by two separate antibodies to AR and is repressed by AR
siRNA (Figure 3.5). As such, this band is likely an AR fragment. Both antibodies used
to detect AR were directed toward the N-terminal domain, but more specific identity of
this "truncated AR" is unknown. Since the population was originally heterogeneous, we
selected several clones to identify those with greatest AR expression and then chose a
single clone with which to work. In all cases, the 42 kDa band persisted. Heightened
sensitivity to 1101 remained, however.
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Despite the low level of full length AR expression in PC3-AR cells, the AR that is
expressed in these cells is functional, increasing transcription of a luciferase reporter
downstream of PSA promoter/enhancer upon induction with androgen (Figure S3.2).
However, unlike LNCaP cells, in which AR protein levels are decreased upon 11 3
treatment, PC3-AR cells respond to 11 p treatment with dramatic increases in AR protein
expression (Figure S3.3A). In sum, while 11[3 was clearly more toxic to PC3-AR cells
than PC3-Neo cells, results of competitive binding and AR siRNA experiments
demonstrate that differential sensitivity is apparently not related to AR expression.
We also measured DNA adduct formation by [14C]-11 in PC3-AR and PC3-Neo
cells as a first step to determine whether AR presence could influence adduct formation.
First, the level of 1 p that was able to get into each cell line was assessed, finding
equivalent association of 11 3 with both PC3-AR and PC3-Neo cells (Figure 3.7A).
However, assessment of adduct formation by accelerator mass spectrometry (AMS)
clearly demonstrated an -2-fold greater adduct burden in PC3-AR cells over that seen in
PC3-Neo (Figure 3.7B).
110 Toxicity is not Affected by AR Expression in PC3-AR1/AR9 Cell Pair
Due to the unexpected effects that are unrelated to AR presence in PC3-AR and
PC3-Neo cells, a separate isogenic pair, (PC3-ARI (AR-) and PC3-AR9 (AR+)), was
acquired. Each of these cell lines displayed equivalent sensitivity to treatment with 11 [3
(Figure 3.8). Furthermore, the level of AR expression, while still less than in LNCaP cells,
was significantly greater than seen in PC3-AR cells (Figure 3.9). Western blotting
detected only full length AR protein in PC3-AR9 cells, making the AR9/AR1 pair a
better model for study. Since the PC3-AR1 cells were equally as sensitive as PC3-AR9
cells to 11 , AR presence does not have an effect on toxicity in these PC3 cells.
DNA Adduct formation was also monitored in PC3-AR1 and PC3-AR9 cells.
There was a greater association of 11 [3 with the AR negative PC3-AR1 cells than with the
AR9 cells (Figure 3.10A). In line with the greater accumulation of 1103 in PC3-AR1 cells,
these cells also acquired a greater quantity of 11 [3-DNA adducts (Figure 3.10B). The
increase in DNA adducts formed in PC3-ARI cells is directly proportional to the
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increased association of 1113 with these cells. Since the quantity of adducts formed in
PC3-AR1 and PC3-AR9 cells matches closely with the quantity of compound that was
able to get into cells, it does not appear that presence of AR has influenced adduct burden.
Synthesis of 17a-OH-110, a New 111 Compound with Reduced AR Binding Affinity
As an additional chemical means to address AR involvement in 1113 toxicity
toward prostate cancer cells, a similar compound with reduced affinity for AR was
synthesized. The 17-hydroxyl group on the steroid backbone was epimerized from P to a
(S to R) stereochemistry by Mitsunobu inversion (Dodge and Lugar, 1996; TapolcsAnyi et
al., 2004) (Scheme 3.1). After inversion, rigorous 2D NMR analysis was used to ensure
correct stereochemistry at this position. A combination of 'H, 13C, two-dimensional
gradient-selected correlation spectroscopy (gCOSY), heteronuclear single quantum
coherence (HSQC), and gradient-selected heteronuclear multiple bond correlation
(gHMBC) NMR experiments were performed in order to make complete structural NMR
assignments (Table 3.1). In the 'H and 13C NMR spectra, differences between the 17a-
OH and 17-OH compounds were consistent with those reported in the literature for 17-
OH epimeric sterols (Eggert et al. 1976; Ciuffreda et al. 2004). The resonance of H-18 at
8 0.83 in the 17a molecule was shifted upfield in comparison to the 171 isomer (H-18, 6
0.91). In the 13C NMR spectrum, the C-18 resonance at 6 10.69 for the 0 isomer was
shifted downfield to 8 16.59 in the 17a-OH compound. In addition, we confirmed
positional assignments using 2D gHMBC to identify long-range couplings between 'H
and '3C atoms. Strong couplings were observed between H-17---C-12 and H-17--+C-18
in the 17P-OH isomer (Figure 3.11). The heteronuclear coupling between H-17--+C-12
was absent or much weaker in the 17cc-OH molecule, while increased coupling was seen
between H-17--+C-14, and H-17--+C-15, demonstrating successful steroid epimerization.
(Figure 3.12). The gHMBC observations are consistent with molecular models in which
the dihedral angle between H-17 and C-14 in the 170 isomer is approximately 800,
resulting in weak heteronuclear coupling, while in the 17a-OH configuration, the dihedral
angle between these nuclei is 1600 and allows strong coupling to occur. A similar
situation occurs for the dihedral angle between C-12 and H-17, which is approximately
900 for 17a-OH and -30 ° for 17P-OH compounds.
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17a-OH-110 Displays Reduced Affinity to AR
In order to determine whether inversion of the 17-alcohol within the steroid
nucleus of 1113 successfully reduced affinity to AR, the ability of both isomers to
compete with [3H]-R1881 for binding to AR in cell extracts was measured. Extracts were
prepared from LNCaP cells that express mutant AR (T877A) or MDA-MB-453 cells that
express wild-type AR. Both compounds were able to compete away [3H]-R1881 for
binding to AR in either cell extract. With LNCaP extracts, 11 3 was shown to have an
RBA compared to R1881 of 15.5, similar to the previously reported value (Marquis et al.,
2005), while 17a-OH-1113 had -10-fold lower RBA of 1.91 (Figure 3.13). With the
wild-type AR expressed in MDA-MB-453 extracts, 1113 was determined to have an RBA
of 5.31, which is slightly lower than in LNCaP, but still very significant. Once again,
17c-OH-1113 displayed -10-fold less affinity than 111, with an RBA of 0.51 (Figure
3.14).
17a-OH-110 is a Weaker AR Antagonist than 113
A luciferase transcriptional reporter assay driven by the PSA promoter/enhancer
was used to determine whether epimerization of the steroid portion of 1113, which
reduced affinity to AR, also resulted in a depressed ability to affect AR-mediated
transcription. Neither 1113 nor 17a-OH-1113 demonstrated very substantial agonistic
activity in the luciferase assay. However, both compounds were significantly
antagonistic toward AR activity (Figure 3.15). Importantly, 1113 was more active as an
antagonist than 17ac-OH-1113, demonstrating that the difference in affinity to AR between
the two compounds is enough to result in a measurably different biological response.
DNA Adducts of 17a-OH-113 Have Lower Affinity to AR than DNA Adducts of 1113
As the designed mechanism of toxicity is the formation of DNA adducts which
will then bind AR, we next measured the relative binding affinity of DNA adducts of 1113
and 17ao-OH- 113P for AR. Compounds were incubated with calf thymus DNA overnight
prior to re-purification of DNA and use as competitors in AR RBA assays. In parallel,
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DNA was treated with [14C]-113 isolated in the same manner, and adducts were
quantified by AMS. Based on the very minor modification made to 11 3 in creating 17a-
OH-11 3p, adduct formation was assumed to be the same. Adduct concentrations used in
the RBA assay were estimated from formation of adducts by radiolabeled compound.
While both compounds formed adducts that displayed significantly lower binding affinity
than their respective free compounds, the approximately 10-fold difference in affinity
between them was maintained (Figure 3.16).
17c-OH-113 is Less Toxic to Cells than 111
Both 11 3 and 17oa-OH- 11 3 were tested for toxicity toward several cell lines. It
was initially anticipated that by reducing affinity of the compounds for AR, toxicity
toward cells expressing the protein would be reduced, and this was confirmed. 113
proved more toxic than 17a-OH-113 to PC3-AR and MDA-MB-453 cells, both
expressing wild-type AR, in a clonogenic survival assay (Figure 3.17A,B). Additionally,
11 3 proved to be slightly more toxic than 17a-OH- 11 3 to LNCaP cells grown for 5 days
in the presence of each compound (Figure 3.17C). However, 11p was also more toxic
than 17ac-OH-113 toward AR negative PC3-Neo cells (Figure 3.17D), suggesting that
factors other than diminished interaction with AR protein were responsible for the
differential toxicity of the two compounds in cells that do express AR.
111 Forms More DNA Adducts than 17a-OH-110 in vitro
To ensure that compounds formed the same quantity of DNA adducts, each was
reacted overnight with calf thymus DNA, which was then re-purified and acid hydrolyzed
to release adducted bases. These bases were analyzed by tandem quadrupole mass
spectrometry (QQQ), and adducts to guanine, adenine, or cross-links of guanine-guanine
were detected. Surprisingly, it was shown that 11 3 forms almost twice as many guanine
adducts as 17a-OH-113P (Figure 3.18). In agreement with this observation, the level of
guanine:guanine cross-links was also significantly higher from 1103 treatment than 17a-
OH-11 3 treatment (Figure 3.18). However, formation of adenine adducts occurred to an
equivalent extent with both compounds, suggesting that interaction of the compounds
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with DNA affected the pattern of reactivity (Figure 3.19). Because adducts of 17a-OH-
11 had slightly longer retention times during reversed-phase HPLC than adducts of 11 P,
we were able to perform analysis by co-administering each compound to calf thymus
DNA, ensuring identical reaction conditions. Furthermore, we verified that the different
formation of adducts was a real event, as HPLC separation of adducts using a UV
detector results in a similar differential between compounds (Figure 3.20). The
extinction coefficients for both compounds are equivalent. The relative quantity of
guanine adducts to adenine adducts formed is approximately 3 for 11 p and approximately
2 for 17a-OH-11 3. As such, the total adduct burden will likely be greater to cells treated
with 11 3, and it seems that the differential toxicity of 11 p and 17a-OH- 11 displayed
toward various cell lines can most easily be explained by this greater DNA adduct burden.
Discussion
The experiments reported here sought to address by multiple means whether the
presence of AR in prostate cancer cell lines was responsible for selective toxicity toward
xenografted tumors (Marquis et al., 2005). LNCaP has been a model cell line of choice
in previous studies, and attempts were first made in these cells to determine if AR
involvement enhanced toxicity of 11 3. However, LNCaP cells depend on AR presence
and activity for survival (Eder et al. 2000; Liao et al. 2005). Thus, it is difficult to
perform AR siRNA experiments to determine what effect 11 3 would have on these cells
in the absence of AR. The most reliable test that can be performed involves the
competition for binding to AR with a large quantity of the synthetic AR ligand R1881.
We were unable to relieve any of the toxicity of 11 3 toward LNCaP cells by competing
for AR binding with 1 LM R1881. Based on R1881 having a 10-fold greater affinity for
AR than 1113, a 1 pM concentration should minimize interaction of 11 p and AR over a
concentration range of 2.5 - 7.5 jiM, where toxicity is evident. As such, it is unlikely
that the direct interaction of 11 with the AR is responsible for its toxicity toward these
cells.
An additional means of determining if AR involvement could be a factor in
toxicity of 11 3 involved the use of isogenic cell lines that differ only in AR expression.
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These cells are all based on the parental PC3 prostate cancer lines, which have lost
expression of AR during disease progression (Tilley et al., 1990). They are thus AR-
independent and do not require androgens for survival. This is an advantage because it
allows for a greater level of manipulation such as use of AR siRNA, as well as the
measurement of effects that are independent of AR antagonism. AR-independent cells
are most useful as a test of our theorized "repair shielding" mechanism, which states that
AR associated with damaged DNA would preclude access of repair enzymes, leading to
adduct persistence and cell death.
Initial results were tantalizing; we saw greater toxicity of 11 3 toward PC3-AR
cells than PC3-Neo cells. However, follow-up experiments involving competition with
R1881 and the repression of AR expression by siRNA did not revert the sensitive
phenotype. It must then be the case that the presence of AR is not the only difference
between the cell lines, and that AR is not responsible for the differential sensitivity to 11 3.
Potentially, during cell line creation, the AR gene may have inserted randomly into the
coding sequence of another gene, such as one involved in DNA repair, and it might have
been the lack of DNA repair capacity, for example, that heightened the sensitivity of
PC3-AR cells to 11 p3. Further studies would be necessary to fully address the source of
differential sensitivity between these cell lines.
A previous study with this cell pair determined that PC3-AR cells were more
sensitive than PC3-Neo cells to the agent emodin, which correlated with decreased
association of AR with Hsp90 and increased association with the ubiquitin ligase Mdm2,
which promoted proteasomal degradation (Cha et al. 2005). However, the mechanism
ultimately leading to these effects is unknown. Emodin is a known tyrosine kinase
inhibitor (Zhang et al. 1995) and can increase reactive oxygen species (ROS) levels and
inhibit NFkB and AP-1 activity (Yi et al., 2004), but is not known to interact directly
with the AR. With regard to selective toxicity of emodin toward AR positive cells, this
explanation is appropriate for cells which depend on AR expression for growth and
survival. In the case of the PC3-AR cells, however, AR is not required for growth, and a
different explanation for their heightened sensitivity is required, but is not provided.
The low level of AR expression and presence of a protein that is likely a truncated
AR ultimately made these cells a non-ideal model of study. However, it was still
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pertinent to identify whether the impressive differential sensitivity between PC3-AR and
PC3-Neo cells was related to AR. It was clearly demonstrated that AR was not the
governing factor driving this differential sensitivity.
We also addressed whether differential uptake or DNA adduct formation could
explain the toxicity differences seen in PC3-AR and PC3-Neo cells. While 113 was
associated to an equivalent extent in each cell line, the adduct level was found to be
higher in PC3-AR cells. During the course of treatment (2 hrs), there was no discernible
difference in growth of either cell line, and the 11 concentration that was used resulted
in greater than 80% viability (data not shown). It is not clear whether the greater level of
DNA damage seen in PC3-AR cells is due to increased formation of adducts, decreased
repair, or both. Whatever the cause, the increased DNA adduct burden seen in PC3-AR
cells provides a reasonable explanation for their heightened sensitivity. However,
considering the finding that AR repression with siRNA did not relieve toxicity to PC3-
AR cells, we find it unlikely that the adduct level is directly related to AR expression,
although this possibility was not rigorously addressed in siRNA treated cells.
A separate pair of AR +/- isogenic cell lines, PC3-AR9 and PC3-AR1, displayed
equal sensitivity to 11 3, making it clear that in these cells, which also do not require the
AR for their survival, 1113 toxicity is not affected by presence or absence of AR.
Furthermore, this isogenic pair was a better model of study due to greater expression of
AR protein and existence of a single, full-length immunoreactive band. Equal sensitivity
suggests once again that it is unlikely for repair shielding with the AR to be a viable
mechanism of 1113 toxicity.
DNA adduct formation in PC3-AR9 and PC3-AR1 cells was tested, and an
opposite scenario from that seen in the PC3-AR/Neo pair was discovered. Slightly more
compound was able to enter the AR null PC3-AR1 cells, which led to a proportionally
greater level of DNA adducts. Since the increased uptake of 1113 into PC3-AR1 cells led
to a proportional increase in DNA adducts, it is suggested that AR presence is not
responsible for greater formation or hindered repair of adducts. If anything, the presence
of AR has limited the formation of 11 1-DNA adducts. Interestingly, as the DNA adduct
formation in PC3-AR9/AR1 cells did not correlate with sensitivity to 1113, other unknown
factors are implicated.
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In all AR expressing PC3 sublines tested (PC3-AR, PC3-AR9, and A103), 1113
causes an increase in the level of immunoreactive AR protein. This is in direct contrast
to the situation occurring in LNCaP cells discussed in Chapter 2. Those experiments
demonstrated that 1113 caused a decrease in AR protein consistent with enhanced
proteasomal degradation. The AR expressed in PC3 sublines is under the control of a
cytomegalovirus (CMV) promoter, which was previously shown to respond to various
stress factors by increasing transcription of the downstream gene (Bruening et al., 1998).
Thus, it may be that cell stress caused by 1113, mediated through pathways such as JNK,
p38, or NFkB, leads to increased transcription of AR in PC3-AR sublines. In further
support of this hypothesis, we have shown that in A103 cells, 110 up-regulates AR
expression at both the protein and mRNA levels (Figure S3.3B,C).
The chemical synthesis of 17a-OH-1113 represented a different angle of attack for
determining relative involvement of AR in toxicity of 1113. Consistent with the literature
(Fang et al., 2003), inversion of the 17-OH stereocenter led to reduced affinity for AR.
However, the loss of affinity was less than anticipated-approximately 10-fold where
epimerization of testosterone or estradiol resulted in 200-fold affinity loss. The
explanation for less impact on binding affinity resulting from alcohol inversion in 1113 is
not entirely clear. In the LNCaP AR, T877A mutation leads to loss of one of two
hydrogen bond partners to the 17P-OH group of androgens, and it might be anticipated
that the binding of 17a-OH steroids to this receptor would not be as significantly reduced
as a result. However, the differential affinity between 1103 and 17a-OH- 1113 is similar,
whether LNCaP (T877A AR) or MDA-MB-453 (WT AR) extract is used as the source of
AR.
Interestingly, the story is slightly different for the dienone steroids lacking any
attachment at the 11-position. The 17P-OH dienone has only a 5-fold greater binding
affinity than the 17a-OH dienone to LNCaP AR, but a 25-fold greater binding affinity to
WT AR (data not shown). Based on this information, the most logical explanation is that
the bulky linker that extends from the steroid nucleus of 1113 limits the conformational
flexibility available to the steroid portion of the molecule. Based on the x-ray structures
of the AR LBD and comparison to the highly homologous ER LBD in complex with
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ICI 164384, which has similar alkyl extension from the steroid nucleus (Chapter 1,
Figure 1.6), it is likely that the linker of 1113 must extend through a pore where helix 12
would normally close in an agonist conformation. As such, the steroid portion of 1113
may be "locked" into a conformation that does not maximize use of hydrogen bond
partners T877 and N705 at the 17 position. If this is true, inversion of the 17-OH
stereocenter would not reduce affinity as greatly as when the steroid is allowed more
conformational flexibility and the 1713-OH can optimally hydrogen-bond. Nonetheless,
the affinity difference between 11 and 17a-OH-1113 was great enough to result in a
measurably different ability to interfere with AR transcriptional activity (1 pM of 11 p
and 17ac-OH- 11 P antagonize -47% and - 19%, respectively, of the transcriptional activity
induced by 1 nM DHT).
11 3 proved to have greater toxicity than 17a-OH-1113 toward several cell lines.
However, these included the PC3-Neo cells which do not express AR, raising suspicion
that there was another variable at play. In light of this finding, we formally tested the
ability of each compound to form DNA adducts. Compounds and associated adducts
have slightly different retention times on HPLC, and with a slow gradient, individual
adducts can be separated enough for quantification. With this attribute, we were able to
co-incubate the compounds with calf thymus DNA and quantify guanine, adenine, and
guanine:guanine adducts of both compounds by QQQ. As it turned out, 1113 formed
almost twice as many guanine and guanine:guanine adducts as 17ca-OH- 113P, while both
compounds formed an equivalent amount of adenine adducts. The co-incubation of
compounds ensured identical reaction conditions. The fact that the guanine/adenine
adduct ratio is different for the two compounds (3.5:1 for 1113, 1.8:1 for 17a-OH-113)
suggests that there is a non-covalent interaction of the compounds with DNA that is able
to affect their ability to form covalent DNA adducts. Furthermore, the greater level of
guanine adducts in each species ultimately means that total adduct formation will be
greater from 11 3 than from 17ac-OH- 113.
Successful testing of relative adduct levels in living cells requires refinement to
address issues of sensitivity, and attempts are ongoing to acquire these data. If we
assume that adduct formation in cells follows the same trends seen in vitro, 113 will
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result in approximately 60% greater total adducts than 17oa-OH-11 3. Furthermore, the
greater level of guanine:guanine cross-links, which are believed to be much more lethal
than mono-adducts, may create a greater disparity than the total adduct burden would
belie. As such, it seems likely that the relatively small differences in sensitivity between
cells treated with 111 or 17a-OH-113 can most easily be attributed to the relative
reactivity of each compound toward DNA, rather than their relative interaction with AR.
The bulk of data collected do not support the hypothesis that AR is a factor in the
mechanism of 113 toxicity. The experiments conducted in PC3 sublines especially
demonstrate that in cell lines that do not depend on AR signaling for survival, toxicity of
1113 is unaffected by AR. This strongly argues against the repair shielding mechanism of
113 toxicity. Between the inability to rescue toxicity of 113 with R1881 and the
relatively small differential toxicity of 113 and 17o-OH- 111 toward LNCaP cell lines,
which can probably be explained most easily by less adduct formation, there is little
support for involvement of AR in toxicity toward LNCaP cells either. However, to
achieve toxicity to LNCaP cells, it is necessary to use micromolar concentrations of 11 .
Given that 113 has roughly 10% the RBA of R1881 for AR, 1 jtM R1881 cannot be
guaranteed to out-compete 113 for binding to AR. Thus, interaction of 11 P with AR may
still occur under these conditions and influence toxicity.
Furthermore, the difference in RBA between 113 and 17a-OH-1p1 is not
outstanding. While a reduced ability to antagonize AR-driven transcription is
demonstrable, 17-OH-113 still retains modest antagonistic activity. It is not therefore a
binary system in which one compound interacts with and influences AR and the other
does not. Unfortunately, a greater reduction in the affinity of 113 for AR is not possible
without significant modification to the steroid moiety. The finding that modification
within the steroid nucleus can affect the compound's ability to damage DNA introduces
another possible confounding factor. With this molecule, it seems that the reduced ability
to damage DNA and the property that it forms a qualitatively different adduct population
(favoring damage of adenines) provide simple explanations for the generally reduced
toxicity. However, since at least two variables were changed in creation of 17a-OH-
11 3 (affinity to AR and DNA damage capacity), we can not rule out the influence of AR
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expression on toxicity of 11 3, so long as the cells being tested depend on this protein for
growth and survival.
In Chapter 2, results showed that 11 could antagonize AR transcriptional activity
in LNCaP cells and even reduce total cellular levels of AR protein in LNCaP,
CWR22Rv 1, and C4-2B cells. While it is difficult to address whether these observations
play causal roles in cell death, it seems that they can only add to overall toxicity when
AR activity is so tightly linked with growth and survival.
The AR is involved in progression through the prostate cancer cell cycle, acting as
a master regulator of the GI/S transition (Knudsen et al. 1998). This is accomplished
through mTOR-dependent increased translation of cyclin D (Xu et al. 2006), through
induction of p21 (Lu et al. 1999) , and by degradation of p27 (Lu et al. 2002), which is
related to persistence of its E3 ubiquitin ligase Skp2 (Wang et al. 2008). As a result of
AR involvement in progression through the cell cycle, its involvement in toxicity can be
complicated. For instance, it has been shown that androgen ablative therapies can hinder
success of taxane-based therapy (Hess-Wilson et al., 2006), despite taxane therapy not
formally utilizing the AR in its mechanism of action. Alternatively, it was shown that
genotoxic agents can limit AR transcriptional activity and could thus increase
effectiveness against prostate cancers via this unexpected mechanism (Mantoni et al.
2006). Based on these findings, and given that 1113 has a demonstrable effect of
antagonizing AR transcriptional activity, the possibility remains that interaction of 11 p
with the AR can increase overall toxicity. Furthermore, it is increasingly apparent that
even in hormone-refractory prostate cancers that no longer require androgens for growth
and survival, the AR protein remains extremely important (Liao et al. 2005; Burnstein
2005; Compagno et al. 2007; Yuan et al. 2006). Since 1113 is able to decrease the
steady-state levels of AR protein in LNCaP, CWR22Rvl, and C4-2B cells, cell cycle
progression is likely to be limited as a result.
It is apparent, however, that 11 3 also causes toxicity that is independent of AR, as
it can kill prostate cancer cells that lack AR without need of significantly increased drug
concentrations. Furthermore, the compound is very toxic to HeLa cells, which do not
express AR (Bogdan Fedeles, unpublished results), and is able to inhibit the growth of
HeLa xenograft tumors (Dr. Shawn Hillier, unpublished results) similarly as the
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inhibition of LNCaP xenogafts. Therefore, other mechanisms responsible for toxicity
will be explored in the subsequent chapter.
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LNCaP Cells are Not Rescued from
113 by Addition of AR Ligand
S1001-
Plated Density
0.0 2.5 5.0 7.5
Concentration 11p (PM)
Fig 3.1
toward
Growth inhibition assay comparing toxicity of 110
LNCaP cells, performed with and without addition of
R1881. Cells were treated for 24 hrs and then counted.
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110 is More Toxic to AR Positive
PC3-AR Cells than AR Negative
PC3-Neo Cells
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Cn
"0
10,
-PC3-Neo
-- PC3-AR
0 1 2 3
Concentration 110 (pM)
Fig 3.2 Clonogenic survival assay. PC3-Neo (AR -) and PC3-
AR (AR +) cells were plated at clonal density, treated as shown,
and colonies were manually counted after 7-10 days growth.
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PC3-AR Cells are Not Rescued
by Addition of AR Ligand
(Growth Inhibition)
0
0
0O
O
100.
10.
1'
0.1--
0.0 2.5 5.0 7.5 10.0
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Fig 3.3 Growth inhibition assay comparing toxicity of 113
toward PC3-AR (AR -) cells with and without addition of AR
ligand. Cells were treated for 24 hrs and then counted.
Treatment was performed in normal media supplemented with
10% FBS, or in media supplemented with 10% charcoal-dextran
treated FBS, either with or without addition of 1 iM R1881.
PC3-Neo cells are shown for comparison.
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PC3-AR Cells are Not Rescued
by Addition of AR Ligand
(Clonogenic Survival Assay)
II
L
3
Cn
O
0.00 0.25 0.50 0.75 1.00
Concentration 1113 (pM)
Fig 3.4 Clonogenic survival assay. PC3-AR cells were plated
at clonal density and treated 48 hrs later with 11 3 at
concentrations shown, with or without addition of 1 pM R1881,
in CDTFBS media. After 7-10 days of continuous exposure to
compounds, colonies were manually counted.
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AR siRNA Effectively Knocks Down
AR Level in PC3-AR cells
Full length AR -- 4
Cross-reactive
AR bands
Unt Neg
Ctri
AR
siRNA
PC3-
neo
Fig 3.5 Western blot showing immunoreactive AR bands in
PC3-AR cells, untreated or treated with negative control or AR
siRNA. Sample from PC3-Neo cells is shown for comparison.
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AR siRNA Does Not Alleviate
1113 Toxicity to PC3-AR Cells
0
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-PC3-AR siRNA
S- PC3-AR Neg Ctrl
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Concentration 1113 (pM)
Fig
AR
3.6 Growth inhibition assay. PC3-AR cells were treated with
or negative control siRNA for 24 hrs prior to treatment with
11 13. After 24 hrs of treatment, cells were counted.
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11 Forms More DNA Adducts in
PC3-AR Cells than PC3-Neo Cells
B.
AR Neo
LM
0
Ma aMa000~
AR Neo
Fig 3.7 Analysis of 1113 uptake and DNA adduct formation. A and B: PC3-
AR and PC3-Neo cells were treated with 1.5 jIM [14C]113 for 2 hrs before
lysis and scintillation counting (A), or DNA isolation and AMS analysis (B).
Error bars are +/- SEM. **p-val < 0.01.
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11i is Equally Toxic to the Isogenic
AR+/- Cell Pair AR9/AR1
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Concentration 110p (piM)
Fig 3.8 Growth inhibition assay. PC3-AR1 (AR -) and PC3-AR9
(AR +) cells were treated with 113 at concentrations shown for
72 hrs before counting. Western blot of immunoreactive AR
(from 20 Vtg total protein extract) in each cell line is shown.
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PC3-AR9 Cells Express Significant
AR; AR1 Cells Express None
LNCaP AR9 AR1
Fig 3.9 Western blot for AR in LNCaP,
cells. Equal quantities of total protein
loaded in each lane.
PC3-AR9, and PC3-AR1
extract (20 gg) were
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11J3 Forms More DNA Adducts in
PC3-AR1 (AR-) Cells than PC3-
AR9 (AR+) Cells
B.
La
"0(U)
"o o
<-
't'-"
AR9 AR1 (-)
Fig 3.10 Analysis of 110 uptake and DNA adduct formation. A and B:
PC3-AR9 (AR+) and PC3-AR1 (AR-) cells were treated with 0.4 gM [14C]-
110 for 2 hrs before lysis and scintillation counting (A), or DNA isolation
and AMS analysis (B). Error bars are +/- SEM. *p-val < 0.1.
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18 OH
170 dienone 17a dienone
Atom 1H shift(s) 13C shift 'H shift(s) 13C shift
1 2.90, 2.54 26.04 2.91, 2.55 26.11
2 2.47, 2.44 37.32 2.48, 2.45 37.37
3 - 200.04 - 200.13
4 5.68 122.35 5.68 122.25
5 - 157.52 - 157.69
6 2.41, 2.36 30.83 2.42, 2.36 31.06
7 1.90, 1.26 27.31 1.95, 1.36 28.00
8 2.24 39.57 2.22 39.69
9 - 146.52 - 146.63
10 - 125.68 - 125.55
11
12
13
14
15
16
17
18
2.82, 2.15 25.84 2.86, 2.18 25.70
- 43.06
51.29
23.63
2.12, 1.53 31.01
81.56
Table 3.1 Complete NMR assignment of 171-OH and 17o-OH
dienones. The most significant differences between the stereo-
isomers are highlighted in gray. Steroid numbering scheme is
shown above table for reference (1713-OH isomer).
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Fig 3.11 2D gHMBC
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gHMBC Plot for 17a Dienone;
Alcohol Inversion is Successful
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Fig 3.12 2D gHMBC NMR for 17a dienone shows significant
cross-coupling between H17 and C14, C15, and C18, having
lost coupling to C12 upon alcohol inversion.
171
4
4
1 II . . . .I I I I I
- .811job- - - - -.... LI
I I I I I I
- Chapter 3 -
17a-OH-11P Has Less Affinity than
113 for AR of LNCaP Cells
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Fig 3.13 Competitive binding assay using LNCaP extracts (AR
T877A Mutant). Extracts were incubated with 5 nM [3H]-R1881
in the presence of competitors at concentrations shown, at 40C
for 18 hrs prior to isolation of total protein and liquid scintillation
counting. Relative binding affinity: R1881=100, 11P1=15.5, 17a-
OH-113=1.91; 17o-OH-1113 has 12.3% RBA of 1113 for LNCaP
AR.
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17a-OH-11 Has Less Affinity than
110 for AR of MDA-MB-453 Cells
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Fig 3.14 Competitive binding assay using MDA-MB-453
extracts (WT AR). Extracts were incubated with 5 nM [3H]-
R1881 in the presence of competitors at concentrations shown,
at 40C for 18 hrs prior to isolation of total protein and liquid
scintillation counting. Relative binding affinity: R1881=100,
11 P=5.31, 17a-OH-113=0.51; 17a-OH-11P has 9.59% RBA of
1113 for WT AR.
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AR Transcriptional Reporter Assay
Shows that 17a-OH-110 is a Weaker
AR Antagonist than 1103
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Fig 3.15 Luciferase reporter assay. LNCaP cells were transfected with
plasmids pGL4PSA and pGL4.74 before treatment for 24 hrs with
compounds shown in androgen-depleted media. Bic = bicalutamide, 10
jIM; 17a=17a-OH-11 P. In antagonist testing, DHT = 1 nM, 11p and 17a-
OH-11P are 1 pM. Error bars are +/- SEM. **p-val < 0.01 (DHT is
compared to DMSO, DHT + 113, 17a, or bic is with reference to DHT).
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DNA Adducts of 17a-OH-11P Have
Lower Affinity to AR than 11i Adducts
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Fig 3.16 Competitive binding assay was used to determine
affinity of 1113 and 17a-OH-110 DNA adducts for AR of LNCaP
extracts. Extracts were incubated with 5 nM [3H]-R1881 in the
presence of competitors at concentrations shown, at 40C for
18hrs prior to isolation of total protein and liquid scintillation
counting. RBA's: R1881=100, Adducts of 1113=0.11, Adducts of
17a-OH-1113=0.008; 17a-OH-110 adducts have 6.7% affinity of
1113 adducts for AR of LNCaP cells. See materials and methods
for information regarding adduct formation and quantitation.
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11ip is More Toxic than 17a-OH-113
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Fig 3.17 Toxicity of 110 and 17c-OH-1113 measured in PC3-AR
(A), MDA-MB-453 (B), LNCaP (C), and PC3-Neo cells (D). For
A, B, and D, cells were treated at clonal density with
concentrations of compound shown and then allowed to form
colonies over 7-10 days before fixing, staining, and counting.
For C, LNCaP cells were treated as shown for 5 days prior to
counting attached cells.
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110 Forms More Guanine Adducts
and Guanine:Guanine Cross-links
than 17a-OH-11 in vitro
52 52.5 53 53.5 54 54.5 55 55.5 56 56.5 57 57.5 58 58.5
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Fig 3.18 Adduction of calf thymus DNA by 110 and 17a-OH-11P3. DNA
was co-incubated with both compounds overnight, re-purified, and acid
hydrolyzed to release adducted bases. Bases were analyzed by
LC/tandem mass spectrometry to quantify compounds adducted to a
single guanine base or guanine:guanine cross-links.
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11P Forms an Equal Quantity of
Adenine Adducts as 17a-OH-11P in
vitro
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Fig 3.19 Adduction of calf thymus DNA by 110 and 17a-OH-113.
DNA was co-incubated with both compounds overnight, re-
purified, and acid hydrolyzed to release adducted bases. Bases
were analyzed by LC/tandem mass spectrometry to identify
compounds adducted to a single adenine base. Relative
abundance of adenine adducts compared to guanine adducts
(Figure 3.17) was independently verified by UV absorbance.
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HPLC Confirms Greater DNA
Adduct Formation by 113
23.0022.75
Minutes
Fig 3.20 HPLC traces of hydrolyzed DNA bases adducted with 11 p or 17a-OH-1 P1. Calf thymus DNA
was reacted with 11 p (A), 17a-OH-1 1 (B), or a combination of the two (C), prior to purification of DNA,
acid hydrolysis to remove bases, and analysis on reversed-phase HPLC with monitoring at 254nm.
Area under the curve (AUC) for major adduct, 22.99 minutes, is 2,350,997; AUC for 17a-OH-11 P-
guanine, 23.32 minutes, is 1,969,266.
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AR Protein Expression is Increased
by 113 Treatment in PC3-AR Cells
Full-length
AR
Unt 11p3
Fig S3.1 Western blot for AR in LNCaP and PC3-AR cells. Cells were
either untreated or treated with 5 !tM 11P for 24 hrs. 20 tg LNCaP whole
cell extract or 66.6 ig PC3-AR whole cell extract were loaded per lane.
Membrane was overexposed to bring out full-length AR expression in
untreated PC3-AR cells.
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AR Protein Expressed in PC3-AR
Cells is a Functional Transcription
Factor
L )
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Fig S3.2 Luciferase assay performed in PC3-AR cells. Cells were
transfected with pGL4PSA and PGL4.74. After 24 hrs, cells were
changed to CDTFBS media, and after an additional 24 hrs, treated with
compounds indicated for 24 hrs before assaying firefly and renilla
luciferase. Error bars are +/- SEM. *p-val < 0.05, **p-val < 0.01.
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AR Protein Expression is Increased
by 113 Treatment in PC3-AR9 and
A103 Cells
A.
AR1 AR9
5 5 5 5 5
3 6 9 15 24
B.
t (hrs) 0 3 6 9 18
AR
Actin
C.
0 3 6 9 15 24
Time (hrs)
Fig S3.3 Analysis of AR protein and mRNA expression in PC3 cells
expressing AR protein. A. Western blot for AR in PC3-AR9 (AR+) cells
treated with 11P, at concentrations and times indicated. PC3-AR1 (AR-)
cells are shown for comparison. B. Western blot for AR protein in A103
cells treated with 5 pM 11 P for times indicated. C. RT-PCR for AR mRNA
in A103 cells treated with 5 ptM 11p. Error bars are +/- SEM. *p-val <
0.05.
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Chapter 4: Global Transcriptional Response of
LNCaP Cells to 111 Treatment
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Introduction
The work discussed here pertains to 11 31', which can form sites of DNA damage
that attract the androgen receptor (AR) (Marquis et al. 2005; Hillier et al. 2006). The
ability of 11 3 to repress strongly the growth of LNCaP xenograft tumors in NIH Swiss
nu/nu mice with low collateral toxicity has demonstrated the potential use of 11 3 as a
prostate cancer therapeutic agent (Marquis et al. 2005; Hillier et al. 2006). Furthermore,
11 is capable of eliciting apoptosis in LNCaP cells within -15 hrs of treatment, while a
control compound, 11 p3-dimethoxy, which lacks the ability to damage DNA, is incapable
of apoptotic induction at similar concentrations (Marquis et al. 2005). Initially it was
thought that 1113 would induce toxicity in a manner that is strongly if not entirely
dependent on the AR. It came as a surprise, therefore, that 1113 is very effective at
preventing growth of HeLa xenograft tumors, which lack AR (Hillier 2005).
Furthermore, toxicity of 1113 is unaffected by AR expression in PC3 cells (Chapter 3).
As such, it is apparent that there are mechanistic explanations for the toxicity of 11 3 that
do not depend on involvement of the AR. Additionally, there are likely to be
mechanisms that are not related to formation of DNA damage, since 11 -dimethoxy has
significant effects on some facets of cellular processes--cell rounding, induction of GI
arrest, Skp2 down-regulation, and p27 up-regulation (Marquis et al. 2005).
Gene microarray experiments provide a relatively rapid and simple method for
acquiring a global perspective of the cellular processes perturbed by a small molecule.
Given the need to find better explanations for the observed success of 11 3 in preventing
growth of xenograft tumors, we have employed a microarray based structure-activity
analysis, making comparisons between the effects of treating LNCaP cells with 1113, 11 P3-
dimethoxy, chlorambucil (a nitrogen mustard DNA damaging agent), R1881 (androgen),
or bicalutamide (anti-androgen). The different treatments were compared to probe how
different portions of the complete 1113 molecule may impinge on specific cellular
processes and coordinate to produce the net effect of cell death. From this analysis, new
2-(6-((8S, 11S,13S,14S,17S)- 17-hydroxy- 13-methyl-3-oxo-
2,3,6,7,8,11,12,13,14,15,16,17 dodecahydro-1H-cyclopenta[a]phenanthren- 1 -
yl)hexylamino)ethyl 3-(4-(bis(2-chloroethyl)amino)phenyl)propylcarbamate
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discoveries have been made related to induction of cholesterol biosynthesis, activation of
the unfolded protein response, and the similar transcriptional modulation triggered by
11 3 and 1 1p-dimethoxy, which together provide potential mechanistic explanations for
observed efficacy.
Materials and Methods
Chemicals: Methyltrienolone (R1881) was acquired from Perkin-Elmer Life Sciences
(Waltham, MA). Bicalutamide was from LKT Laboratories, Inc. (St. Paul, MN).
Chlorambucil was acquired from Sigma-Aldrich (St. Louis, MO). Synthesis of 1113-
dichloro (referred to here as 1113) and 11 p-dimethoxy were performed in our laboratory
and have previously been described (Marquis et al. 2005).
Cell Culture: LNCaP cells (ATCC, Rockville, MD) were maintained in RPMI 1640
media supplemented with glucose (2.5 g/L), 1 mM sodium pyruvate, 10 mM HEPES, and
10% fetal bovine serum. Media and supplements were obtained from Invitrogen
(Carlsbad, CA), except for fetal bovine serum (Hyclone, Salt Lake City, UT). All cells
were grown in a humidified 5% CO2/air atmosphere at 370C.
Cell Treatment for Microarray Preparation: LNCaP cells were plated at a density of
800,000 cells in 10 cm diameter tissue culture dishes and allowed to grow for 48 hrs prior
to treatment. At this time, cells were treated with compounds indicated, diluted 1000x
into fresh media. Three control treatments were performed: 1) no treatment, cells
harvested at treatment time (unt 0 hrs), 2) fresh, untreated media, and 3) DMSO vehicle.
Other treatments were: 4) 1113 1 iM, 5) 1113 5 ptM, 6) 1 1-dimethoxy 5 jiM, 7)
chlorambucil 5 jiM, 8) bicalutamide 1 jiM, and 9) R1881 1 nM. Samples 2-9 were
harvested after 6 hrs of treatment. Please refer to Figure 4.1 and Table 4.1 for structures
of compounds used and treatment details. Cells were scraped into media, centrifuged to
pellet, washed once with PBS, re-pelleted, and stored at -700C until RNA isolation.
Individual treatments were repeated twice more, each three days (and one passage)
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following the prior treatment, in order to obtain more meaningful biological replicates,
producing each sample in triplicate.
RNA Isolation: RNA was isolated from frozen cell pellets with RNeasy® Mini kit,
employing QIAshredder columns for sample homogenization (Qiagen, Valencia, CA).
RNA concentration was assessed by UV absorbance, and quality was assessed with
Agilent Technologies 2100 Bioanalyzer.
Microarray: Microarray analysis was performed at Paradigm Genetics, Inc. (Research
Triangle Park, NC). Samples were processed by a standard Affymetrix protocol, and
amplified complementary DNA was hybridized to Affymetrix HGU133Plus2.0
GeneChips®.
Data Analysis: Analysis of microarray data was performed in the statistical environment
R (http://www.r-project.org) with the Bioconductor package (Gentleman et al. 2004). All
samples were normalized using the GCRMA method (Li & Wong 2001; Irizarry et al.
2003; Wu et al. 2008). As a first step toward data reduction, the Affymetrix Microarray
Suite 5.0 (MAS5) algorithm (as implemented in Bioconductor) was used to identify
present transcripts. Transcripts were required to have a present call with p-value < 0.01
in at least 50% of the samples for any single treatment group (unt 0 hrs, unt 6 hrs, DMSO
6 hrs, 113 1 ptM 6 hrs, 113 5 jtM 6 hrs, 11 1-dimethoxy 5 pM 6 hrs, chlorambucil 5 jLM 6
hrs, R1881 1 nM 6 hrs, or bicalutamide 1 jM 6 hrs), leaving 20909 probe sets for further
analysis. -Next, to determine significance of differential expression, a linear modeling
approach was used according to the limma package within Bioconductor (Smyth 2005).
Standard linear modeling data analysis (MANOVA) was applied to identify probe sets
with significantly different expression in pair-wise comparisons (unt 6hrs vs unt Ohrs;
DMSO 6 hrs vs unt 6 hrs; 113 1 tM 6 hrs vs DMSO 6 hrs; 1113 5 ptM 6 hrs vs DMSO 6
hrs; 11 3-dimethoxy 5 jM 6 hrs vs DMSO 6 hrs; chlorambucil 5 jM 6 hrs vs DMSO 6
hrs; R1881 1 nM 6 hrs vs DMSO 6 hrs; Bicalutamde 1 jlM 6 hrs vs DMSO 6 hrs) (Table
4.1). The significance of each comparison was evaluated using t-statistics. Genes with
associated p-values for differential expression of < 0.05, corrected by the method of
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Benjamini & Hochberg to minimize false discovery (Benjamini & Hochberg 1995), and
having a fold-change of at least two were selected for further analysis. Fold-change
values for each pair-wise comparison are reported as Log2 fold change (LFC); an LFC of
1 (or -1) is equivalent to a 2-fold difference in expression. A total of 615 probe sets was
identified from the above requirements. All scripts for use in Bioconductor were
provided by Dr. Jadwiga Bienkowska (Biogen-Idec, Cambridge, MA). Microsoft Excel
(Redmond, WA) and Spotfire DecisionSite (TIBCO, Palo Alto, CA) were used for
subsequent sorting and visualization of data.
Gene Classification: In order to classify genes into categories according to biological
functions, genetools (http://genetools.microarray.ntnu.no) was used to annotate genes.
Genes were sorted according to G03 level biological process and manually refined to
classify each gene into a single category for analysis.
Gene Ontology: WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/) was used to
identify over-represented categories of genes differentially expressed by individual
treatments. Differentially expressed probe sets were compared against the reference list
of all probe sets included on the HGU133Plus2.0 array, using a hypergeometric test to
identify over-represented categories with a significance level of 0.01 or less. Categories
were chosen from the GOTree Directed Acyclic Graph by identifying the enriched
groupings on the lowest "branches", providing the most detailed categorical descriptions.
Connectivity Map: The connectivity map (CMAP) is a tool developed through the
Broad Institute in order to compare gene expression data between treatments of cultured
human cells with various compounds having disparate biological mechanisms (Lamb et
al. 2006; Lamb 2007). The software allows a researcher to compare the expression
profile of a single compound against this reference library in order to identify other
compounds that produce similar effects on global transcription. As such, new
mechanisms can be discovered when it is learned that an expression profile is similar to
agents or classes of agents with better-understood activities. We used this tool for further
analysis of the expression profiles of agents tested, working with build 02 of the
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connectivity map, which contains over 7,000 expression profiles representing 1,309
different compounds. All but four of the profiles contained in the CMAP library were
generated by treatment with compounds for 6 hrs.
RT-PCR: RNA from isolation for microarray analysis was used for RT-PCR
verification of a subset of genes. RT-PCR was performed with Quantitect SYBR Green
RT-PCR kit (Qiagen) at MIT BioMicro Center on MJ Research Real-Time PCR Machine
with GAPDH as control. Primers were designed using Primer3 software (Rozen &
Skaletsky 2000) and are as follows: GAPDH (based on accession NM_002046) Forward:
ACA GTC AGC CGC ATC TTC TT, Reverse: GCC CAA TAC GAC CAA ATC C;
GDF15 Forward: GAG GTG CAA GTG ACC ATG TG, Reverse: GTG CAG GCT CGT
CTT GAT CT; DDIT3 Forward: GAG GTG CAA GTG ACC ATG TG, Reverse: GTG
CAG GCT CGT CTT GAT CT; HMGCS1 Forward: GCT CAG AGA GGA CAC CCA
TC, Reverse: GCC GAG CGT AAG TTC TTC TG; ATF3 Forward: CTA ACC TGA
CGC CCT TTG TC, Reverse: TTG TTC TGG ATG GCA AAC CT; TRIB3 Forward:
TTA GGC AGG GTC TGT CCT GT, Reverse: GTA TGG ACC TGG GAT TGT GG;
GADD45A Forward: AAC GGT GAT GGC ATC TGA AT, Reverse: CCC TTG GCA
TCA GTT TCT GT. A method was also developed to identify XBPJ, both in its
unspliced (XBPlu) and spliced (XBPls) forms. To identify only the unspliced form, the
forward primer was designed to anneal within the intronic region, while the forward
primer used for identification of the spliced form was designed to span the intron.
Primers for this were XBPlu Forward: CAG ACT ACG TGC ACC TCT GC, Reverse:
ACT GGG TCC AAG TTG TCC AG; XBPls Forward: CTG AGT CCG CAG CAG
GTG, Reverse: ACT GGG TCC AAG TTG TCC AG.
Statistics: Significance tests were performed with unpaired 2-tailed student's t-test as
implemented in Excel 2002 (Microsoft).
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Results
Experimental Design
In order to explore potential mechanistic explanations for the anticancer activity
of 11 P, we chose to monitor the global gene transcriptional profiles of LNCaP cells
treated with this agent. Concentrations of 1 tM and 5 pM were used in hopes of
capturing the immediate effects of 11i treatment on cellular biochemical processes
without unwanted side effects of general toxicity. A 5 pM concentration is a threshold
for 11i toxicity to LNCaP cells in a 24 hr treatment; concentrations 5 pLM and below
result in growth inhibition (as discussed in Chapter 3, Figure 3.1), while higher
concentrations result in apoptosis (Marquis et al. 2005). The 1 pM concentration was
included to explore the relationship between drug concentration and transcriptional
response. Treatments were performed for 6 hrs in order to identify the most immediate
responses while minimizing secondary, downstream, or general toxicity effects. We also
included the non-DNA damaging 11 analogue, 11 p-dimethoxy, at 5 pM. In so doing,
we were able to identify which effects on transcription could be attributed to covalent
interactions. Furthermore, we included the nitrogen mustard chlorambucil at 5 p.M in
order to identify any transcriptional responses that a similar DNA damaging agent would
have, irrespective of the steroid and linker regions of 11p. Finally, we included an
androgen receptor agonist (R1881, 1 nM) and an AR antagonist (bicalutamide, I jiM) to
shed further light on how the interaction of 11 p with the AR may influence cellular
processes. Figure 4.1 provides the structures of all compounds tested. We hoped that by
analyzing changes in gene expression induced in LNCaP cells exposed to this set of
compounds, we could identify structure-activity relationships for the steroid and
alkylating activities of the I 1 molecule. Controls included: 1) isolation of cells at time
of treatment (unt 0 hrs), 2) replacement with fresh media for the 6 hr duration (unt 6 hrs),
or 3) treatment with DMSO vehicle. Control treatments were examined in comparison to
the 0 hrs unt control sample and reveal very little significant transcriptional change
elicited by either the 6 hrs fresh media treatment (2) or vehicle treatment (3) (Tables
S4.13-S4.16, Figures S4.7, S4.8). As such, all comparisons discussed hereafter are with
respect to DMSO vehicle.
193
- Chapter 4 -
Affymetrix Human Genome U133 Plus 2.0 microarrays, each containing 54,613
probe sets representing over 38,500 well-characterized human genes and Unigenes, were
used to identify global mRNA transcript levels in each of these treatment groups. Pair-
wise comparisons were made between each treatment and DMSO (Table 4.1). A cutoff
of two-fold differential expression was used for most analyses, while this requirement
was relaxed in a few indicated circumstances to acquire a more complete understanding.
In all data discussed, p-values are < 0.05 unless otherwise specified. Fold-changes are
often referred to by their log2 fold change (LFC); an LFC of 1 (or -1) is equivalent to a 2-
fold difference in expression between treatment groups.
11f3 Significantly Alters Expression of Many Genes from Diverse Pathways
Figure 4.2 shows the numbers of unique genes significantly up- or down-
regulated in each of the treatment groups, demonstrating that 5 ptM 113 produced the
most significant transcriptional response, increasing expression of 119 genes and
decreasing expression of another 42 genes. 11 3-Dimethoxy followed somewhat closely
behind, increasing expression of 78 genes and decreasing expression of 13. As expected,
1 ptM 110 had less effect than the higher concentration on overall transcription. R1881
treatment resulted in almost exclusive up-regulation of a set of genes, while bicalutamide
only caused the decreased expression of 2 genes. Finally, using a 2-fold differential
expression cutoff, no significantly differentially expressed genes were generated by
treatment with chlorambucil or DMSO relative to the 6 hr untreated sample, or the 6 hr
untreated sample relative to untreated cells isolated at time of treatment.
The key, primary question we sought to address by monitoring the expression
profile of treatment with 11p was "Which biological pathways are activated or
repressed?" The answer to this question can offer insight into the mechanisms
responsible for 11 toxicity. After filtering data as discussed, different tools were used to
increase our biochemical understanding of what these differentially expressed genes
represent. First, known genes were classified into functional categories based on their
associated biological processes as discussed in Materials and Methods. From this
analysis, some striking effects of 5 pM 1113 treatment were immediately noticed. As
anticipated, 11 P affects the expression of several genes related to progression through the
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cell cycle--generally up-regulating cell cycle inhibitory genes and down-regulating cell
cycle promotional genes, various aspects of transcription, and apoptosis (Figure 4.3,
Table 4.2). More surprisingly, 113 treatment resulted in significant up-regulation of
genes associated with cholesterol or lipid biosynthesis, and also those associated with a
response to unfolded protein. There is a robust increase in expression of genes associated
with various aspects of transport as well. While most of these processes are
overwhelmingly up-regulated, protein synthesis and DNA repair are heavily down-
regulated (Figure 4.3, Table 4.3).
It is even more meaningful to ask which gene categories are over-represented in
each dataset. Over-representation refers to the statistical enrichment of genes belonging
to a specific functional category, above what would be expected if genes were chosen
randomly, and suggests that any changes seen in that class of genes can be interpreted to
not have arisen by chance. A hypergeometric test addresses the likelihood that a certain
subset would be selected at random, taking into account the total number of genes
represented on a microarray, the number of genes included in a functional category, and
the number of"hits" identified. This hypergeometric analysis demonstrates that 11 up-
regulates an over-represented set of genes related to cell cycle arrest and sterol
biosynthesis, among others (Table 4.4). While a response to unfolded protein is not over-
represented by this test, genes related to endoplasmic reticulum (ER) membrane, which
are often the same as those involved in response to unfolded protein, are over-represented.
113 is also shown by this analysis to have decreased expression of genes over-
represented in categories of G1/S cell cycle transition, mitosis, rRNA processing, and
mismatch and base-excision DNA repair (Table 4.5).
Performing the same analysis with genes affected by treatment with 1 lpM 11i
produces no significant category over-representation if a 2-fold differential cutoff is used.
If this is relaxed to a 1.4-fold cutoff, however, cholesterol biosynthesis remains
significantly over-represented as induced, while protein transport is the most striking
category of genes whose expression is reduced by treatment (Table 4.6). Comparing 1
p.M 11 3 with 5 pM 11 3 demonstrates that activation of several pathways depends on
reaching a higher concentration. Cholesterol biosynthetic genes, being most sensitive to
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1 ptM 11 treatment, may provide a clue to the more specific effects of 11I I treatment that
can lead to growth inhibition and apoptosis.
110 and 11j-Dimethoxy Modulate a Strikingly Similar Set of Genes And Processes
Comparison between 11 3 and 1 1-dimethoxy is valuable in determining which
effects of 11 depend on DNA damage or other covalent interactions of the compound.
While 11P 3-dimethoxy is less toxic than 11 3 to LNCaP cells, it is not without effects: it
produces a GI cell cycle arrest, reduces expression of Skp2, and increases expression of
p27 (Marquis et al. 2005). Somewhat surprisingly, however, 11 3-dimethoxy produced a
very similar transcriptional response to that achieved with 113. Of the 477 probe sets
significantly altered in expression by 5 iM 1113, 200 are also significantly affected by
11 p-dimethoxy (Figure 4.4). Generally, for most of these probe sets, the magnitude of
change is greater with 11 3 treatment than with 11I I-dimethoxy. Further, of the remaining
277 probe sets differentially expressed 2-fold by 113, but less than 2-fold by 11 3-
dimethoxy, 209 of these are significantly differentially expressed (in the same direction)
by 1 f3-dimethoxy by at least 1.4-fold (Figure 4.4, Table S4.1, S4.2). Thus, by drawing
an arbitrary line at a 2-fold expression difference, some genes falling on either side of this
line will be bracketed and considered unique, while in reality the story is more complex,
with both compounds having similar effects on transcription of those genes.
Analysis of gene categories over-represented by 11 -dimethoxy produces many
of the same associations seen with 11 3, such as increased expression of genes related to
cholesterol biosynthesis (Table 4.7, Table 4.8). Additionally, 11P 3-dimethoxy increases
expression of genes over-represented in the category of response to unfolded protein.
These same genes (EIF2AK3, HERPUDI, EDEMI) are also significantly up-regulated by
1113, and for the category of response to unfolded protein, 1113 has a p-value of 0.012
(because a greater number of probe sets are perturbed by 1113 treatment, thereby
decreasing significance). As such, this pathway can be considered significantly over-
represented by treatment with either compound.
A category that is uniquely over-represented by 11 3, but not by 1 1-dimethoxy, is
cell-cycle arrest, which includes genes CDKNIA, GADD45A, SESN2, HBPJ, and DDIT3.
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However, the only gene in this group that is not also affected by 1 1-dimethoxy
treatment is CDKNIA; each of the other genes is induced at least 2-fold by 1113-
dimethoxy, albeit more so by 1113 treatment. CDKNIA codes for the protein p21, a
downstream effector of p53 activation regulating the GU/S cell cycle progression (Harper
et al. 1993). Its expression is initially decreased by 11 3 and 11 -dimethoxy, but it then
recovers to untreated levels in 11 -dimethoxy treated cells, while amplifying several fold
in cells treated with 1113 (Marquis et al. 2005). The detailed biochemical understanding
of how and why p21 levels initially decrease before being amplified by 1113 treatment is
still lacking. However, the microarray data support a hypothesis that the eventual
amplification, which occurs with 11 but not with 11P -dimethoxy treatment, results from
increased CDKNIA transcription.
Expression changes unique to 1113 treatment were also identified by direct
comparison of the gene expression levels in LNCaP cells following 1113 or 11 p-
dimethoxy treatment. To do this, we calculated the ALFC, the difference between the
LFC of treatment with 11 3 and the LFC of treatment with 11I I-dimethoxy. We identified
57 probe sets that are more significantly perturbed by 1113 treatment than by 11 3-
dimethoxy treatment (ALFC > 0.8, or 1.74-fold difference between treatments; complete
list available in Table S4.17 and Table S4.18). Each of these probe sets also has a
significance of differential expression p-value for 1113 < 0.05, and the absolute value of
LFC for 1113 is at least 0.5 (-1.4-fold). This group of 57 probe sets was analyzed for
enrichment of categories, identifying cell cycle related processes and response to DNA
damage stimulus (Table 4.9). The response to DNA damage stimulus is likely very
important, as this is presumably the functional difference between 1113 and 1113-
dimethoxy.
BTG2 and DDIT3 were identified among the 57 probe sets as members of the
category that are responsive to DNA damage stimulus. BTG2 is truly unique to 1113
treatment (LFC = 1.29 for 1113, LFC = 0.30 for 1 1-dimethoxy). BTG2 (also known as
PC3 or TIS21) is a DNA-damage responsive, p53-regulated protein involved in GU/S cell
cycle transition (Rouault et al. 1996; Guardavaccaro et al. 2000). Additionally DDIT3
(DNA-Damage Induced Transcript 3), which encodes the protein CHOP (or GADD153),
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was also identified in the category of response to DNA damage stimulus. While DDIT3
was initially identified as DNA-damage responsive (Fornace, Alamo & Hollander 1988),
it has since been observed to also respond to oxidative stress (Halleck et al. 1997) or
other insults that result in endoplasmic reticulum stress (Wang et al. 1996). The ER
stress pathway that is activated is also known as the unfolded protein response (UPR),
and in this framework, CHOP plays a role in promoting apoptosis in cells that can not
overcome the assault (Zinszner et al. 1998; McCullough et al. 2001; Marciniak et al.
2004). Unlike BTG2, The DDIT3 gene is induced by both 113 (LFC = 3.46) and 1 1j3-
dimethoxy (LFC = 1.70). This suggests that the DNA-damage inflicted by 113 may
enhance induction of DDIT3, but it is not absolutely required for this response.
We also identified a group of genes for which 11 3-dimethoxy effects a
significantly greater magnitude change than 113. Interestingly, these genes can be
roughly sorted into two categories. The first contains genes that respond similarly to
treatment with 11 -dimethoxy or the AR agonist R1881 (Table 4.10), which suggests that
these genes are likely androgen-regulated. This class includes PMEPAJ, FAM110B,
ROR1, IGFIR, HPGD, FKBP5, PHLDB2, CSGALNACTI, MAF, and SNAI2. Several of
these, including PMEPA1, HPGD, FKBP5, PHLDB2, MAF, and SNAI2 have previously
been identified as androgen-regulated genes (Xu et al. 2000; Tong & Tai 2000; Nelson et
al. 2002; Chen et al. 2006; Ngan et al. 2009). IGFIR has also been identified as a protein
that is up-regulated by androgens and estrogens in prostate cancer cells via a pathway that
does not depend on AR or ER binding to DNA (nongenotropic) (Pandini et al. 2009).
SNAI2, MAF, PMEPA1, and FAM110B are significantly decreased in expression by the
AR antagonist bicalutamide, increasing confidence that expression of these genes is
related to interaction of 11P3-dimethoxy with the AR (Table 4.10). FAM110OB, ROR1, and
CSGALNACTI have not previously been identified as androgen-regulated genes and may
represent new AR transcriptional targets. However, most studies aiming to identify
androgen-regulated genes compare mRNA levels after androgen treatment to those
present in cells grown in androgen-depleted media. In contrast, all treatments for
microarray analysis discussed here were performed in normal media supplemented with
10% FBS. It is not entirely surprising that 11p-dimethoxy affected the expression of
androgen-regulated genes to a greater extent than 113 in this analysis. It was
198
- Chapter 4 -
demonstrated in Chapter 2 that 1 p-dimethoxy is a slightly more potent AR agonist.
However, in the results discussed in Chapter 2, 11 also acted as an AR agonist, whereas
the subset of apparently androgen-regulated genes discovered in this expression analysis
(Table S4.7) demonstrates no response to 11i treatment. This also likely reflects the
different assay conditions: media containing serum with testosterone (here) or
charcoal/dextran treated serum lacking it (Chapter 2).
The other category of genes that is more responsive to 11 p-dimethoxy than 11I I
treatment is related to cholesterol and lipid biosynthesis (Table 4.10). This group
includes the genes HMGCS1, SQLE, LDLR, FDFT1, and THRSP. HMGCSJ (3-
hydroxyl-3-methylglutaryl coenzyme A synthase 1) encodes the protein that catalyzes
condensation of acetoacetyl-CoA with acetyl-CoA to form HMG-CoA, initiating the
cholesterol biosynthetic pathway. SQLE encodes squalene epoxidase, which acts at a
later stage in cholesterol synthesis, catalyzing the first oxygenation step, and is
considered to be one of the rate-limiting enzymes in the pathway. LDLR encodes a low-
density lipoprotein receptor, a cell-surface receptor that binds low-density lipoprotein,
which is the major carrier of cholesterol in blood plasma. FDFT1 (famesyl-diphosphate
farnesyltransferase) is the first cholesterol-specific enzyme in the biosynthetic pathway,
catalyzing dimerization of two farnesyl diphosphate molecules to form squalene. Finally,
THRSP (thyroid-hormone responsive) does not have a specific known function, but is
associated with enhanced lipogenesis in tumors (Moncur et al. 1998), and as its name
suggests, is responsive to thyroid hormone. LDLR induction appeared to be unique to
1 j3-dimethoxy treatment (LFC = 1.66 for 1 p-dimethoxy, 0.42 for 11i). There is also
one probe set for SQLE which is uniquely affected by 1 f3-dimethoxy, but two other
probe sets are induced by both compounds (to a greater extent with 11 -dimethoxy). The
generalization that 1 P-dimethoxy is more inducive to the processes of cholesterol
biosynthesis and lipogenesis holds true for other genes of this type as well, including
HMGCR (HMGCoA reductase), INSIG1 (insulin-induced gene 1), STARD4, SC4MOL,
DHCR7, FASN (Fatty Acid Synthase), FADS1 (Fatty Acid Desaturase 1), and IDII. It is
known that androgens can increase lipogenic gene expression in AR positive cell lines
(Heemers et al. 2001). This provides a simple explanation for the greater induction of
lipogenesis-related genes by 1 f3-dimethoxy, since it behaves more as an androgen.
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However, it is clear that interaction with the AR is not required for induction of
cholesterol biosynthetic pathways, as HMGCS1 was also shown to be significantly up-
regulated by 11 3 in HeLa cells that lack AR expression (Bogdan Fedeles, unpublished
results). Potentially, however, the interaction of 1 p-dimethoxy with the AR enhances
induction of cholesterol biosynthetic genes.
Chlorambucil has Minor Effects on Transcription
Treatment of LNCaP cells with 5gM chlorambucil, a DNA damaging mustard
analogous to the DNA damaging portion of 11 (Figure 4.1), did not result in very strong
repression or induction of gene expression. Chlorambucil is significantly less toxic
toward LNCaP cells compared to 1113 and is unable to induce apoptosis as 11 3 does
(Marquis et al. 2005). Chlorambucil was unable to perturb expression of any genes
beyond a 2-fold difference. However, relaxation of this filter to -1.4-fold (absolute value
of LFC > 0.5) allows for identification of eight unique up-regulated genes and five
unique down-regulated genes. Only one of the genes down-regulated by chlorambucil
(ESC02) is significantly down-regulated by 113 treatment greater than 2-fold (LFC
= -1.1). However, this same gene is also significantly down-regulated by 11 3-dimethoxy
(LFC = -0.84), making it unlikely that the capacity of 11 3 to damage DNA is responsible
for down-regulation of this gene. There are also a handful of genes which are up-
regulated greater than LFC = 0.5 with chlorambucil and greater than LFC = 1 with 11 3.
KLHL24 and ELF3 are two of these for which the induction by 1113 is significantly
greater than that by 11 3-dimethoxy, increasing likelihood that the DNA damage
component is responsible for the greater induction of these genes. However, to our
knowledge these genes have not previously been associated with a response to DNA
damage.
Transcriptional Effects Identified by Microarray are Confirmed with RT-PCR
We used RT-PCR to verify that a subset of the genes identified from gene
microarrays are affected by 11 3 or 11 -dimethoxy treatment. The genes GDF15, DDIT3,
ATF3, GADD45A, TRIB3, and HMGCS1 were chosen as a subset representing some of
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the interesting classes of perturbed genes. Figure 4.5 demonstrates that each of these
genes was significantly increased in expression by either 1113 or 1130-dimethoxy.
Furthermore, analysis accurately identified HMGCSI as more greatly up-regulated by
1 p-dimethoxy than by 113, while transcription of each of the remaining genes is
amplified more greatly by 1113. The expression of GDF15 and DDIT3 was also
monitored as a function of treatment duration. Their analysis showed a transient increase
in expression, which lasted for -6 hrs before leveling off or regressing (Figure 4.6).
Having identified the UPR as a pathway potentially activated by 1113, further
testing was performed to confirm this finding. The UPR consists of three primary
enzymes located in the membrane bilayer of endoplasmic reticulum: IRElao, PERK, and
ATF6. These enzymes respond to the stimulus of an unfolded protein burden in the
endoplasmic reticulum in multiple ways. One hallmark of this pathway's activation is
unconventional splicing of X-box binding protein 1 (XBPJ) mRNA by IREla to remove
a 26-base intron, which shifts the reading frame and results in expression of active
transcription factor (Yoshida et al. 2001; Calfon et al. 2002). This spliced form (XBPls)
drives expression of various genes related to protection from the unfolded protein assault
(Lee et al. 2003). Levels of both the unspliced form (XBPlu) and XBPls were tested
after treatment with 5 pM 11 3. While XBPlu is not significantly affected by treatment,
XBPls is increased -10-fold, indicating an activated IRE arm of the UPR (Figure 4.7).
Several genes were also analyzed for expression changes in HeLa cells to
determine effects that are general for 1103 treatment or that potentially depend on factors
unique to LNCaP cells. GDFJ5, DDIT3, TRIB3, CCNG2, and HMGCSI were all
demonstrated to be increased in expression to a similar extent as in LNCaP cells, while
CCNE2 was demonstrated as down-regulated, also consistent with its repression in
LNCaP cells (Bogdan Fedeles, personal communication). Furthermore, splicing ofXBP1
was shown to occur, increasing XBPls levels several fold (Bogdan Fedeles, personal
communication).
The Connectivity Map Identifies Various Agents with Similar Effects as 1 p on
Global Transcriptional Profiles
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The connectivity map (CMAP) was used to identify other compounds that induce
a similar transcriptional profile as 11 3. CMAP allows a researcher to compare an
interesting set of genes (often from microarray experiments using small molecules)
against a large library of microarray data produced by individually treating cultured
human cells with many different pharmacologically active small molecules (Lamb et al.
2006; Lamb 2007). CMAP calculates similarity between the input list of genes and each
of the profiles within its library, ultimately providing a list of compounds with similar
activity. From this list, one can infer logical hypotheses about the activity of a tested
compound, taking into account the known mechanisms of other compounds.
To determine similarity, CMAP analysis calculates "up" and "down" scores,
which are absolute measures (Lamb et al. 2003) of overlap between the up- and down-
regulated genes within a query list and those of the reference gene list (produced from
individual treatments within the CMAP library). Essentially, the up values are largest in
magnitude when the genes up-regulated in the query list are among the most up-regulated
genes for any particular treatment from the reference library (and vice-versa). A perfect
up score would mean that the submitted list was identical to the most up-regulated genes
from one treatment. The up and down scores are combined to produce an overall
"connectivity score" for each individual treatment. The connectivity scores are arbitrarily
scaled from +1 for the most positively correlated treatment to -1 for the most negatively
correlated treatment, and data is sorted accordingly. Connectivity scores are also
sometimes averaged over multiple individual treatments (for one compound or class of
compounds), further indicating that a certain correlation is generally applicable.
Query of the CMAP database with the set of genes perturbed by 5 PM 113
treatment produces quite interesting results. The best overall match for a single treatment
is the antihelminthic agent pyrvinium, at a concentration of 3 p.M in MCF7 breast cancer
cells (Table 4.10A). Other compounds in this table include the antihistamine astemizole
and another antihelminthic, niclosamide. Interestingly, niclosamide, which has been
reported to decouple oxidative phosphorylation (Weinbach & Garbus 1969; MacDonald
et al. 2006), exhibits the highest mean connectivity score for correlation with 11 3 when
averaged over treatments, whether this average is independent of (mean score 0.801,
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n = 5, p-val = 4e-5), or with respect to, cell line (MCF7, mean score = 0.933, n = 2,
p-val < 2e-5).
In addition to antihelminthics and antihistamines, two quaternary ammonium
detergents, benzethonium chloride and methylbenzethonium chloride, are identified in
the top 20 compounds most correlated with 11 3. Additional agents with high correlation
to 113 include those with general effects on ion transport, for example monensin (#24
overall), ionomycin (#57 overall), and the calcium channel blockers bepridil and
fendiline (represented in Table 4.11B by ATC category C08EA, best match is fendiline,
#39).
Other agents of interest include the classic UPR inducer thapsigargin, which,
while only the 6 8th best match of individual treatments, is the 15th best match when
considering only up-regulated genes. Thus, 11 p3 and thapsigargin induce a common set
of genes related to UPR. Interestingly, compounds that are inhibitory toward the
proteasome correlate well with 11p, including MG-132, MG-262, celastrol (Yang et al.
2006), and withaferin A (Yang et al. 2007) (mean score = 0.634, n = 9), perhaps due to
their ability to induce the UPR by preventing protein degradation (Bush et al. 1997;
Fribley et al. 2004; Obeng et al. 2006).
Another useful means of averaging connectivity scores is based on the
Anatomical Therapeutic Chemical (ATC) classification of compounds, which only
considers therapeutically relevant molecules. Averaging connectivity scores with respect
to ATC classification shows that 11 3 correlates well with several agents that belong to
the class of phenothiazines, including thioridazine, chlorpromazine, trifluoperazine,
fluphenazine, and prochlorperazine (Table 4.11). Additionally, this comparison identifies
phenylalkamine derivatives and non-selective monoamine reuptake inhibitors such as
trimipramine.
Figure 4.8 provides a graphical view of the correlation between 1103 and some of
the phenothiazines. A bar view demonstrates that most of the treatments with agents
from the ATC class NO5AB (phenothiazines with piperazine structure, including
trifluoperazine, prochlorperazine, fluphenazine, and thioproperazine) have strong
correlation (green) with the transcriptional profile generated with 11 (Figure 4.8A). The
antipsychotic agent trifluoperazine from this class has even better correlation with 11 3
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(Figure 4.8B). Chlorambucil, on the other hand, does not produce a transcriptional
profile with significant correlation to 113 treatment, in line with the findings reported
here (Figure 4.8C).
Discussion
Analyzing the effects of treating LNCaP cells with 11 3, 1 p-dimethoxy, and
control compounds on global transcription has provided new avenues worthy of
exploration. From this examination, it was discovered that 11 3 significantly increases
expression of genes related to cholesterol biosynthesis, UPR, cell cycle arrest, and
apoptosis, while decreasing expression of those related to protein synthesis, DNA
damage repair, and cell cycle progression. Quite interestingly, 11 p-dimethoxy, despite
being significantly less toxic to LNCaP cells than 11 3, modulates a very similar set of
genes as 11p3. Importantly, there are some genes affected by 11 3 expression that are
unaffected with 1 1-dimethoxy, such as the DNA-damage responsive CDKNIA and
BTG2 genes. However, the magnitude change for a majority of genes affected by 11 3 is
simply larger than the change induced by 11 -dimethoxy. This observation suggests that
covalency of interaction, a subtle difference of intracellular trafficking, or association
with specific proteins may be involved in the relative differences in toxicity between the
two compounds. In other words, 11p does not seem to affect transcription of a
significant set of genes that are unaffected by 11I I-dimethoxy, as one might expect if the
activities of these compounds were strikingly different. Instead, the transcriptional
profiles suggest that both compounds have very similar activities, while 11p is more
effective at eliciting them. However, it is important not to overanalyze these data, which
at this stage have only captured the effects of treatment at the transcriptional level.
Potentially, many of the effects of 11 3 treatment occur at translational and post-
translational stages and could provide better explanation as to the mechanistic differences
between 11 3 and 11 3-dimethoxy.
Cholesterol biosynthesis and lipogenesis are two pathways that are significantly
up-regulated by both 11I I and 11 3p-dimethoxy. Furthermore, these pathways are the ones
most significantly up-regulated by the low dose of 1 pM 11 3, making it likely that their
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activation is more immediate or specific. These genes are regulated by the sterol
regulatory element-binding protein (SREBP) family of transcription factors, which are
located in the ER membrane and are responsible for adapting to changes in cholesterol
availability (Horton et al. 2002). During conditions of low cholesterol, SREBPs associate
with SREBP cleavage-activating protein (SCAP). SCAP then transports SREBP to the
golgi apparatus, where it is cleaved by site 1 and site 2 proteases, producing an active
transcription factor that drives synthesis of cholesterol and lipids (Goldstein et al. 2002;
Horton et al. 2002). However, when cholesterol is present, it is directly sensed by SCAP,
causing SCAP to bind to insulin-induced genes 1 and 2 (INSIG-1 and INSIG-2) (Yang et
al. 2002; Yabe et al. 2002). These proteins thereby inhibit SCAP transport of SREBP to
the golgi, and cholesterol biosynthesis is not activated. INSIG-1 is also up-regulated by
active cleaved SREBP, providing a feedback mechanism of regulation. INSIGs have
their own ability to directly bind oxysterols, cholesterol derivatives with additional
hydroxyl or keto groups. Binding of oxysterols to INSIGs produces the same net effect
as binding of sterols to SCAP-increased association of SCAP and INSIG, which retains
SREBP in the ER membrane and disallows cholesterol biosynthetic gene expression
(Radhakrishnan et al. 2007).
Beyond this canonical cholesterol homeostatic paradigm lie other agents of
diverse structure that are also able to modulate cholesterol and lipid biosynthesis. In
direct contrast to sterols and oxysterols, a class of cationic amphiphiles, including
trifluoperazine and imipramine, increases expression of genes related to cholesterol and
lipid biosynthesis (Lange & Steck 1994), generating transcriptional profiles identified
through CMAP as similar to 1103. A prevailing model for the effect of cationic
amphiphiles on cholesterol homeostasis is that they partition into lipid bilayers and
"confuse" the machinery that normally senses sterols.
Yet other compounds that elicit transcriptional effects similar to 11 3, including
phenothiazines (Prozialeck & Weiss 1982), antihistamines, tricyclic antidepressants, and
antimalarials (Weiss et al. 1980; Prozialeck & Weiss 1982) are capable of inhibiting
calmodulin. This protein binds calcium and regulates various cellular processes, and its
functional disruption can lead to toxicity. The ionophoric polyether antibiotic monensin,
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identified by CMAP analysis as a modulator of the same pathways as 11 3, can similarly
dysregulate calcium localization and gradients and cause the same toxic effects.
One of the primary functions of the ER is sequestration of calcium. Agents such
as thapsigargin, which interfere with the maintenance of this gradient, will lead to an
integrated ER stress response--the UPR (Ghosh et al. 1991; Berridge 1993; Kaufman
1999). Calcium is involved in folding of a subset of proteins within the ER, presumably
due to interaction with certain folding chaperones (Lodish & Kong 1990; Lodish et al.
1992; Corbett et al. 1999). Thus, interference with calcium homeostasis can lead directly
to the effects consistent with UPR.
The UPR in mammalian cells consists of three main paths of activation from ER-
resident proteins IREla, PERK (EIF2AK3), and ATF6. Each of these proteins has a
translumenal domain extending into the ER where it can sense the protein folding
environment. It is believed that BiP (HSPA5, GRP78) is a negative regulator of these
pathways that functions by binding to the lumenal regions of these proteins and
preventing their dimerization or activation. However, when unfolded proteins are present
in excess, BiP is attracted to their unfolded regions, freeing IRE , PERK, and ATF6 for
activation. When IRE1 is freed from BiP, it dimerizes and activates a ribonuclease
activity which will act on XBPJ mRNA, cleaving it in a non-conventional manner into an
active transcription factor coding sequence. This transcription factor then drives
expression of various genes related to protein folding. PERK also dimerizes, after which
it phosphorylates eukaryotic translation initiation factor 2 (eIF2) on the alpha subunit at
Ser51, thereby limiting its ability to recognize AUG start codons and minimizing general
protein translation. However, a subset of transcripts is preferentially translated when
eIF2a is phosphorylated, possibly by cap-independent translational initiation. This class
includes the protein ATF4, which is involved in the transcriptional up-regulation of
DDIT3 (CHOP) (Fawcett et al. 1999; Harding et al. 2000). Finally, ATF6 is translocated
to the golgi apparatus as a result of unfolded protein excess in a manner reminiscent of
the SREBP activation. In fact, ATF6 is processed in the golgi by the exact same site 1
and site 2 proteases, producing another activated transcription factor (Ye et al. 2000; Lee
et al. 2002).
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It has recently been appreciated that ER stress can lead directly to activation of
SREBP2, manifesting in enhanced lipogenesis (Colgan et al. 2007). Enhanced
lipogenesis during ER stress is logical, since the increased need for protein folding may
require synthesis of new ER, composed of lipids and cholesterol. Finally, a connection
between calcium, UPR, and cholesterol biosynthesis may provide an explanation for why
ionophores like monensin can increase cholesterol biosynthesis (Lange & Steck 1994), as
well as provide an additional explanation for how phenothiazines modulate this pathway.
UPR activation may be an important factor in the mechanism of 113 toxicity
toward LNCaP and other cancer cells. It was demonstrated that XBP1 splicing occurs in
both LNCaP and HeLa cells upon 11 3 treatment, providing evidence that the IRE1 arm
of the UPR is activated. Several other genes belonging to this class are up-regulated
greater than 2-fold by treatment, including HSPA5, EIF2AK3, DDIT3, DNAJB9, EDEM1,
and HERPUDI, among others (Table 4.2). Furthermore, ATF6 is up-regulated 1.7-fold,
and ATF4 is up-regulated just under 2-fold (LFC = 0.99). The UPR functions much like
p53 in the sensing of DNA damage-initially protecting a cell in this case by generally
halting protein synthesis, assessing the situation, and recovering if possible. However,
just as p53 will signal apoptotic processes in the face of unbearable genome damage, the
UPR will activate apoptotic processes when the unfolded protein burden is too great. The
UPR can effect apoptosis with or without mitochondrial involvement (Rao et al. 2002;
Breckenridge et al. 2003). For example, CHOP is able to down-regulate BCL2
expression, increasing reactive oxygen species and cytochrome c release (McCullough et
al. 2001). The de-activation of BCL2 could provide enhanced understanding for our
ability to use alkylation therapy for prostate cancer treatment, a situation that is usually
not amenable to this strategy (McDonnell et al. 1992; DiPaola & Aisner 1999).
Cancer cells often display increased expression of genes related to the UPR, likely
as a result of the general dysregulation of many systems in these tumors and of limiting
nutrients (Gazit et al. 1999; Fernandez et al. 2000; Song et al. 2001; Chen et al. 2002;
Shuda et al. 2003). Furthermore, hypoxia, a common condition in solid tumor formation,
can lead to up-regulation of the PERK arm of the UPR (Koumenis et al. 2002). With the
UPR pathway already activated, it is possible that further assault in the form of ER stress
will overwhelm this system and create cell death, while normal cells have an ability to
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up-regulate protective mechanisms and overcome the insult. In support of targeting UPR
as an anticancer therapy, it has been demonstrated in some cases that induction of UPR in
cancer cells sensitizes them to treatment with DNA damaging agents or other
chemotherapeutics (Chatterjee et al. 1997; Belfi et al. 1999; Wu et al. 2009). In this
manner, selective toxicity may be achieved.
It is not entirely clear which aspects of 11 3 treatment are initiators and which are
effectors of cholesterol biosynthesis and UPR. Perhaps the simplest explanation is that
1113 acts like some cationic amphiphiles that modulate cholesterol biosynthesis by
diffusing into lipid bilayers. 11 3 could be described as a cationic amphiphile, as it is a
very lipophilic molecule and will bear a positive charge on the secondary amine within
the linker at physiological pH (pKa - 9-10). Furthermore, the chlorine groups will have
partial negative charges associated with them, increasing the amphiphilicity of the overall
compound. This may create a type of membrane damage that displays its effects through
disruption of cholesterol homeostasis, leakage of calcium gradients, and down-stream
activation of UPR. Of course it is also possible that like the phenothiazines, 1113 first
specifically inhibits calmodulin, disrupting calcium levels and leading to the other
processes.
While 1113 was originally designed to create selective toxicity toward cells
expressing the androgen receptor, increasing evidence argues against the direct
involvement of AR in the mechanisms related to toxicity (Chapter 3). Paradoxically, 11 P
is effective at preventing growth of both LNCaP and HeLa xenograft tumors, while
displaying relatively little toxicity to the mice in which they grow. Therefore, it is
important to address other potential mechanisms that may influence and explain selective
toxicity. Here we have identified the UPR as a pathway that is activated by 11 3, and this
may provide the sought-after explanation as to why cancer cells have heightened 1113
sensitivity. 1113-Dimethoxy treatment also causes increased expression of UPR-related
genes, but in almost all cases, the magnitude is greater with 11 3. Therefore, it is possible
that 11 3 generally acts upon the same cellular targets as 11P -dimethoxy, but has a greater
activity due to unknown reasons. The ability of 1113 to damage DNA or to form other
covalent attachments with macromolecules probably aids in its toxicity. Further
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experiments are necessary to address the intricate details that explain the different
activities of 11 3 and 11P -dimethoxy.
It is not entirely clear what the initial activator of the UPR is, but a few potential
explanations have been offered, including membrane damage, calmodulin inhibition,
calcium dysregulation, or general disruption of cholesterol homeostasis. Cholesterol
biosynthetic dysregulation may be the most specific of these mechanisms, since it is the
most significantly affected process at 1 glM 11P3. However, the heightened ability of 11 -
dimethoxy to modulate this pathway argues that there is another factor necessary for
creating maximum toxicity.
We could also add another pathway to this list of potential effectors of 111
toxicity: the increase of intracellular reactive oxygen species. It was demonstrated that in
HeLa cells, 113, at concentrations as low as 2.5 pM, is able to elicit a rapid increase
(within 2-3 hrs) in ROS levels (Bogdan Fedeles, personal communication). ROS levels
have not as yet been monitored in LNCaP cells, but if the subset of gene transcription
analyzed by RT-PCR is any indication, the mechanisms responsible for toxicity in these
cells could be quite similar. Furthermore, it was shown that intracellular calcium levels
increase quite significantly within 30 minutes following addition of 8 M 1113 to HeLa
cells (Bogdan Fedeles, personal communication). Lower concentrations more
comparable to the experiments reported here have not been tested as yet. The oxidative
stress represented by increased ROS could also be the initial event that leads to UPR and
other aforementioned processes. The CMAP finding that niclosamide produces a similar
transcriptional profile as 1113 provides a potential mechanistic explanation for the
induction of ROS by 1113, since niclosamide is an agent known to decouple oxidative
phosphorylation. Lipophilic cations have a tendency to accumulate in mitochondria and
can act as protonophores, releasing the H+ gradient, without concurrent generation of
ATP. This could result in accelerated electron transport, causing an increased release of
ROS, in addition to loss of energy as heat. In line with this possibility, the second best
correlated compound identified from CMAP, chlorpromazine, also has reported oxidative
phosphorylation decoupling ability (Berger et al. 1956).
Clearly, further experiments are necessary to elucidate the order of events that
occur upon exposure of cells to 11 3. Some of these include a more thorough comparison
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of dose-response relationships of both 11 3 and 11 -dimethoxy, in order to determine
whether concentrations of 11 30-dimethoxy exist that yield equivalent responses as lower
concentrations of 11 . Alternatively, certain genes such as CDKNIA and BTG2 may not
respond to any concentration of 11 -dimethoxy, or the magnitude change of genes such
as DDIT3, GDF15, and ATF3 may never be as great from any concentration of 11 3-
dimethoxy. In those instances, it would be valuable to attempt modulation of such genes
through gain or loss of function experiments to determine if susceptibility of a cell to
treatment with 11 3 or 11 P-dimethoxy could be equalized.
Activation of the UPR provides a reasonable explanation for enhanced sensitivity
of cancer cells to 11 p. A crucial experiment will involve detection of UPR activation in
xenograft tumors at therapeutically relevant concentrations of 11 3. In cells, there are
several experiments that can be conducted to identify some of the initial effectors that are
likely to lead to UPR induction and apoptosis. Some of these are already underway; for
example, it has been found that addition of radical scavengers such as N-acetylcysteine
and vitamin E to HeLa cells that are treated with 1113 decreases cell death (Bogdan
Fedeles, personal communication). Along these lines, it should be determined whether
the reduction in toxicity achieved with N-acetylcyesteine also correlates with decreased
activation of UPR. Other experiments will address whether interference with 1113-
induced calcium redistribution by small-molecules (i.e. BAPTA, A23187) can modulate
toxicity. The genes identified through this transcriptional analysis can be used as
biomarkers of specific pathways in all cases.
Please refer to supplemental Tables S4.1-S4.16 for top 50 (or fewer in some cases,
absolute value of LFC must be > 0.5 for inclusion) lists of genes significantly
differentially expressed in each pair-wise comparison, and also Figures S4.1-S4.8 for
volcano plots of these comparisons. Finally, Figure S4.9 includes structures of
compounds identified from CMAP analysis as inducing similar transcriptional profiles as
5 LM 11 3 for reference.
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Table 4.1. Treatments and pai
analysis.
r-wise comparisons for gene microarray
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Treatment Duration Sample Name Pair-wise
comparison with
reference to:
None; harvested at 0 hrs Unt 0 hrs N/A
treatment time
Fresh media 6 hrs Unt 6 hrs Unt 0 hrs
DMSO 6 hrs DMSO Unt 6 hrs
113 1 JM 6 hrs 11P 1 M DMSO
11 5 pM 6 hrs 113 5 pM DMSO
11 p-Dimethoxy 5 pM 6 hrs 11 -dimethoxy DMSO
Chlorambucil 5 pM 6 hrs Cbl DMSO
R1881 1 nM 6 hrs R1881 DMSO
Bicalutamide 1 ptM 6 hrs Bicalutamide DMSO
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of Several Genes
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Figure 4.2 Numbers of unique genes significantly differentially
expressed by various treatments. Growth in fresh media for 6 hrs as
compared to cells at treatment time, DMSO compared to 6 hrs untreated
sample, and 5 gIM chlorambucil did not significantly affect expression of
any genes (p-value < 0.05, 2-fold change, present in at least one
treatment group)
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111 Affects Expression of
Genes Involved in Specific
Biological Processes
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Figure 4.3 Numbers of genes in functional categories affected by
treatment with 5 gM 1113.
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Table 4.2 Genes significantly up-regulated by treatment with 5
M 113. Genes are categorized with respect to biological
process.
Category Gene Symbols
Apoptosis ATXN1, DDIT4, DRAM ,GADD45A, GDF15, JMY, NUPR1,
RRAGC, SQSTM1, TNFSF15, TP531NP1, TRIB3, WIPI1
Cell Cycle BTG2, CCNG2, DCTN2, FICD, FLCN, FNIP1, GPNMB, JUB,
LIFR, PTCH1, RB1CC1, SIRT2, TNFSF4, TSPYL2, VEGFA, NA
(226725_a), CDKN1A, HBP1, SESN2
Cell Organization/Motility GABARAPL1, PKD1, TUBE1
Development AHNAK, FBN1, HECA, IFRD1, PTPRR, RNF103
Lipid/Fatty Acid Biosynthesis ACSL1, ACSS2, ALDH1A3, ANKRA2, CHKA, CHPT1, FADS1,
FASN, FDFT1, HMGCR, HMGCS1, HSD17B7, INSIG1, LPIN1,
LSS, PNLIPRP3, SC4MOL, SQLE, STARD4, THRSP, VLDLR
Metabolism DIO1, ENPP5, FUT1, GDPD1, GFPT1, NEU1, RDH10
Metal Ion Binding CHAC1, MT1F, SLC30A1, SLC3A2, STC2
Other CD55, DSE, GOLGA2, INHBE, KDSR, KIAA0247, LGALS8,
LYSMD3, N4BP2L2, TRIM2
Protein Degradation PRSS8, SYVN1, TAGLN, USP54
Protein Synthesis MARS, MTHFR
Signal Cascade AKAP5, BLNK, C20orf74, CBLB, DUSP16, EFNA1, FZD7, FZD8,
GUCY1A3, NEK8, PIK3C2A, RPS6KA2, SAV1, TBC1D8B
Transcription ANG, RNASE4, ATF3, BHLHB2, CEBPB, CEBPG, CHD2,
CREB3L2, ELF3, JMJD1A, JMJD1C, JUND, KLF4, LARP6,
MEF2A, MLXIP, NFAT5, NR1D2, OVOL1, RBM35A, RFX6,
SFRS1, TSC22D1, TSC22D3, TULP3, ZNF165
Transport ATP8B2, CDRT4, COG3, LYST, MCFD2, RAB39B, SEC24D,
SLC17A5, SLC1A4, SLC25A36, SLC33A1, SLC7A1, SLC7A11,
SNX9, SPIRE1, STX3, STX5, TMCO3, TMED10, TMED5,
CNNM2
Unfolded Protein DDIT3, DNAJB9, EDEM1, EDEM3, EIF2AK3, FAM129A,
FKBP11, FKBP14, HERPUD1, HSPA13, HSPA5
Unknown ARMCX3, BTN3A3, C4orf34, C5orf41, TTC39B, CTAGE5,
KLHL24, LOC729873, PPAPDC2, TMEM170, TMEM39A,
TMEM56, TOR1AIP2, TTC39B
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Table 4.3 Genes significantly down-regulated by treatment with
5 tM 113. Genes are categorized according to biological
process.
Category Gene Symbols
Apoptosis CARD10, NEK6
Cell Cycle AGGF1, CCNA2, CCNE1, CCNE2, CCNF,
CDC25A, CDCA2, FBXO5, PLK1, SKP2,
SUV39H2, E2F8
Cell Organization/Motility MYLIP, TUBA4A
DNA Repair ESCO2, EXO1, MCM10, MCM4, MSH6, NEIL3,
RIF1, RRM2
Lipid/Fatty Acid Biosynthesis DGAT2
Metabolism ALDH1 B1, DHODH, NFS1, PFKFBP3, PPCDC
Other MAT2A
Protein Synthesis EXOSC2, EXOSC3, EXOSC4, EXOSC6,
GEMIN5, MRPS12, NOL5A, POP1, PUS1
Signal Cascade DDIT4L, EFNB2, PRAGMIN
Transcription CDCA7, CHD9, ID1, MAFB, MYB, NARG1,
PINX1, PITX1, PSPC1, SFRS7, SP110,
ZBTB24, ZNF239
Transport SLC16A14, SLC16A6, SLC29A1, TIMM8A
Unfolded Protein DNAJB1, HSPA1A, PPIF
Unknown CMTM7, DCTN5, DSEL, KLHL29, LRFN1,
TMEM177, TRIM59
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Table 4.4 Gene ontological class enrichment of genes
significantly up-regulated by 5 M 1113 treatment.
BIOLOGICAL
PROCESS GENE SYMBOLS P-VALUE
cell fate determination IFRD1, KLF4 9.59E-03
cell cycle arrest CDKN1A, HBP1, GADD45A, SESN2, DDIT3 1.33E-03
sterol biosynthesis SQLE, SC4MOL, HMGCR, HMGCS1 4.49E-04
amino acid transport SLC1A4, SLC7A11, SLC3A2, SLC7A1 1.16E-03
germ cell migration HMGCR, PPAP2B 4.70E-04
MOLECULAR
FUNCTION GENE SYMBOLS P-VALUE
low-density lipoprotein
binding ANKRA2, VLDLR 5.02E-03
protein kinase binding SQSTM1, TRIB3, FASN, PTPRR 5.38E-03
protein dimerization RRAGC, CEBPG, VEGFA, CREB3L2, ATF3, JUND,
activity CEBPB, DDIT3, MAFF 6.74E-04
OVOL1, MEF2A, CEBPG, NR1D2, ELF3,
CREB3L2, BTG2, NFAT5, NR1D2, BHLHB2,
transcription factor TSC22D1, ATF3, KLF4, CEBPB, TSC22D3, DDIT3,
activity AFF4, MAFF, ZNF165 1.70E-03
mannosyl-
oligosaccharide 1\2-
alpha-mannosidase
activity EDEM1, EDEM3 3.93E-03
non-G-protein coupled
7TM receptor activity FZD7, FZD8 7.55E-03
Wnt receptor activity FZD7, FZD8 2.97E-03
amino acid permease
activity SLC7A11, SLC7A1 2.97E-03
CELLULAR
COMPONENT GENE SYMBOLS P-VALUE
endoplasmic reticulum
membrane HMGCR, SLC33A1, HERPUD1, HSPA5, EDEM1 5.12E-03
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Table 4.5 Ontological class enrichment of genes significantly
down-regulated by 5 pM 113 treatment.
BIOLOGICAL PROCESS GENE SYMBOLS P-VALUE
regulation of cyclin-dependent protein
kinase activity CCNE2, CDC25A, CCNA2 9.52E-04
G1/S transition of mitotic cell cycle SKP2, CCNE1 4.89E-03
NEK6, CCNF, PLK1, CDC25A,
mitosis CCNA2 8.53E-04
rRNA processing EXOSC2, EXOSC4, GEMIN4, NOL5A 5.48E-04
nuclear mRNA splicing via spliceosome GEMIN4, MYB, SFRS7, GEMIN5 3.96E-03
mismatch repair EXO1, MSH6 4.42E-03
base-excision repair EXO1, MSH6, NEIL3 2.00E-04
MOLECULAR FUNCTION GENE SYMBOLS P-VALUE
3'-5'-exoribonuclease activity EXOSC2, EXOSC4 1.81 E-03
DNA N-glycosylase activity NEIL3, MSH6 2.13E-03
endodeoxyribonuclease activity EXO1, NEIL3 2.85E-03
CELLULAR COMPONENT GENE SYMBOLS P-VALUE
exosome (RNAse complex) EXOSC2, EXOSC4 1.10E-03
chromosome, telomeric region RIF1, PINX1 3.64E-03
POP1, GEMIN4, EXOSC4, ZNF239,
nucleolus NOL5A 1.29E-04
spliceosome complex GEMIN4, MYB, GEMIN5 3.73E-03
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Table 4.6 Ontological class enrichment of genes significantly
up-regulated (A) or down-regulated (B) by 1 M 110 treatment.
BIOLOGICAL PROCESS GENE SYMBOLS P-VALUE
cholesterol biosynthesis IDI1, FDFT1, HMGCS1, DHCR7 1.52E-06
MOLECULAR FUNCTION GENE SYMBOLS P-VALUE
NEK8, FDFT1, IDI1, ATP8B2, MAP3K2,
magnesium ion binding ACSL1 3.64E-04
ligase activity\forming carbon-
sulfur bonds ACSL1, ACSL2 9.49E-04
oxidoreductase activity\acting
on the CH-CH group of donors\
NAD or NADP as acceptor FASN, DHCR7 8.15E-04
CELLULAR COMPONENT GENE SYMBOLS P-VALUE
perinuclear region MAP1S, HSPA5 3.06E-03
peroxisome IDI 1, ACSL1, PEX10 1.30E-03
B.
BIOLOGICAL PROCESS GENE SYMBOLS P-VALUE
protein amino acid acetylation PCAF, NARG1L 8.74E-04
protein transport RIMS1, KIF18A, LRSAM1, RAB23, NUP43 9.74E-03
MOLECULAR FUNCTION GENE SYMBOLS P-VALUE
acetyltransferase activity PCAF, NARG1L 4.15E-03
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11p and 11-Dimethoxy Affect
Expression of Many of the Same Genes
11 p 2x,
68
Di 2x,
101
Figure 4.4 Venn diagram showing common genes between 11
and 11 3-dimethoxy treatment. Yellow circle represents all probe
sets significantly differentially expressed by 5 IM 110 treatment >
2-fold (477). Blue circle represents all probe sets significantly
differentially expressed by 111 -dimethoxy (Di) treatment > 2-fold
(301). 200 of these probe sets are common to both 11P and 110-
dimethoxy. The green circle represents all probe sets differentially
expressed greater than 1.4-fold by 11 P-dimethoxy in order to
emphasize the minor subset of probe sets which are most unique
to 11 3 treatment (68). Drawing is to scale.
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Table 4.7 Gene ontological class enrichment of genes significantly up-
regulated by 5 jM 11 p-dimethoxy treatment
BIOLOGICAL PROCESS GENE SYMBOLS P-VALUE
parturition HPGD, MAFF 2.31 E-03
allene biosynthesis IDI1, HPGD 7.23E-03
fatty acid biosynthesis SCD, FASN, HPGD 8.83E-03
isoprenoid biosynthesis ID11, FDFT1 6.23E-03
HMGCS1, DHCR7, ID11, FDFT1,
cholesterol biosynthesis HMGCR 1.83E-06
germ cell migration PPAP2B, HMGCR 2.55E-04
lipid transport LDLR, VLDLR, CHKA, STARD4 2.43E-03
response to unfolded protein EIF2AK3, HERPUD1, EDEM1 5.18E-03
MOLECULAR FUNCTION GENE SYMBOLS P-VALUE
protein kinase binding PTPRR, TRIB3, FASN, AKAP5 1.47E-03
ATF3, VEGFA, MAF, CREB3L2,
protein dimerization activity FOSL2, HPGD, DDIT3, MAFF 2.68E-04
low-density lipoprotein receptor activity LDLR, VLDLR 1.05E-03
non-G-protein coupled 7TM receptor
activity FZD7, FZD8 3.75E-03
Wnt receptor activity FZD7, FZD8 1.46E-03
transmembrane receptor protein
tyrosine phosphatase activity PTPRR, PTPRK 8.98E-03
mannosyl-oligosaccharide 1\2-alpha-
mannosidase activity EDEM1, EDEM3 1.94E-03
oxidoreductase activity\ acting on the
CH-CH group of donors\ NAD or
NADP as acceptor DHCR7, FASN 5.26E-03
ligase activity\ forming carbon-sulfur
bonds ACSL1, ACSS2 6.11E-03
lipid transporter activity LDLR, ATP8B2, VLDLR, STARD4 2.00E-03
neutral amino acid transporter activity SLC7A11, SLC1A4 5.26E-03
CELLULAR COMPONENT GENE SYMBOLS P-VALUE
peroxisome IDI1, PEX10, ACSL1, HMGCR 3.95E-03
integral to endoplasmic reticulum
membrane RRBP1, EDEM1, HSPA5 3.28E-03
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Table 4.8 Gene ontological class enrichment of genes significantly
down-regulated by 5 tM 11 3-dimethoxy treatment.
BIOLOGICAL PROCESS GENE SYMBOLS P-VALUE
steroid hormone receptor signaling pathway CCNE1, RBM14 2.57E-03
RBL1, CCNE1, PIK3CB,
regulation of progression through cell cycle CCNE2 6.38E-03
nucleobase\nucleoside\nucleotide and nucleic acid
transport NUP160, SLC29A1 5.08E-03
regulation of kinase activity RBL1, PIK3CB, CCNE2 2.42E-03
MOLECULAR FUNCTION GENE SYMBOLS P-VALUE
DNA-dependent ATPase activity MCM4, DHX9 1.89E-03
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Table 4.9 Ontological class enrichment of genes more greatly altered in
expression by 5 pM 11p treatment than 11 -dimethoxy treatment (ALFC
_ 0.8).
BIOLOGICAL PROCESS GENE SYMBOLS P-VALUE
cell fate determination IFRD1, KLF4 5.76E-04
transcription from RNA polymerase II MEF2A, ID1 (down), SQSTM1,
promoter MDM2, DDIT3 9.26E-03
CDKN1A, GADD45A, DDIT3,
cell cycle arrest SESN2 4.11E-05
regulation of cyclin-dependent protein
kinase activity CDKN1A, GADD45A 5.54E-03
response to DNA damage stimulus BTG2, DDB2, GADD45A, DDIT3 4.65E-03
MOLECULAR FUNCTION GENE SYMBOLS P-VALUE
transcriptional repressor activity ID1 (down), ATF3, KLF4, DDIT3 1.29E-03
CELLULAR COMPONENT GENE SYMBOLS P-VALUE
basement membrane FBN1, LAMA1 (down) 9.58E-03
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Table 4.10 Genes which are more greatly altered in expression by 111 -dimethoxy (Di) treatment than
5 CIM 11fP treatment (ALFC _ 0.8). For these genes, LFC for R1 881 and Bicalutamide (Bic) are shown
for comparison. Gray cells indicate p-value > 0.05; *p-value is < 0.05 for another probe set for this
aene.
Gene
Probe ID Symbol Gene Name 11p Di R1881 Bic
236207 at SSFA2 sperm specific antigen 2 -0.37 -1.36 4 0.12
ATP-binding cassette, sub-family G
204567 s at ABCG1 (WHITE), member 1 0.41 -0.91 -0.81 0.47
Fas (TNF receptor superfamily,
member 6)
Mdm2 p53 binding protein homolog
217373_x_at MDM2 (mouse)
224856_at FKBP5 FK506 binding protein 5
family with sequence similarity 110,
228790_at FAM110B member B
225330_at IGF1R insulin-like growth factor 1 receptor
213158_at NA NA
receptor tyrosine kinase-like orphan
205805_s_at ROR1 receptor 1
CSGALNA chondroitin sulfate N-
219049_at CT1 acetylgalactosaminyltransferase 1
hydroxyprostaglandin dehydrogenase
211548_s at HPGD 15-(NAD)
pleckstrin homology-like domain, family
225688_s_at PHLDB2 B, member 2
v-maf musculoaponeurotic
fibrosarcoma oncogene homolog
206363_at MAF (avian)
213139_at SNAI2 snail homolog 2 (Drosophila)
1557352_at SQLE squalene epoxidase
prostate transmembrane protein,
222450_at PMEPA1 androgen induced 1
low density lipoprotein receptor
0.62
0.42
-0.73 -0.27 0.13
-0.51 .3 -22
0.79 1.69 -0.49
0.90 0.95 -0.86
0.91 1.30 -0.34
0.97 0.29 0.
1.04 1.08 024
1.06 2.13 0.00
1.07 1.37 -0.22
1.16 1.97 -0.36
1.31 2.38
1.34
1.48
1.51
1.66
2.64 -1.57
230256_at Clorfl04 chromosome 1 open reading frame 104 0.89 1.89
238666_at NA NA 0.97 2.02
farnesyl-diphosphate
241954_at FDFT1 farnesyltransferase 1 1.08 2.20
3-hydroxy-3-methylglutaryl-Coenzyme
205822_s_at HMGCS1 A synthase 1 (soluble) 1.89 2.81
thyroid hormone responsive (SPOT14
229476 s at THRSP homolog, rat) 1.48 2.98
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Microarray Findings are Verified by RT-
PCR of a Subset of Genes
I GDF15
M DDIT3
M GADD45A
M ATF3
E TRIB3
MI HMGCS1
I**
1ip
Treatment
ii,
Ilp-dimethoxy
Figure 4.5 RT-PCR analysis of interesting genes
identified with microarrays as up-regulated by 51.M 113
and 11 -dimethoxy treatment. LNCaP cells were treated
for 6 hrs. *p-val < 0.1, **p-val < 0.05
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The Two Genes Most Up-Regulated by
113 Treatment are Maximized in
Expression after 6 hrs
S-IGDF15
SDDIT3
0 2 4 6 8
Time (hrs)
16 24
Figure 4.6 RT-PCR analysis of GDF15 and DDIT3.
These two genes, which were determined to have the
greatest response to 5 gM 110 treatment, were monitored
for expression over a 24 hr period in LNCaP cells. Each
increases to a similar extent but is maximized after 6 hrs.
*p-val < 0.1, **p-val < 0.05
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11P Induces Cleavage of XBP1 into
an Active Transcription Factor,
Consistent with Activation of Unfolded
Protein Response
30-
0~
0c
.
I-
20-
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CJ XBP1(u)
m XBP1(s) T
I I - -
Unt lp1
Treatment
Tg
Figure 4.7 RT-PCR analysis of XBP1 cleavage in LNCaP
cells treated with 5tM 113. XBPI(u) is the unspliced form
while XBPI(s) is the spliced, active transcription factor.
Thapsigargin (Tg), 200 nM, is included as a positive control.
Cells were treated for 6 hrs with 113, 5 hrs with Tg.
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Table 4.11 Top Matches from Connectivity Map for 5 pIM 11 P. A. Top 10 matches for correlation with
5pM 11 3 treatment. Score is arbitrarily set as 1 for best match, -1 for worst match, and scaled
accordingly, while Up and Down Scores represent absolute measures of similarity (1 means up-
regulated genes in query list are the most up-regulated genes in treatment instance within CMAP
library, -1 means down-regulated genes in query list are identical to most down-regulated genes in
treatment instance within CMAP library). B. Top five results averaged by Anatomical Therapeutic
Chemical (ATC) classification, sorted by p-value. Mean is the average score for all instances, N is
number of instances in category, Enrich is a measure of over-representation of an ATC class, while
P-val is a permutation p-value reflecting the likelihood that this level of enrichment is by chance.
Specificity is a measure of the uniqueness of a score by comparing against public expression data
available from MSigDB: http://www.broad.mit.edu/lsealmsigdb/ (higher value indicates greater
number of gene lists from this database which score at least as well as the queried gene list; lower
value means greater specificity). % non-null represents the percentage of instances in each category
which have a score in the same direction as the gene list queried
A.
Compound Dose Cell Score Up Down Instance ID
pyrvinium 3 pM MCF7 1 0.407 -0.524 3518
chlorpromazine 11 pM PC3 0.988 0.487 -0.432 5074
thioridazine 10 pM MCF7 0.982 0.518 -0.397 1010
pyrvinium 3 pM MCF7 0.965 0.434 -0.465 5439
astemizole 9 pM MCF7 0.965 0.541 -0.357 6807
niclosamide 12 pM MCF7 0.964 0.463 -0.434 1498
perhexiline 10 pM MCF7 0.912 0.443 -0.406 7441
trifluoperazine 10 pM PC3 0.91 0.453 -0.394 4448
niclosamide 12 pM MCF7 0.903 0.425 -0.416 4136
thioridazine 10 pM MCF7 0.901 0.467 -0.372 5227
B.
% Non-
ATC Category Mean N Enrich P-Val Specificity null
NO5AC;
phenothiazines with piperidine
structure 0.601 24 0.727 < 2e-5 0 87
NO5AB; phenothiazines with
piperazine structure 0.615 60 0.709 < 2e-5 0 95
NO6AA; non-selective monoamine
reuptake inhibitors 0.501 46 0.616 < 2e-5 0 86
DO1AC; imidazole and triazole
derivatives 0.388 35 0.414 < 2e-5 0.0118 74
C08EA; phenylalkamine
derivatives (non-selective calcium
channel blockers) 0.621 7 0.782 2e-5 0.0104 100
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11p Evokes a Similar Transcriptional
Profile as Phenothiazines
I
NO5AB
+1
E
IA~
,£0
_O
c
-1
+1
E
0)
C
1g
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3
Trifluoperazine
I .- -.. - -- 2 3
Chlorambucil
Figure 4.8 Connectivity Map visual display of 5 pM 11 transcriptional similarity with phenothiazines.
A. bar view display of instances in the ATC class NO5AB (phenothiazines with piperazine structure).
Green area represents positive correlation, red denotes inverse correlation, gray indicates overall
score of zero. Black horizontal lines are individual treatment instances. B. Bar view and plot of
trifluoperazine. Plot shown is for one instance of trifluoperazine treatment. Green line represents probe
sets up-regulated by 11 P, while red line denotes probe sets down-regulated. Probes for each instance
are ordered with most upregulated at the left and most down regulated at the right. Thus, good
correlation can be visualized by the green line being more positive in the left portion of the graph and
the red line being more negative toward the right portion of the graph, as seen. C. Bar view and plot
for chlorambucil is shown for comparison to an agent with poor correlation (plot is of treatment with the
highest correlation to 110).
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Table S4.1 Top 50 probe sets up-regulated by treatment with 5 pM 11 .
Probe ID is identifier for probe set from Affymetrix HGU 133 Plus 2.0
GeneChip@. Values shown are Log 2 fold-changes (LFC of 1 = 2-fold
change). LFC of treatment with 11p-dimethoxy (Di) is shown for
comparison. Gray cells indicate p-value > 0.05.
LFC
Gene 1113 Di
Probe ID Symbol Gene Name 51M 5pM
221577_x_at GDF15 growth differentiation factor 15 3.48 2.08
209383_at DDIT3 DNA-damage-inducible transcript 3 3.46 1.71
225239_at NA NA 3.25 2.45
1554018_at GPNMB glycoprotein (transmembrane) nmb 3.00 2.34
234989_at TncRNA trophoblast-derived noncoding RNA 2.93 2.30
238695 s at RAB39B RAB39B, member RAS oncogene family 2.93 2.25
227062_at TncRNA trophoblast-derived noncoding RNA 2.77 2.09
SEC24 related gene family, member D (S.
215209_at SEC24D cerevisiae) 2.75 1.36
1554462 a at DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.70 1.92
219910 at FICD FIC domain containing 2.69 2.32
v-maf musculoaponeurotic fibrosarcoma oncogene
36711_at MAFF homolog F (avian) 2.68 2.03
226158 at KLHL24 kelch-like 24 (Drosophila) 2.63 1.88
202843_at DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.59 1.84
SEC24 related gene family, member D (S.
202375_at SEC24D cerevisiae) 2.50 2.22
202887 s at DDIT4 DNA-damage-inducible transcript 4 2.48 2.13
201627 s at INSIG1 insulin induced gene 1 2.46 3.10
230075_at RAB39B RAB39B, member RAS oncogene family 2.42 1.82
225957_at C5orf41 chromosome 5 open reading frame 41 2.40 1.52
202842 s at DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.38 1.84
225956_at C5orf41 chromosome 5 open reading frame 41 2.35 1.42
242088_at KLHL24 kelch-like 24 (Drosophila) 2.34 1.26
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
221750 at HMGCS1 (soluble) 2.24 2.61
221986_s_at KLHL24 kelch-like 24 (Drosophila) 2.21 1.58
208763_s_at TSC22D3 TSC22 domain family, member 3 2.20 1.38
203725_at GADD45A growth arrest and DNA-damage-inducible, alpha 2.19 1.22
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LFC
Gene 11 Di
Probe ID Symbol Gene Name 5pM 5pM
201625_s_at INSIG1 insulin induced gene 1 2.18 2.96
221985_at KLHL24 kelch-like 24 (Drosophila) 2.17 1.49
210587_at INHBE inhibin, beta E 2.16
201626_at INSIG1 insulin induced gene 1 2.12 2.32
238476_at C5orf41 chromosome 5 open reading frame 41 2.12 1.26
212274_at LPIN1 lipin 1 2.11 2.25
202557_at HSPA13 heat shock protein 70kDa family, member 13 2.11 1.62
solute carrier family 1 (glutamate/neutral amino acid
212810 s at SLC1A4 transporter), member 4 2.11 2.02
212276_at LPIN1 lipin 1 2.10 2.22
214696_at C17orf91 chromosome 17 open reading frame 91 2.09 1.53
226771_at ATP8B2 ATPase, class I, type 8B, member 2 2.09 2.15
212272_at LPIN1 lipin 1 2.07 2.06
218696_at EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3 2.05 1.63
219270_at CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 2.02 0.90
202766 s at FBN1 fibrillin 1 2.02 0.98
238320_at TncRNA trophoblast-derived noncoding RNA 2.01 0.87
227020_at YPEL2 yippee-like 2 (Drosophila) 2.01 1.32
223195_s_at SESN2 sestrin 2 1.97 0.95
228234_at TICAM2 toll-like receptor adaptor molecule 2 1.95 1.16
210675_s_at PTPRR protein tyrosine phosphatase, receptor type, R 1.95 1.50
201170_s_at BHLHB2 basic helix-loop-helix domain containing, class B, 2 1.95 2.19
218145_at TRIB3 tribbles homolog 3 (Drosophila) 1.93 1.44
202672_s_at ATF3 activating transcription factor 3 1.92 1.11
235369_at C14orf28 chromosome 14 open reading frame 28 1.91 1.12
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Table S4.2 Top 50 probe sets down-regulated by treatment with 5 liM 11 P. Probe ID is identifier forprobe set from Affymetrix HGU133 Plus 2.0 GeneChip®. Values shown are Log2 fold-changes (LFC
of 1 = 2-fold change). LFC of treatment with 11 P-dimethoxy (Di) is shown for comparison. Gray cellsindicate p-value > 0.05.
LFC
Gene 111 DiProbe ID Symbol Gene Name 5pM 5pM
226064_s_at DGAT2 diacylglycerol O-acyltransferase homolog 2 (mouse) -2.14 -1.32
200769_s_at MAT2A methionine adenosyltransferase II, alpha 
-2.10 -1.63
209645_s_at ALDH1B1 aldehyde dehydrogenase 1 family, member B1 -1.78 -1.36
v-myb myeloblastosis viral oncogene homolog
204798_at MYB (avian) 
-1.76 -1.67
227048_at LAMA1 laminin, alpha 1 
-1.70
solute carrier family 16, member 6 (monocarboxylic
207038_at SLC16A6 acid transporter 7) 
-1.60
201008_s_at TXNIP thioredoxin interacting protein 
-1.54 -1.40
212525_s_at H2AFX H2A histone family, member X -1.51 -0.78
213523_at CCNE1 cyclin El 
-1.49 -1.00
1554036_at ZBTB24 zinc finger and BTB domain containing 24 -1.47
translocase of inner mitochondrial membrane 8
205217_at TIMM8A homolog A (yeast) 
-1.46 -0.95
210387_at HIST1H2BG histone cluster 1, H2bg 
-1.46 -0.72
238953_at NA NA 
-1.44 -0.78
228990_at Clorf79 chromosome 1 open reading frame 79 -1.39 -1.44
204695_at CDC25A cell division cycle 25 homolog A (S. pombe) -1.38 -0.82
212170_at RBM12 RNA binding motif protein 12 -1.38 -0.68
223159_sat NEK6 NIMA(never in mitosis gene a)-related kinase 6 -1.38 -0.83
202668_at EFNB2 ephrin-B2 
-1.37 -0.73
solute carrier family 16, member 6 (monocarboxylic
230748_at SLC16A6 acid transporter 7) 
-1.34
235476_at TRIM59 tripartite motif-containing 59 
-1.34 -0.61
244852_at DSEL dermatan sulfate epimerase-like -1.33 -1.46
224428_s_at CDCA7 cell division cycle associated 7 -1.33 -1.24
v-maf musculoaponeurotic fibrosarcoma oncogene
218559_s_at MAFB homolog B (avian) 
-1.33 -1.21
minichromosome maintenance complex component
220651 s at MCM10 10 
-1.30 -1.11
201490_s_at PPIF peptidylprolyl isomerase F (cyclophilin F) -1.29 -1.24
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LFC
Gene 11ip Di
Probe ID Symbol Gene Name 5pM 5pM
218974_at SOBP sine oculis binding protein homolog (Drosophila) -1.28 -0.93
219262_at SUV39H2 suppressor of variegation 3-9 homolog 2 (Drosophila) -1.28 -0.86
214963_at NUP160 nucleoporin 160kDa -1.27 -0.91
219990_at E2F8 E2F transcription factor 8 -1.26 -0.85
212168_at RBM12 RNA binding motif protein 12 -1.25 -0.73
transmembrane protein with EGF-like and two
224321_at TMEFF2 follistatin-like domains 2 -1.23 -1.09
223773_s_at C1orf79 chromosome 1 open reading frame 79 -1.23 -1.24
1553947_at EXOSC6 exosome component 6 -1.23 -0.79
226998_at NARG1 NMDA receptor regulated 1 -1.23 -0.62
200874_s_at NOL5A nucleolar protein 5A (56kDa with KKE/D repeat) -1.22 -0.96
229310_at KLHL29 kelch-like 29 (Drosophila) 
-1.22
transmembrane and tetratricopeptide repeat
1554101a_at TMTC4 containing 4 
-1.22
203418_at CCNA2 cyclin A2 
-1.22 -0.45
205241_at SCO2 SCO cytochrome oxidase deficient homolog 2 (yeast) -1.21 -0.86
processing of precursor 1, ribonuclease P/MRP
213449_at POP1 subunit (S. cerevisiae) 
-1.21 -0.54
225687_at FAM83D family with sequence similarity 83, member D -1.20 -0.60
CKLF-like MARVEL transmembrane domain
226017_at CMTM7 containing 7 
-1.19 -0.88
219502_at NEIL3 nei endonuclease VIII-like 3 (E. coli) -1.19 -0.67
218726_at HJURP Holliday junction recognition protein -1.19 -0.44
218897_at TMEM177 transmembrane protein 177 -1.19 -0.94
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
202464_s_at PFKFB3 3 
-1.18 -0.86
200768_s_at MAT2A methionine adenosyltransferase II, alpha -1.17 -0.85
1555639_a_at RBM14 RNA binding motif protein 14 -1.17 -1.22
232825_s_at DSEL dermatan sulfate epimerase-like 
-1.17 -0.82
206261_at ZNF239 zinc finger protein 239 -1.17 -0.68
233
Chapter 4 -
Table S4.3 Top 50 probe sets up-regulated by treatment with 5 jM 1113-dimethoxy.
Probe ID is identifier for probe set from Affymetrix HGU133 Plus 2.0 GeneChip®.
Values shown are Log2 fold-changes (LFC of 1 = 2-fold change). LFC of treatment
with 11 3 is shown for comparison.
LFC
Gene 11p Di
Probe ID Symbol Gene Name 5pM 5pM
201627 s at INSIG1 insulin induced gene 1 2.46 3.10
229476_s_at THRSP thyroid hormone responsive (SPOT14 homolog, rat) 1.48 2.98
201625 s at INSIG1 insulin induced gene 1 2.18 2.96
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
205822_s_at HMGCS1 (soluble) 1.89 2.81
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
221750_at HMGCS1 (soluble) 2.24 2.61
229477_at THRSP thyroid hormone responsive (SPOT14 homolog, rat) 1.09 2.56
225239_at NA NA 3.25 2.45
1554018_at GPNMB glycoprotein (transmembrane) nmb 3.00 2.34
234312 s at ACSS2 acyl-CoA synthetase short-chain family member 2 1.64 2.32
219910_at FICD FIC domain containing 2.69 2.32
201626_at INSIG1 insulin induced gene 1 2.12 2.32
234989_at TncRNA trophoblast-derived noncoding RNA 2.93 2.30
212274_at LPIN1 lipin 1 2.11 2.25
238695 s at RAB39B RAB39B, member RAS oncogene family 2.93 2.25
202375_at SEC24D SEC24 related gene family, member D (S. cerevisiae) 2.50 2.22
212276_at LPIN1 lipin 1 2.10 2.22
241954_at FDFT1 farnesyl-diphosphate farnesyltransferase 1 1.08 2.20
201170_s_at BHLHB2 basic helix-loop-helix domain containing, class B, 2 1.95 2.19
226771_at ATP8B2 ATPase, class I, type 8B, member 2 2.09 2.15
202887 s at DDIT4 DNA-damage-inducible transcript 4 2.48 2.13
227062_at TncRNA trophoblast-derived noncoding RNA 2.77 2.09
221577_x_at GDF15 growth differentiation factor 15 3.48 2.08
212272_at LPIN1 lipin 1 2.07 2.06
209218_at SQLE squalene epoxidase 1.36 2.04
v-maf musculoaponeurotic fibrosarcoma oncogene
36711_at MAFF homolog F (avian) 2.68 2.03
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LFC
11 Di
Probe ID Gene Symbol Gene Name 5pM 5pM
solute carrier family 1 (glutamate/neutral amino acid
212810_s_at SLC1A4 transporter), member 4 2.11 2.02
238666_at NA NA 0.97 2.02
StAR-related lipid transfer (START) domain containing
226390_at STARD4 4 1.49 1.98
1554462_aat DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.70 1.92
230256_at Clorfl04 chromosome 1 open reading frame 104 0.89 1.89
213577_at SQLE squalene epoxidase 1.21 1.89
226158_at KLHL24 kelch-like 24 (Drosophila) 2.63 1.88
209146_at SC4MOL sterol-C4-methyl oxidase-like 1.38 1.86
202842_s_at DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.38 1.84
202843_at DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.59 1.84
230075_at RAB39B RAB39B, member RAS oncogene family 2.42 1.82
206457_s_at DIO1 deiodinase, iodothyronine, type I 1.82 1.77
213562_s_at SQLE squalene epoxidase 1.12 1.74
211986_at AHNAK AHNAK nucleoprotein 1.04 1.74
205945_at IL6R interleukin 6 receptor 1.47 1.73
209383_at DDIT3 DNA-damage-inducible transcript 3 3.46 1.71
218764_at PRKCH protein kinase C, eta 1.55 1.70
1563571_at LOC285463 hypothetical protein LOC285463 1.22 1.68
226929_at MTHFR 5,10-methylenetetrahydrofolate reductase (NADPH) 1.57 1.68
213836_s_at WIPI1 WD repeat domain, phosphoinositide interacting 1 1.89 1.67
solute carrier family 7, (cationic amino acid transporter,
217678_at SLC7A11 y+ system) member 11 1.90 1.66
202068_s_at LDLR low density lipoprotein receptor 0.42 1.66
lanosterol synthase (2,3-oxidosqualene-lanosterol
202245_at LSS cyclase) 1.09 1.65
202540 s at HMGCR 3-hydroxy-3-methylglutaryI-Coenzyme A reductase 1.18 1.65
solute carrier family 1 (glutamate/neutral amino acid
209610 s at SLC1A4 transporter), member 4 1.67 1.64
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Table S4.4 Top 50 probe sets down-regulated by treatment with 5 gM 11 P-
dimethoxy. Probe ID is identifier for probe set from Affymetrix HGU133 Plus 2.0
GeneChip@. Values shown are Log2 fold-changes (LFC of 1 = 2-fold change). LFC
of treatment with 11 p is shown for comparison. Gray cells indicate p-value > 0.05.
LFC
Gene 11 Di
Probe ID Symbol Gene Name 5AM 5AM
204798_at MYB v-myb myeloblastosis viral oncogene homolog (avian) -1.76 -1.67
200769_s_at MAT2A methionine adenosyltransferase II, alpha -2.10 -1.63
211814 s at CCNE2 cyclin E2 -1.14 -1.51
244852_at DSEL dermatan sulfate epimerase-like -1.33 -1.46
228990_at C1lorf79 chromosome 1 open reading frame 79 -1.39 -1.44
201008_s_at TXNIP thioredoxin interacting protein -1.54 -1.40
1560224_at AHCTF1 AT hook containing transcription factor 1 -1.37
209645_s_at ALDH1B1 aldehyde dehydrogenase 1 family, member B1 -1.78 -1.36
236207_at SSFA2 sperm specific antigen 2 437 -1.36
226064 s_at DGAT2 diacylglycerol O-acyltransferase homolog 2 (mouse) -2.14 -1.32
223774_at C1lorf79 chromosome 1 open reading frame 79 -1.16 -1.25
201490 s at PPIF peptidylprolyl isomerase F (cyclophilin F) -1.29 -1.24
223773_s_at Clorf79 chromosome 1 open reading frame 79 -1.23 -1.24
237215_s_at TFRC transferrin receptor (p90, CD71) -1.24
224428 s at CDCA7 cell division cycle associated 7 -1.33 -1.24
230543_at USP9X ubiquitin specific peptidase 9, X-linked -1.22
1555639 a at RBM14 RNA binding motif protein 14 -1.17 -1.22
solute carrier family 29 (nucleoside transporters),
201801_s_at SLC29A1 member 1 -1.11 -1.21
v-maf musculoaponeurotic fibrosarcoma oncogene
218559_s_at MAFB homolog B (avian) -1.33 -1.21
214962_s_at NUP160 nucleoporin 160kDa -0.88 -1.21
1555465_at MCOLN2 mucolipin 2 -0.85 -1.19
212105_s_at DHX9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 -0.79 -1.18
1557217 a at FANCB Fanconi anemia, complementation group B -0.94 -1.15
222108_at AMIGO2 adhesion molecule with Ig-like domain 2 -0.52 -1.15
206902 s at ENDOGL1 endonuclease G-like 1 -1.08 -1.14
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LFC
11ip Di
Probe ID Gene Symbol Gene Name 5pJM 5pM
220007_at METTL8 methyltransferase like 8 -0.87 -1.13
v-maf musculoaponeurotic fibrosarcoma
222670 s at MAFB oncogene homolog B (avian) -1.13 -1.13
minichromosome maintenance complex
212142_at MCM4 component 4 -1.04 -1.13
207199_at TERT telomerase reverse transcriptase -0.85 -1.11
221440_s_at RBBP9 retinoblastoma binding protein 9 -0.80 -1.11
minichromosome maintenance complex
220651 s at MCM10 component 10 -1.30 -1.11
transmembrane protein with EGF-like and two
224321_at TMEFF2 follistatin-like domains 2 -1.23 -1.09
222611 s at PSPC1 paraspeckle component 1 -1.11 -1.09
phosphoinositide-3-kinase, catalytic, beta
217620_s_at PIK3CB polypeptide -0.54 -1.09
228098_s_at MYLIP myosin regulatory light chain interacting protein -1.07 -1.08
228057 at DDIT4L DNA-damage-inducible transcript 4-like -1.06 -1.07
239316 at LOC751071 hypothetical protein LOC751071 -0.56 -1.07
223130 s at MYLIP myosin regulatory light chain interacting protein -0.89 -1.07
225449_at RDH13 retinol dehydrogenase 13 (all-trans/9-cis) -0.81 -1.07
223785_at FANCI Fanconi anemia, complementation group I -0.69 -1.07
232309_at LOC202181 hypothetical protein LOC202181 -1.02 -1.05
201009 s_at TXNIP thioredoxin interacting protein -1.15 -1.05
1559307 s at RBL1 retinoblastoma-like 1 (p107) -0.86 -1.04
234728_s_at DHX35 DEAH (Asp-Glu-Ala-His) box polypeptide 35 -1.03
213606_s_at ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha -0.89 -1.03
228281_at C11 orf82 chromosome 11 open reading frame 82 -0.90 -1.02
222527 s_at RBM22 RNA binding motif protein 22 -0.63 -1.01
209646 x_at ALDH1B1 aldehyde dehydrogenase 1 family, member B1 -1.12 -1.01
213523_at CCNE1 cyclin El -1.49 -1.00
205461_at RAB35 RAB35, member RAS oncogene family -0.94 -1.00
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Table S4.5 Top 50 probe sets up-regulated by treatment with 1 jIM 113.
Probe ID is identifier for probe set from Affymetrix HGU 133 Plus 2.0
GeneChip@. Values shown are Log2 fold-changes (LFC of 1 = 2-fold
change).
Gene
Probe ID Symbol Gene Name LFC
225239_at NA NA 1.57
234989_at TncRNA trophoblast-derived noncoding RNA 1.40
201627 s at INSIG1 insulin induced gene 1 1.35
201625_s_at INSIG1 insulin induced gene 1 1.28
1559360_at NA NA 1.22
232528_at NA NA 1.21
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
205822_s_at HMGCS1 (soluble) 1.21
212274_at LPIN1 lipin 1 1.13
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
221750_at HMGCS1 (soluble) 1.11
212276_at LPIN1 lipin 1 1.05
215385_at NA NA 1.03
232668_at NA NA 1.01
234314_at C20orf74 chromosome 20 open reading frame 74 1.00
201626_at INSIG1 insulin induced gene 1 0.99
235028_at NA NA 0.97
235879_at MBNL1 muscleblind-like (Drosophila) 0.94
1563649_at NA NA 0.93
237839_at NA NA 0.92
213577_at SQLE squalene epoxidase 0.90
242476_at NA NA 0.90
210230_at NA NA 0.89
241893_at NA NA 0.88
233303 at NA NA 0.87
209218_at SQLE squalene epoxidase 0.87
225157_at MLXIP MLX interacting protein 0.85
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Gene
Probe ID Symbol Gene Name LFC
212218 s at FASN fatty acid synthase 0.83
239264_at NA NA 0.82
1556543_at NA NA 0.81
201791_s_at DHCR7 7-dehydrocholesterol reductase 0.80
1559739_at CHPT1 choline phosphotransferase 1 0.79
226390_at STARD4 StAR-related lipid transfer (START) domain containing 4 0.79
E74-like factor 3 (ets domain transcription factor, epithelial-
229842_at ELF3 specific ) 0.78
208962_s_at FADS1 fatty acid desaturase 1 0.77
228674 s at EML4 echinoderm microtubule associated protein like 4 0.76
217042_at RDH11 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 0.76
229470_at NA NA 0.74
218764_at PRKCH protein kinase C, eta 0.74
232344 at NA NA 0.73
202245_at LSS lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) 0.73
234312_s_at ACSS2 acyl-CoA synthetase short-chain family member 2 0.73
232034_at LOC203274 hypothetical protein LOC203274 0.73
1558695_at NA NA 0.73
220091_at SLC2A6 solute carrier family 2 (facilitated glucose transporter), member 6 0.72
LOC1001349
229685_at 37 hypothetical LOC100134937 0.70
242439_s_at ASXL1 additional sex combs like 1 (Drosophila) 0.70
244826_at NA NA 0.69
208806_at CHD3 chromodomain helicase DNA binding protein 3 0.69
208881_x_at IDI1 isopentenyl-diphosphate delta isomerase 1 0.69
210950 s at FDFT1 farnesyl-diphosphate farnesyltransferase 1 0.68
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Table S4.6 Top 50 probe sets down-regulated by treatment with 1 g.M
110. Probe ID is identifier for probe set from Affymetrix HGU133 Plus
2.0 GeneChip@. Values shown are Log2 fold-changes (LFC of 1 = 2-fold
change).
Gene
Probe ID Symbol Gene Name LFC
206953 s at LPHN2 latrophilin 2 
-0.93
207324_s_at DSC1 desmocollin 1 
-0.77
214598_at CLDN8 claudin 8 
-0.76
1553645_at CCDC141 coiled-coil domain containing 141 -0.76
potassium voltage-gated channel, Shal-related subfamily,
207103_at KCND2 member 2 
-0.74
1561969_at ZPLD1 zona pellucida-like domain containing 1 -0.74
1554036_at ZBTB24 zinc finger and BTB domain containing 24 -0.72
204897_at PTGER4 prostaglandin E receptor 4 (subtype EP4) -0.72
v-maf musculoaponeurotic fibrosarcoma oncogene homolog B
218559 s at MAFB (avian) 
-0.71
210233_at IL1RAP interleukin 1 receptor accessory protein -0.69
1564381_s_at NA NA 
-0.69
212420_at ELF1 E74-like factor 1 (ets domain transcription factor) -0.68
238336 s at DNAJC21 DnaJ (Hsp40) homolog, subfamily C, member 21 -0.68
230060 at CDCA7 cell division cycle associated 7 -0.65
1554099_a_at SPIN3 spindlin family, member 3 -0.64
1553768 a at DCBLD1 discoidin, CUB and LCCL domain containing 1 -0.63
209535_s_at NA NA 
-0.63
203845_at KAT2B K(lysine) acetyltransferase 2B -0.62
203890_s_at DAPK3 death-associated protein kinase 3 -0.61
FGFR1OP
1556283 s at 2 FGFR1 oncogene partner 2 -0.60
236219_at NA NA -0.59
228937_at C13orf31 chromosome 13 open reading frame 31 -0.58
LOC1001
220549_at 28414 similar to fibrinogen silencer binding protein -0.58
220295_x_at DEPDC1 DEP domain containing 1 -0.57
241820_at RIF1 RAP1 interacting factor homolog (yeast) -0.57
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Probe ID Symbol Gene Name LFC
LOC64713
231343_at 1 hypothetical LOC647131 -0.57
208167_s_at MMP16 matrix metallopeptidase 16 (membrane-inserted) -0.57
216944 s at ITPR1 inositol 1,4,5-triphosphate receptor, type 1 -0.56
TEA domain family member 1 (SV40 transcriptional enhancer
214600_at TEAD1 factor) -0.56
228395_at GNL3 guanine nucleotide binding protein-like 3 (nucleolar) -0.56
238474_at NUP43 nucleoporin 43kDa -0.56
213618_at CENTD1 centaurin, delta 1 -0.55
219473_at GDAP2 ganglioside induced differentiation associated protein 2 -0.54
200769_s_at MAT2A methionine adenosyltransferase II, alpha -0.54
1568817_at NA NA -0.54
1553244_at FANCB Fanconi anemia, complementation group B -0.54
219502_at NEIL3 nei endonuclease VIII-like 3 (E. coli) -0.54
209681_at SLC19A2 solute carrier family 19 (thiamine transporter), member 2 -0.53
221258_s_at KIF18A kinesin family member 18A -0.53
242349_at HECTD1 HECT domain containing 1 -0.53
221686_s_at RECQL5 RecQ protein-like 5 -0.53
216184 s at RIMS1 regulating synaptic membrane exocytosis 1 -0.52
239598_s_at LPCAT2 lysophosphatidylcholine acyltransferase 2 -0.52
240690_at NA NA -0.52
220955 x at RAB23 RAB23, member RAS oncogene family -0.52
235449_at- LRSAM1 leucine rich repeat and sterile alpha motif containing 1 --0.51
1555450_a_at NARG1L NMDA receptor regulated 1-like -0.51
204085_s_at CLN5 ceroid-lipofuscinosis, neuronal 5 -0.50
228735_s_at PANK2 pantothenate kinase 2 -0.50
204781_s_at FAS Fas (TNF receptor superfamily, member 6) -0.50
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Table 84.7 Top 50 probe sets up-regulated by treatment with 1 nM R1881. Probe
ID is identifier for probe set from Affymetrix HGU133 Plus 2.0 GeneChip®. Values
shown are Log 2 fold-changes (LFC of 1 = 2-fold change).
Gene
Probe ID Symbol Gene Name LFC
201739_at SGK1 serum/glucocorticoid regulated kinase 1 3.37
1553645_at CCDC141 coiled-coil domain containing 141 3.17
225987_at STEAP4 STEAP family member 4 3.09
235146_at TMCC3 transmembrane and coiled-coil domain family 3 2.64
213139_at SNAI2 snail homolog 2 (Drosophila) 2.64
220786 s at SLC38A4 solute carrier family 38, member 4 2.43
1555345_at SLC38A4 solute carrier family 38, member 4 2.42
v-maf musculoaponeurotic fibrosarcoma oncogene homolog
206363_at MAF (avian) 2.38
v-maf musculoaponeurotic fibrosarcoma oncogene homolog
229327 s at MAF (avian) 2.36
v-maf musculoaponeurotic fibrosarcoma oncogene homolog
209348 s at MAF (avian) 2.19
224657_at ERRFI1 ERBB receptor feedback inhibitor 1 2.16
235419_at NA NA 2.15
CSGALNA
219049_at CT1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 2.13
LOC28546
1563571_at 3 hypothetical protein LOC285463 2.03
225688 s at PHLDB2 pleckstrin homology-like domain, family B, member 2 1.97
223169_s_at RHOU ras homolog gene family, member U 1.79
224856_at FKBP5 FK506 binding protein 5 1.69
203627_at IGF1R insulin-like growth factor 1 receptor 1.67
205876_at LIFR leukemia inhibitory factor receptor alpha 1.65
solute carrier family 2 (facilitated glucose transporter),
202499_s_at SLC2A3 member 3 1.65
223168_at RHOU ras homolog gene family, member U 1.61
227771_at LIFR leukemia inhibitory factor receptor alpha 1.60
219694_at FAM105A family with sequence similarity 105, member A 1.59
217028_at CXCR4 chemokine (C-X-C motif) receptor 4 1.59
214446_at ELL2 elongation factor, RNA polymerase II, 2 1.58
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203372_s_at SOCS2 suppressor of cytokine signaling 2 1.58
204560_at FKBP5 FK506 binding protein 5 1.57
225571_at LIFR leukemia inhibitory factor receptor alpha 1.57
202644_s_at TNFAIP3 tumor necrosis factor, alpha-induced protein 3 1.53
235445_at NA NA 1.51
230082_at LOC100133660 hypothetical LOC100133660 1.51
200632_s_at NDRG1 N-myc downstream regulated gene 1 1.50
209286_at CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 1.49
224840_at FKBP5 FK506 binding protein 5 1.47
219551_at EAF2 ELL associated factor 2 1.43
v-myb myeloblastosis viral oncogene homolog (avian)-like
213906_at MYBL1 1 1.42
210095_s_at IGFBP3 insulin-like growth factor binding protein 3 1.41
235606_at LOC344595 hypothetical LOC344595 1.41
204121_at GADD45G growth arrest and DNA-damage-inducible, gamma 1.40
204897_at PTGER4 prostaglandin E receptor 4 (subtype EP4) 1.39
232397_at NA NA 1.39
226393_at CYP2U1 cytochrome P450, family 2, subfamily U, polypeptide 1 1.37
211548_s_at HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 1.37
209822_s_at VLDLR very low density lipoprotein receptor 1.36
211596_s_at LRIG1 leucine-rich repeats and immunoglobulin-like domains 1 1.36
205214 at STK17B serine/threonine kinase 17b 1.35
209212 s at KLF5 Kruppel-like factor 5 (intestinal) 1.35
1559360_at NA NA 1.34
1552673_at RFX6 regulatory factor X, 6 1.34
225330_at IGF1R insulin-like growth factor 1 receptor 1.30
243
- Chapter 4 -
Table S4.8 Top 50 probe sets down-regulated by treatment with 1 nM
R1881. Probe ID is identifier for probe set from Affymetrix HGU133 Plus
2.0 GeneChip@. Values shown are Log2 fold-changes (LFC of 1 = 2-fold
change).
Gene
Probe ID Symbol Gene Name LFC
205027_s at MAP3K8 mitogen-activated protein kinase kinase kinase 8 -1.40
222108_at AMIGO2 adhesion molecule with Ig-like domain 2 -1.22
229242_at NA NA 
-1.14
212558_at SPRY1 sprouty homolog 1, antagonist of FGF signaling (Drosophila) -1.00
238622_at RAP2B RAP2B, member of RAS oncogene family -0.96
BMP and activin membrane-bound inhibitor homolog
203304_at BAMBI (Xenopus laevis) -0.93
230300 at NA NA -0.92
LOC100131
210929_s_at 613 PRO1454 -0.90
228708_at RAB27B RAB27B, member RAS oncogene family -0.89
226884_at LRRN1 leucine rich repeat neuronal 1 -0.89
201340_s_at ENC1 ectodermal-neural cortex (with BTB-like domain) -0.87
232914_s_at SYTL2 synaptotagmin-like 2 -0.87
238479 at NA NA -0.85
1554757_a_at INPP5A inositol polyphosphate-5-phosphatase, 40kDa -0.84
244852_at DSEL dermatan sulfate epimerase-like -0.84
ectonucleotide pyrophosphatase/phosphodiesterase 5
237054_at ENPP5 (putative function) -0.83
LOC100131
1558819 at 819 similar to hCG1778814 -0.82
209890_at TSPAN5 tetraspanin 5 -0.81
230179_at LOC285812 hypothetical protein LOC285812 -0.81
204567_sat ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 -0.81
204021_s_at PURA purine-rich element binding protein A -0.80
235783_at MRTO4 mRNA turnover 4 homolog (S. cerevisiae) -0.80
minichromosome maintenance complex component 3
232740_at MCM3APAS associated protein antisense -0.79
229058_at ANKRD16 ankyrin repeat domain 16 -0.78
1568817 at NA NA -0.78
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Probe ID Symbol Gene Name LFC
232395_x_at AGBL3 ATP/GTP binding protein-like 3 -0.78
213803_at KPNB1 karyopherin (importin) beta 1 -0.77
227481_at CNKSR3 CNKSR family member 3 -0.77
222541_at RSF1 remodeling and spacing factor 1 -0.77
204180 s at ZBTB43 zinc finger and BTB domain containing 43 -0.77
229944_at OPRK1 opioid receptor, kappa 1 -0.76
232055 at SFXN1 sideroflexin 1 -0.76
221823_at C5orf30 chromosome 5 open reading frame 30 -0.76
207078_at MED6 mediator complex subunit 6 -0.75
1554544 a at MBP myelin basic protein -0.75
207655 s at BLNK B-cell linker -0.75
223642_at ZIC2 Zic family member 2 (odd-paired homolog, Drosophila) -0.74
213568_at OSR2 odd-skipped related 2 (Drosophila) -0.73
242273_at NA NA -0.73
223322_at RASSF5 Ras association (RalGDS/AF-6) domain family member 5 -0.73
LOC12037
228338_at 6 hypothetical protein LOC120376 -0.72
220353_at FAM86C family with sequence similarity 86, member C -0.72
1554029_aat TTC37 tetratricopeptide repeat domain 37 -0.72
217997_at PHLDA1 pleckstrin homology-like domain, family A, member 1 -0.72
226272_at RCAN3 RCAN family member 3 -0.71
233341 s at POLR1B polymerase (RNA) I polypeptide B, 128kDa -0.71
223204_at C4orf18 chromosome 4 open reading frame 18 -0.71
1559190 s at RDH13 retinol dehydrogenase 13 (all-trans/9-cis) -0.71
212977_at CXCR7 chemokine (C-X-C motif) receptor 7 -0.70
231943_at ZFP28 zinc finger protein 28 homolog (mouse) -0.70
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Table S4.9 Top 50 probe sets up-regulated by treatment with 1 pM
bicalutamide. Probe ID is identifier for probe set from Affymetrix
HGU133 Plus 2.0 GeneChip®. Values shown are Log 2 fold-changes
(LFC of 1 = 2-fold change).
Gene
Probe ID Symbol Gene Name LFC
210756_s_at NOTCH2 Notch homolog 2 (Drosophila) 0.91
242691 at NA NA 0.85
244790_at MTCP1 mature T-cell proliferation 1 0.84
1552735_at PCDHGC3 protocadherin gamma subfamily C, 3 0.84
208633_s_at MACF1 microtubule-actin crosslinking factor 1 0.83
235801 at NA NA 0.81
223581_at ZNF577 zinc finger protein 577 0.76
224218_s_at TRPS1 trichorhinophalangeal syndrome I 0.76
232272_at ZNF624 zinc finger protein 624 0.75
232231_at RUNX2 runt-related transcription factor 2 0.74
214908_s_at TRRAP transformation/transcription domain-associated protein 0.74
225999_at FAM80B family with sequence similarity 80, member B 0.72
226811_at FAM46C family with sequence similarity 46, member C 0.72
235924 at NA NA 0.71
E74-like factor 3 (ets domain transcription factor,
229842_at ELF3 epithelial-specific) 0.71
216944_s_at ITPR1 inositol 1,4,5-triphosphate receptor, type 1 0.71
210057_at SMG1 PI-3-kinase-related kinase SMG-1 0.69
LOC20327
232034_at 4 hypothetical protein LOC203274 0.69
205842s_at JAK2 Janus kinase 2 (a protein tyrosine kinase) 0.69
212249_at PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 0.68
229944_at OPRK1 opioid receptor, kappa 1 0.68
212796_s_at TBC1 D2B TBC1 domain family, member 2B 0.68
1570482 at NA NA 0.67
222413_s_at MLL3 myeloid/lymphoid or mixed-lineage leukemia 3 0.66
208806_at CHD3 chromodomain helicase DNA binding protein 3 0.65
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Probe ID Symbol Gene Name LFC
235952_at NA NA 0.64
1558719 s at NA NA 0.64
211986_at AHNAK AHNAK nucleoprotein 0.63
230403_at NA NA 0.63
potassium voltage-gated channel, KQT-like subfamily, member
244623_at KCNQ5 5 0.62
235472_at FUT10 fucosyltransferase 10 (alpha (1,3) fucosyltransferase) 0.62
217104_at ST20 suppressor of tumorigenicity 20 0.62
242245_at NA NA 0.61
207108_s_at NIPBL Nipped-B homolog (Drosophila) 0.61
microtubule associated monoxygenase, calponin and LIM
212472_at MICAL2 domain containing 2 0.61
227415_at DGKH diacylglycerol kinase, eta 0.61
235585_at NA NA 0.60
221695_s_at MAP3K2 mitogen-activated protein kinase kinase kinase 2 0.60
221103_s_at WDR52 WD repeat domain 52 0.60
218854_at DSE dermatan sulfate epimerase 0.60
213159_at PCNX pecanex homolog (Drosophila) 0.59
211928_at DYNC1H1 dynein, cytoplasmic 1, heavy chain 1 0.59
226203 at NA NA 0.58
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
212256_at GALNT10 acetylgalactosaminyltransferase 10 (GaINAc-T10) 0.57
225980_at C14orf43 chromosome 14 open reading frame 43 0.57
-222771 s at MYEF2 myelin expression factor 2 0.57
LOC28616
225033_at 7 hypothetical LOC286167 0.57
242635_s_at NAPEPLD N-acyl phosphatidylethanolamine phospholipase D 0.56
236471_at NFE2L3 nuclear factor (erythroid-derived 2)-like 3 0.56
membrane protein, palmitoylated 7 (MAGUK p55 subfamily
238778_at MPP7 member 7) 0.56
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Table S4.10 Top 50 probe sets down-regulated by treatment with 1 pM
bicalutamide. Probe ID is identifier for probe set from Affymetrix
HGU133 Plus 2.0 GeneChip®. Values shown are Log2 fold-changes
(LFC of 1 = 2-fold change).
Gene
Probe ID Symbol Gene Name LFC
213139_at SNAI2 snail homolog 2 (Drosophila) -1.57
v-maf musculoaponeurotic fibrosarcoma oncogene homolog
209348 s at MAF (avian) -1.50
220786 s at SLC38A4 solute carrier family 38, member 4 -1.34
221419 s at NA NA -1.18
230543_at USP9X ubiquitin specific peptidase 9, X-linked -1.18
223169_s_at RHOU ras homolog gene family, member U -1.06
205883_at ZBTB16 zinc finger and BTB domain containing 16 -0.97
228854_at NA NA -0.91
222449_at PMEPA1 prostate transmembrane protein, androgen induced 1 -0.86
228790_at FAM110B family with sequence similarity 110, member B -0.86
221959_at FAM110B family with sequence similarity 110, member B -0.85
204560_at FKBP5 FK506 binding protein 5 -0.79
1553645_at CCDC141 coiled-coil domain containing 141 -0.77
243641 at NA NA -0.73
236168 at NA NA -0.69
238474_at NUP43 nucleoporin 43kDa -0.68
217875_s_at PMEPA1 prostate transmembrane protein, androgen induced 1 -0.68
231880_at FAM40B family with sequence similarity 40, member B -0.65
235445 at NA NA -0.65
209854_s_at KLK2 kallikrein-related peptidase 2 -0.63
219856_at C1orfl16 chromosome 1 open reading frame 116 -0.63
oxoglutarate (alpha-ketoglutarate) dehydrogenase
1554152_aat OGDH (lipoamide) -0.63
223168_at RHOU ras homolog gene family, member U -0.62
230333_at NA NA -0.62
231232 at NA NA -0.60
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207891_s_at UCHL51P UCHL5 interacting protein -0.60
219653_at LSM14B LSM14B, SCD6 homolog B (S. cerevisiae) -0.59
220606_s_at C17orf48 chromosome 17 open reading frame 48 -0.58
215034_s_at TM4SF1 transmembrane 4 L six family member 1 -0.58
240757_at CLASP1 cytoplasmic linker associated protein 1 -0.57
207993_s_at CHP calcium binding protein P22 -0.57
1555733_s_at AP1S3 adaptor-related protein complex 1, sigma 3 subunit -0.56
230397_at NA NA -0.55
238848_at OTUD4 OTU domain containing 4 -0.55
226553_at TMPRSS2 transmembrane protease, serine 2 -0.55
240038_at NA NA -0.55
243750 x at C21orf70 chromosome 21 open reading frame 70 -0.55
227332_at LOC100129022 hypothetical protein LOC100129022 -0.55
212105 s at DHX9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 -0.54
231343_at LOC647131 hypothetical LOC647131 -0.54
1553565_s_at DDAH1 dimethylarginine dimethylaminohydrolase 1 -0.54
210339_s_at KLK2 kallikrein-related peptidase 2 -0.54
224840_at FKBP5 FK506 binding protein 5 -0.53
210233_at ILl RAP interleukin 1 receptor accessory protein -0.53
240690_at NA NA -0.52
225604_s_at GLIPR2 GLI pathogenesis-related 2 -0.52
238495_at NA NA -0.52
240572_s_at LOC374443 CLR pseudogene -0.52
1556082_a_at NA NA -0.51
210783 x at CLEC11A C-type lectin domain family 11, member A -0.51
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Table S4.11 Top 50 probe sets up-regulated by treatment with 5 pM
chlorambucil. Probe ID is identifier for probe set from Affymetrix
HGU133 Plus 2.0 GeneChip®. Values shown are Log 2 fold-changes
(LFC of 1 = 2-fold change). Requirement for LFC > 0.5 omitted some
values from the top 50 list.
Gene
Probe ID Symbol Gene Name LFC
235801 at NA NA 0.88
207247_s_at ZFY zinc finger protein, Y-linked 0.85
242691_at NA NA 0.77
222309_at C6orf62 chromosome 6 open reading frame 62 0.76
210756_s_at NOTCH2 Notch homolog 2 (Drosophila) 0.73
235924_at NA NA 0.70
212730 at DMN desmuslin 0.69
227476_at NA NA 0.68
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
212256_at GALNT10 acetylgalactosaminyltransferase 10 (GaINAc-T10) 0.66
208633_s_at MACF1 microtubule-actin crosslinking factor 1 0.66
221103 s at WDR52 WD repeat domain 52 0.64
214752_x_at FLNA filamin A, alpha (actin binding protein 280) 0.63
228502_at NA NA 0.62
211986_at AHNAK AHNAK nucleoprotein 0.62
223027_at SNX9 sorting nexin 9 0.62
235472_at FUT10 fucosyltransferase 10 (alpha (1,3) fucosyltransferase) 0.61
212523 s at KIAA0146 KIAA0146 0.60
E74-like factor 3 (ets domain transcription factor, epithelial-
201510_at ELF3 specific) 0.60
238744 at NA NA 0.60
220739 s at CNNM3 cyclin M3 0.60
232095_at NA NA 0.59
227229_at VPS53 vacuolar protein sorting 53 homolog (S. cerevisiae) 0.59
E74-like factor 3 (ets domain transcription factor, epithelial-
229842_at ELF3 specific ) 0.58
208830_s_at SUPT6H suppressor of Ty 6 homolog (S. cerevisiae) 0.58
222771_s_at MYEF2 myelin expression factor 2 0.58
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Probe ID Symbol Gene Name LFC
1563649_at NA NA 0.58
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog,
212076_at MLL Drosophila) 0.58
microtubule associated monoxygenase, calponin and LIM domain
212472_at MICAL2 containing 2 0.57
223581_at ZNF577 zinc finger protein 577 0.57
218522_s_at MAP1S microtubule-associated protein 1S 0.57
1569133 x
at ARSK arylsulfatase family, member K 0.56
203061_s_at MDC1 mediator of DNA damage checkpoint 1 0.55
1558105 a
at NA NA 0.55
1558277_at ZNF740 zinc finger protein 740 0.55
208989 s at FBXL11 F-box and leucine-rich repeat protein 11 0.53
DYNC1H
211928_at 1 dynein, cytoplasmic 1, heavy chain 1 0.53
240574_at NA NA 0.53
206540_at GLB1L galactosidase, beta 1-like 0.52
232667_at NA NA 0.52
1554887_at NA NA 0.51
SMARCC SWI/SNF related, matrix associated, actin dependent regulator of
201073_s_at 1 chromatin, subfamily c, member 1 0.50
226158_at KLHL24 kelch-like 24 (Drosophila) 0.50
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Table S4.12 Top 50 probe sets down-regulated by treatment with 5 LpM
chlorambucil. Probe ID is identifier for probe set from Affymetrix
HGU133 Plus 2.0 GeneChip®. Values shown are Log2 fold-changes
(LFC of 1 = 2-fold change). Requirement for LFC > 0.5 omitted some
values from the top 50 list.
Probe ID Gene Symbol Gene Name LFC
232964_at WBSCR19 Williams Beuren syndrome chromosome region 19 -0.97
243495 s at NA NA -0.95
231152_at INO80D IN080 complex subunit D -0.95
214336 s at COPA coatomer protein complex, subunit alpha -0.91
214668_at C13orfl chromosome 13 open reading frame 1 -0.87
217544_at LOC729806 similar to hCG1725380 -0.83
1566115 at NA NA -0.80
76897 s at FKBP15 FK506 binding protein 15, 133kDa -0.79
212105_s_at DHX9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 -0.77
241816_at C14orflO6 chromosome 14 open reading frame 106 -0.76
235179_at ZNF641 zinc finger protein 641 -0.73
223169_s_at RHOU ras homolog gene family, member U -0.71
202547_s_at ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 -0.71
236985 at NA NA -0.70
238474_at NUP43 nucleoporin 43kDa -0.66
1554029_a_at TTC37 tetratricopeptide repeat domain 37 -0.65
TAF13 RNA polymerase II, TATA box binding protein (TBP)-
205966_at TAF13 associated factor, 18kDa -0.65
238336 s at DNAJC21 DnaJ (Hsp40) homolog, subfamily C, member 21 -0.64
214592_s_at SNAPC5 small nuclear RNA activating complex, polypeptide 5, 19kDa -0.63
215046_at C2orf67 chromosome 2 open reading frame 67 -0.63
242349_at HECTD1 HECT domain containing 1 -0.63
231500 s at BOLA2 bolA homolog 2 (E. coli) -0.62
205448_s_at MAP3K12 mitogen-activated protein kinase kinase kinase 12 -0.62
nuclear casein kinase and cyclin-dependent kinase substrate
223661 at NUCKS1 1 -0.61
228790_at FAM110B family with sequence similarity 110, member B -0.60
252
- Chapter 4 -
253
Gene
Probe ID Symbol Gene Name LFC
232613_at PBRM1 polybromo 1 -0.60
209136_s_at USP10 ubiquitin specific peptidase 10 -0.59
1555733_s_at AP1S3 adaptor-related protein complex 1, sigma 3 subunit -0.56
LOC64713
231343_at 1 hypothetical LOC647131 -0.56
230098_at PHF20L1 PHD finger protein 20-like 1 -0.55
209754_s_at TMPO thymopoietin -0.55
223888_s_at LARS leucyl-tRNA synthetase -0.53
FCF1 small subunit (SSU) processome component
219927_at FCF1 homolog (S. cerevisiae) -0.53
240690 at NA NA -0.53
235588_at ESCO2 establishment of cohesion 1 homolog 2 (S. cerevisiae) -0.52
223481_s_at MRPL47 mitochondrial ribosomal protein L47 -0.52
LOC28386
1554520_at 1 hypothetical locus LOC283861 -0.51
1564381 s at NA NA -0.51
231640_at LYRM5 LYR motif containing 5 -0.51
210733_at TRAM1 translocation associated membrane protein 1 -0.51
1556082 a at NA NA -0.51
alpha thalassemia/mental retardation syndrome X-linked
211022_s_at ATRX (RAD54 homolog, S. cerevisiae) -0.51
213747_at AZIN1 antizyme inhibitor 1 -0.50
CTD (carboxy-terminal domain, RNA polymerase II,
1555106_aat CTDSPL2 polypeptide A) small phosphatase like 2 -0.50
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Table S4.13 Top probe sets up-regulated by treatment with DMSO,
relative to 6 hr untreated sample. Probe ID is identifier for probe set
from Affymetrix HGU133 Plus 2.0 GeneChip®. Values shown are Log 2
fold-changes (LFC of 1
omitted other values.
= 2-fold change). Requirement for LFC > 0.5
Gene
Probe ID Symbol Gene Name LFC
217544 at LOC729806 similar to hCG1725380 0.78
231933_at MARCH8 membrane-associated ring finger (C3HC4) 8 0.65
238336_s_at DNAJC21 DnaJ (Hsp40) homolog, subfamily C, member 21 0.62
215339_at NKTR natural killer-tumor recognition sequence 0.57
205637 s at SH3GL3 SH3-domain GRB2-like 3 0.56
231343_at LOC647131 hypothetical LOC647131 0.52
228937_at C13orf31 chromosome 13 open reading frame 31 0.51
240690 at NA NA 0.51
231035_s_at OTUD1 OTU domain containing 1 0.50
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Table S4.14 Top probe sets down-regulated by treatment with DMSO,
relative to 6 hr untreated sample. Probe ID is identifier for probe set
from Affymetrix HGU133 Plus 2.0 GeneChip@. Values shown are Log2
fold-changes (LFC of 1
omitted other values.
= 2-fold change). Requirement for LFC > 0.5
Gene
Probe ID Symbol Gene Name LFC
207247_s_at ZFY zinc finger protein, Y-linked -0.83
235729_at ZNF514 zinc finger protein 514 -0.81
LOC28546
1563571_at 3 hypothetical protein LOC285463 -0.74
235801 at NA NA -0.72
240574 at NA NA -0.71
1554103 at NA NA -0.68
ANKRD13
227720_at B ankyrin repeat domain 13B -0.62
protein tyrosine phosphatase, non-receptor type 18
1569552_at PTPN18 (brain-derived) -0.62
1557170_at NEK8 NIMA (never in mitosis gene a)- related kinase 8 -0.60
213758_at COX411 cytochrome c oxidase subunit IV isoform 1 -0.59
209386_at TM4SF1 transmembrane 4 L six family member 1 -0.58
219996_at ASB7 ankyrin repeat and SOCS box-containing 7 -0.51
241352 at NA NA -0.51
226419_s_at SFRS1 splicing factor, arginine/serine-rich 1 -0.50
1557701_s_at POLH polymerase (DNA directed), eta -0.50
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Table S4.15 Top probe sets up-regulated by 6 hr incubation in fresh
media relative to cells isolated at treatment time. Probe ID is identifier
for probe set from Affymetrix HGU133 Plus 2.0 GeneChip@. Values
shown are Log 2 fold-changes (LFC of 1 = 2-fold change). Requirement
for LFC 2 0.5 omitted other values.
Gene
Probe ID Symbol Gene Name LFC
1558148 x at FLJ90757 hypothetical protein LOC440465 0.63
211833 s at BAX BCL2-associated X protein 0.61
201340 s at ENC1 ectodermal-neural cortex (with BTB-like domain) 0.60
cleavage stimulation factor, 3' pre-RNA, subunit 2,
212901 s at CSTF2T 64kDa, tau variant 0.56
225831_at LUZP1 leucine zipper protein 1 0.53
224387_at COMMD5 COMM domain containing 5 0.52
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Table S4.16 Top probe sets down-regulated by 6 hr incubation in fresh media
relative to cells isolated at treatment time. Probe ID is identifier for probe set from
Affymetrix HGU133 Plus 2.0 GeneChip®. Values shown are Log 2 fold-changes
(LFC of 1 = 2-fold change). Requirement for LFC _ 0.5 omitted some values from
the top 50 list.
Gene
Probe ID Symbol Gene Name LFC
LOC100127
239493_at 893 similar to ribosomal protein L7 -1.06
1569664 at NA NA -0.82
226444 at NA NA -0.81
239091 at NA NA -0.79
205841_at JAK2 Janus kinase 2 (a protein tyrosine kinase) -0.77
239014_at CCAR1 cell division cycle and apoptosis regulator 1 -0.76
220946_s_at SETD2 SET domain containing 2 -0.72
1568817 at NA NA -0.71
229246_at FLJ44342 hypothetical LOC645460 -0.71
240105 at NA NA -0.70
1556678 a at NA NA -0.70
minichromosome maintenance complex component 3
232740_at MCM3APAS associated protein antisense -0.69
229899_s_at C20orf199 chromosome 20 open reading frame 199 -0.68
221015 s at CDADC1 cytidine and dCMP deaminase domain containing 1 -0.68
219171_s_at ZNF236 zinc finger protein 236 -0.67
230241 at NA NA -0.66
1570227 at NA NA -0.66-
228506_at NSMCE4A non-SMC element 4 homolog A (S. cerevisiae) -0.65
210425 x at GOLGA8A golgi autoantigen, golgin subfamily a, 8A -0.64
239372_at NA NA -0.63
228047_at RPL30 ribosomal protein L30 -0.61
208798 x at GOLGA8A golgi autoantigen, golgin subfamily a, 8A -0.61
239653_at NA NA -0.61
221103_s_at WDR52 WD repeat domain 52 -0.59
218978_s_at SLC25A37 solute carrier family 25, member 37 -0.58
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Gene
Probe ID Symbol Gene Name LFC
238299 at NA NA -0.57
236887_at KIN KIN, antigenic determinant of recA protein homolog (mouse) -0.57
225949_at NRBP2 nuclear receptor binding protein 2 -0.57
225496_s_at SYTL2 synaptotagmin-like 2 -0.57
1556035_s_at ZNF207 zinc finger protein 207 -0.57
sema domain, immunoglobulin domain (Ig), short basic domain,
203788_s_at SEMA3C secreted, (semaphorin) 3C -0.56
LOC72782
227383_at 0 hypothetical protein LOC727820 -0.56
215029 at NA NA -0.56
transmembrane protein with EGF-like and two follistatin-like
205122 at TMEFF1 domains 1 -0.56
235288 at NA NA -0.55
224336_s_at DUSP16 dual specificity phosphatase 16 -0.54
1554161_at SLC25A27 solute carrier family 25, member 27 -0.53
DKFZp686
1561961_at A1627 putative PHD finger protein 2 pseudogene -0.53
207105_s_at PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) -0.53
212980_at USP34 ubiquitin specific peptidase 34 -0.52
jumonji C domain containing histone demethylase 1 homolog D
221778_at JHDM1D (S. cerevisiae) -0.52
1563259 at NA NA -0.52
LOC72884
222040_at 4 hypothetical LOC728844 -0.51
230742_at RBM5 RNA binding motif protein 5 -0.51
236224 at RIT1 Ras-like without CAAX 1 -0.51
212913_at C6orf26 chromosome 6 open reading frame 26 -0.50
206038 s at NR2C2 nuclear receptor subfamily 2, group C, member 2 -0.50
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Table S4.17 Probe sets more greatly up-regulated by 5 IM 11P treatment than by 5 pIM 11-
dimethoxy treatment. Probe ID is identifier for probe set from Affymetrix HGU133 Plus 2.0
GeneChip@. Values shown are Log 2 fold-changes (LFC of 1 = 2-fold change). For these probe sets,
the difference in expression level between 110 and 11 P-dimethoxy (di) is greater than -1.74-fold
(ALFC - 0.8), p-val for 110 (relative to DMSO) < 0.05, and 11P LFC 2 0.5. Gray cells indicate p-val 2
0.05.
Gene
Probe Set ID Symbol Gene Name 11 Di
221577_x_at GDF15 growth differentiation factor 15 3.48 2.08
209383_at DDIT3 DNA-damage-inducible transcript 3 3.46 1.71
SEC24 related gene family, member D (S.
215209_at SEC24D cerevisiae) 2.75 1.36
225956_at C5orf41 chromosome 5 open reading frame 41 2.35 1.42
242088_at KLHL24 kelch-like 24 (Drosophila) 2.34 1.26
growth arrest and DNA-damage-inducible,
203725_at GADD45A alpha 2.19 1.22
210587_at INHBE inhibin, beta E 2.16
ChaC, cation transport regulator homolog 1
219270_at CHAC1 (E. coli) 2.02 0.90
202766_s_at FBN1 fibrillin 1 2.02 0.98
238320_at TncRNA trophoblast-derived noncoding RNA 2.01 0.87
223195_sat SESN2 sestrin 2 1.97 0.95
1554980_a_at ATF3 activating transcription factor 3 1.85
203438_at STC2 stanniocalcin 2 1.78 0.78
207001_x at TSC22D3 TSC22 domain family, member 3 1.76 0.85
tumor necrosis factor (ligand) superfamily,
221085 at TNFSF15 member 15 1.74
CD55 molecule, decay accelerating factor
201925_s at CD55 for complement (Cromer blood group) 1.68
213672_at MARS methionyl-tRNA synthetase 1.62 0.80
216985_s_at STX3 syntaxin 3 1.60 0.44
202146_at IFRD1 interferon-related developmental regulator 1 1.57 0.53
La ribonucleoprotein domain family,
218651_s_at LARP6 member 6 1.54 0.31
cyclin-dependent kinase inhibitor 1A (p21,
202284_s_at CDKN1A Cipl) 1.47 0.16
solute carrier family 30 (zinc transporter),
212907_at SLC30A1 member 1 1.45 0.54
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Gene
Probe Set ID Symbol Gene Name 11li Di
213629_x_at MT1F metallothionein 1F 1.37 0.44
ectonucleotide
pyrophosphatase/phosphodiesterase 5
237054_at ENPP5 (putative function) 1.36 0.45
1553622 a at FSIP1 fibrous sheath interacting protein 1 1.32
208935 s at LGALS8 lectin, galactoside-binding, soluble, 8 1.32 0.36
208933 s_at LGALS8 lectin, galactoside-binding, soluble, 8 1.30 0.48
201236 s_at BTG2 BTG family, member 2 1.29
1559517_a_at SPIRE1 spire homolog 1 (Drosophila) 1.28
213112 s at SQSTM1 sequestosome 1 1.28
1558846_at PNLIPRP3 pancreatic lipase-related protein 3 1.22
224336 s at DUSP16 dual specificity phosphatase 16 1.19
metastasis associated lung adenocarcinoma
226675_s_at MALAT1 transcript 1 (non-protein coding) 1.16
220622_at LRRC31 leucine rich repeat containing 31 1.08
221841 s at KLF4 Kruppel-like factor 4 (gut) 1.03
208328 s at MEF2A myocyte enhancer factor 2A 1.01
glycerophosphodiester phosphodiesterase
1555606_a_at GDPD1 domain containing 1 0.96
226404_at RBM39 RNA binding motif protein 39 0.94
phorbol-12-myristate-1 3-acetate-induced
204286 s at PMAIP1 protein 1 0.86
ATP-binding cassette, sub-family A (ABC1),
203504_s_at ABCA1 member 1 0.85
215719 x at FAS Fas (TNF receptor superfamily, member 6) 0.69 -0.60
205386_s_at MDM2 Mdm2 p53 binding protein homolog (mouse) 0.58 -0.24
LOC72777 similar to ankyrin repeat domain 20 family,
237737_at 0 member Al 0.57
203409_at DDB2 damage-specific DNA binding protein 2, 48kDa 0.55
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Table S4.18 Probe sets more greatly down-regulated by 5 jiM 11p
treatment than by 5 iM 11P-dimethoxy treatment. Probe ID is identifier
for probe set from Affymetrix HGU133 Plus 2.0 GeneChip®. Values
shown are Log2 fold-changes (LFC of -1 = 2-fold change). For these
probe sets, the difference in expression level between 110 and 11-
dimethoxy (Di) is greater than ~1.74-fold (ALFC _ 0.8), p-val for 11p
(relative to DMSO) < 0.05, and 11P LFC 5 0.5. Gray cells indicate p-val
> 0.05.
Probe Set ID
Gene
Symbol Gene Name 11p Di I
220302_at MAK male germ cell-associated kinase -0.50
226811_at FAM46C family with sequence similarity 46, member C -0.64
204560_at FKBP5 FK506 binding protein 5 -0.67
204826_at CCNF cyclin F -0.92
PIF1 5'-to-3' DNA helicase homolog (S.
228252_at PIF1 cerevisiae) -0.94
inhibitor of DNA binding 1, dominant negative
208937 s at ID1 helix-loop-helix protein -1.07
231892_at C9orf100 chromosome 9 open reading frame 100 -1.13
transmembrane and tetratricopeptide repeat
1554101_a_at TMTC4 containing 4 -1.22
229310_at KLHL29 kelch-like 29 (Drosophila) -1.22
1554036_at ZBTB24 zinc finger and BTB domain containing 24 -1.47
solute carrier family 16, member 6
207038_at SLC16A6 (monocarboxylic acid transporter 7) -1.60
227048_at LAMA1 laminin, alpha 1 -1.70
226064 s at DGAT2
diacylglycerol O-acyltransferase homolog 2
(mouse) -2.14 I -1.32 I
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Figure S4.1 Volcano plot for 5 jM 113 compared to DMSO. Each point
is a probe set, displayed as the relationship between the Log2 fold
change (LFC 1 = 2-fold change) on the x-axis and the Logo0 of the p-
value. Green points are up-regulated relative to DMSO, while red points
are down-regulated. Circles are points with p-value 2 0.05, while
triangles have p-value < 0.05. As such, significance of comparison
increases as points approach the bottom of the graph while magnitude
change increases as they spread from the center, creating what looks
like a volcano.
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Figure S4.2 Volcano plot for 5 tM 11 P-dimethoxy compared to DMSO.
Each point is a probe set, displayed as the relationship between the
Log 2 fold change (LFC 1 = 2-fold change) on the x-axis and the Logo0 of
the p-value. Green points are up-regulated relative to DMSO, while red
points are down-regulated. Circles are points with p-value > 0.05, while
triangles have p-value < 0.05. As such, significance of comparison
increases as points approach the bottom of the graph while magnitude
change increases as they spread from the center, creating what looks
like a volcano.
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Figure S4.3 Volcano plot for 1 M 110 compared to DMSO. Each point
is a probe set, displayed as the relationship between the Log 2 fold
change (LFC 1 = 2-fold change) on the x-axis and the Logo0 of the p-
value. Green points are up-regulated relative to DMSO, while red points
are down-regulated. Circles are points with p-value > 0.05, while
triangles have p-value < 0.05. As such, significance of comparison
increases as points approach the bottom of the graph while magnitude
change increases as they spread from the center, creating what looks
like a volcano.
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Figure S4.4 Volcano plot for 5 gIM chlorambucil (Cbl) compared to
DMSO. Each point is a probe set, displayed as the relationship
between the Log2 fold change (LFC 1 = 2-fold change) on the x-axis and
the Log10 of the p-value. Green points are up-regulated relative to
DMSO, while red points are down-regulated. Circles are points with p-
value 2 0.05, while triangles have p-value < 0.05. As such, significance
of comparison increases as points approach the bottom of the graph
while magnitude change increases as they spread from the center,
creating what looks like a volcano.
265
- Chapter 4 -
0
* A
S-2- A AA 
A
0- -6 2 - A 2 A
AA
> A
-10 A A
LFC R1881 1 nM vs DMSO
Figure S4.5 Volcano plot for 1 nM R1881 compared to DMSO. Each
point is a probe set, displayed as the relationship between the Log2 fold
change (LFC 1 = 2-fold change) on the x-axis and the Log10 of the p-
value. Green points are up-regulated relative to DMSO, while red points
are down-regulated. Circles are points with p-value _ 0.05, while
triangles have p-value < 0.05. As such, significance of comparison
increases as points approach the bottom of the graph while magnitude
change increases as they spread from the center, creating what looks
like a volcano.
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Figure S4.6 Volcano plot for 1 pM bicalutamide compared to DMSO.
Each point is a probe set, displayed as the relationship between the
Log2 fold change (LFC 1 = 2-fold change) on the x-axis and the Logo0 of
the p-value. Green points are up-regulated relative to DMSO, while red
points are down-regulated. Circles are points with p-value 2 0.05, while
triangles have p-value < 0.05. As such, significance of comparison
increases as points approach the bottom of the graph while magnitude
change increases as they spread from the center, creating what looks
like a volcano.
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Figure S4.7 Volcano plot for DMSO compared to 6 hr untreated sample.
Each point is a probe set, displayed as the relationship between the
Log2 fold change (LFC 1 = 2-fold change) on the x-axis and the Loglo of
the p-value. Green points are up-regulated relative to DMSO, while red
points are down-regulated. Circles are points with p-value 2 0.05, while
triangles have p-value < 0.05. As such, significance of comparison
increases as points approach the bottom of the graph while magnitude
change increases as they spread from the center, creating what looks
like a volcano.
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Figure S4.8 Volcano plot for 6 hr untreated sample compared to sample
collected at treatment time. Each point is a probe set, displayed as the
relationship between the Log 2 fold change (LFC 1 = 2-fold change) on
the x-axis and the Loglo of the p-value. Green points are up-regulated
relative to DMSO, while red points are down-regulated. Circles are
points with p-value 2 0.05, while triangles have p-value < 0.05. As such,
significance of comparison increases as points approach the bottom of
the graph while magnitude change increases as they spread from the
center, creating what looks like a volcano.
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Figure S4.9 Structures of compounds identified by CMAP analysis as
inducing similar transcriptional profile as 5 M 11 3.
270
HNY
"N
14 1:1
Fendiline
- Chapter 4 -
References
Belfi, CA, Chatterjee, S, Gosky, DM, Berger, SJ & Berger, NA 1999, "Increased
sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78
up-regulation." Biochemical and Biophysical Research Communications, vol. 257,
no. 2, pp. 361-8.
Benjamini, Y & Hochberg, Y 1995, "Controlling the False Discovery Rate: A Practical
and Powerful Approach to Multiple Testing." Journal of the Royal Statistical
Society. Series B (Methodological), vol. 57, no. 1, pp. 289-300.
Berger, M, Strecker, HJ & Waelsch, H 1956, "Action of chlorpromazine on oxidative
phosphorylation of liver and brain mitochondria." Nature, vol. 177, no. 4522, pp.
1234-5.
Berridge, MJ 1993, "Inositol trisphosphate and calcium signalling." Nature, vol. 361, no.
6410, pp. 315-25.
Breckenridge, DG, Germain, M, Mathai, JP, Nguyen, M & Shore, GC 2003, "Regulation
of apoptosis by endoplasmic reticulum pathways." Oncogene, vol. 22, no. 53, pp.
8608-18.
Bush, KT, Goldberg, AL & Nigam, SK 1997, "Proteasome Inhibition Leads to a Heat-
shock Response, Induction of Endoplasmic Reticulum Chaperones, and
Thermotolerance." J. Biol. Chem., vol. 272, no. 14, pp. 9086-9092.
Calfon, M, Zeng, H, Urano, F, Till, JH et al. 2002, "IRE 1 couples endoplasmic reticulum
load to secretory capacity by processing the XBP-1 mRNA." Nature, vol. 415, no.
6867, pp. 92-96.
Chatterjee, S, Hirota, H, Belfi, CA, Berger, SJ & Berger, NA 1997, "Hypersensitivity to
DNA cross-linking agents associated with up-regulation of glucose-regulated
stress protein GRP78." Cancer Research, vol. 57, no. 22, pp. 5112-6.
Chen, M, Chen, L & Chai, KX 2006, "Androgen regulation of prostasin gene expression
is mediated by sterol-regulatory element-binding proteins and SLUG." The
Prostate, vol. 66, no. 9, pp. 911-20.
Chen, X, Ding, Y, Liu, C, Mikhail, S & Yang, CS 2002, "Overexpression of glucose-
regulated protein 94 (Grp94) in esophageal adenocarcinomas of a rat surgical
model and humans." Carcinogenesis, vol. 23, no. 1, pp. 123-130.
Colgan, SM, Tang, D, Werstuck, GH & Austin, RC 2007, "Endoplasmic reticulum stress
causes the activation of sterol regulatory element binding protein-2." The
International Journal ofBiochemistry & Cell Biology, vol. 39, no. 10, pp. 1843-
51.
271
- Chapter 4 -
Corbett, EF, Oikawa, K, Francois, P, Tessier, DC et al. 1999, "Ca2+ Regulation of
Interactions between Endoplasmic Reticulum Chaperones." J. Biol. Chem., vol.
274, no. 10, pp. 6203-6211.
DiPaola, RS & Aisner, J 1999, "Overcoming bcl-2- and p53-mediated resistance in
prostate cancer." Seminars in Oncology, vol. 26, no. 1 Suppl 2, pp. 112-116.
Fawcett, TW, Martindale, JL, Guyton, KZ, Hai, T & Holbrook, NJ 1999, "Complexes
containing activating transcription factor (ATF)/cAMP-responsive-element-
binding protein (CREB) interact with the CCAAT/enhancer-binding protein
(C/EBP)-ATF composite site to regulate Gadd153 expression during the stress
response." The Biochemical Journal, vol. 339 ( Pt 1), pp. 135-41.
Fernandez, PM, Tabbara, SO, Jacobs, LK, Manning, FCR et al. 2000, "Overexpression of
the glucose-regulated stress gene GRP78 in malignant but not benign human
breast lesions." Breast Cancer Research and Treatment, vol. 59, no. 1, pp. 15-26.
Fornace, AJ, Alamo, I & Hollander, MC 1988, "DNA damage-inducible transcripts in
mammalian cells." Proceedings of the National Academy of Sciences of the
United States ofAmerica, vol. 85, no. 23, pp. 8800-8804.
Fribley, A, Zeng, Q & Wang, C 2004, "Proteasome Inhibitor PS-341 Induces Apoptosis
through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in
Head and Neck Squamous Cell Carcinoma Cells." Mol. Cell. Biol., vol. 24, no. 22,
pp. 9695-9704.
Gazit, G, Lu, J & Lee, AS 1999, "De-regulation of GRP stress protein expression in
human breast cancer cell lines." Breast Cancer Research and Treatment, vol. 54,
no. 2, pp. 135-46.
Gentleman, R, Carey, V, Bates, D, Bolstad, B et al. 2004, "Bioconductor: open software
development for computational biology and bioinformatics." Genome Biology,
vol. 5, no. 10, p. R80.
Ghosh, T, Bian, J, Short, A, Rybak, S & Gill, D 1991, "Persistent intracellular calcium
pool depletion by thapsigargin and its influence on cell growth." J. Biol. Chem.,
vol. 266, no. 36, pp. 24690-24697.
Goldstein, JL, Rawson, RB & Brown, MS 2002, "Mutant mammalian cells as tools to
delineate the sterol regulatory element-binding protein pathway for feedback
regulation of lipid synthesis." Archives ofBiochemistry and Biophysics, vol. 397,
no. 2, pp. 139-48.
Guardavaccaro, D, Corrente, G, Covone, F, Micheli, L et al. 2000, "Arrest of G1-S
Progression by the p53-Inducible Gene PC3 Is Rb Dependent and Relies on the
272
- Chapter 4 -
Inhibition of Cyclin D I Transcription." Mol. Cell. Biol., vol. 20, no. 5, pp. 1797-
1815.
Halleck, MM, Holbrook, NJ, Skinner, J, Liu, H & Stevens, JL 1997, "The molecular
response to reductive stress in LLC-PK 1 renal epithelial cells: coordinate
transcriptional regulation of gaddl53 and grp78 genes by thiols." Cell Stress &
Chaperones, vol. 2, no. 1, pp. 31-40.
Harding, HP, Novoa, I, Zhang, Y, Zeng, H et al. 2000, "Regulated translation initiation
controls stress-induced gene expression in mammalian cells." Molecular Cell, vol.
6, no. 5, pp. 1099-108.
Harper, JW, Adami, GR, Wei, N, Keyomarsi, K & Elledge, SJ 1993, "The p21 Cdk-
interacting protein Cip 1 is a potent inhibitor of G 1 cyclin-dependent kinases."
Cell, vol. 75, no. 4, pp. 805-16.
Heemers, H, Maes, B, Foufelle, F, Heyns, W et al. 2001, "Androgens stimulate lipogenic
gene expression in prostate cancer cells by activation of the sterol regulatory
element-binding protein cleavage activating protein/sterol regulatory element-
binding protein pathway." Molecular Endocrinology (Baltimore, Md.), vol. 15, no.
10, pp. 1817-28.
Hillier, SM 2005, "Novel genotoxins that target estrogen receptor- and androgen
receptor- positive cancers : identification of DNA adducts, pharmacokinetics, and
mechanism." Retrieved April 7, 2009, from
http://dspace.mit.edu/handle/1721.1/32480
Hillier, SM, Marquis, JC, Zayas, B, Wishnok, JS et al. 2006, "DNA adducts formed by a
novel antitumor agent 11 {beta}-dichloro in vitro and in vivo." Mol Cancer Ther,
vol. 5, no. 4, pp. 977-984.
Horton, JD, Goldstein, JL & Brown, MS 2002, "SREBPs: activators of the complete
program of cholesterol and fatty acid synthesis in the liver." The Journal of
Clinical Investigation, vol. 109, no. 9, pp. 1125-31.
Irizarry, RA, Hobbs, B, Collin, F, Beazer-Barclay, YD et al. 2003, "Exploration,
normalization, and summaries of high density oligonucleotide array probe level
data." Biostatistics (Oxford, England), vol. 4, no. 2, pp. 249-64.
Kaufman, RJ 1999, "Stress signaling from the lumen of the endoplasmic reticulum:
coordination of gene transcriptional and translational controls." Genes &
Development, vol. 13, no. 10, pp. 1211-33.
Koumenis, C, Naczki, C, Koritzinsky, M, Rastani, S et al. 2002, "Regulation of protein
synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK
273
- Chapter 4 -
and phosphorylation of the translation initiation factor elF2alpha." Molecular and
Cellular Biology, vol. 22, no. 21, pp. 7405-16.
Lamb, J 2007, "The Connectivity Map: a new tool for biomedical research." Nat Rev
Cancer, vol. 7, no. 1, pp. 54-60.
Lamb, J, Crawford, ED, Peck, D, Modell, JW et al. 2006, "The Connectivity Map: Using
Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease."
Science, vol. 313, no. 5795, pp. 1929-1935.
Lamb, J, Ramaswamy, S, Ford, HL, Contreras, B et al. 2003, "A mechanism of cyclin Dl
action encoded in the patterns of gene expression in human cancer." Cell, vol. 114,
no. 3, pp. 323-34.
Lange, Y & Steck, T 1994, "Cholesterol homeostasis. Modulation by amphiphiles." J.
Biol. Chem., vol. 269, no. 47, pp. 29371-29374.
Lee, A, Iwakoshi, NN & Glimcher, LH 2003, "XBP-1 regulates a subset of endoplasmic
reticulum resident chaperone genes in the unfolded protein response." Molecular
and Cellular Biology, vol. 23, no. 21, pp. 7448-59.
Lee, K, Tirasophon, W, Shen, X, Michalak, M et al. 2002, "IREl-mediated
unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to
regulate XBPI in signaling the unfolded protein response." Genes & Development,
vol. 16, no. 4, pp. 452-66.
Li, C & Wong, WH 2001, "Model-based analysis of oligonucleotide arrays: Expression
index computation and outlier detection." Proceedings of the National Academy
ofSciences of the United States ofAmerica, vol. 98, no. 1, pp. 3 1-36.
Lodish, H & Kong, N 1990, "Perturbation of cellular calcium blocks exit of secretory
proteins from the rough endoplasmic reticulum." J. Biol. Chem., vol. 265, no. 19,
pp. 10893-10899.
Lodish, H, Kong, N & Wikstrom, L 1992, "Calcium is required for folding of newly
made subunits of the asialoglycoprotein receptor within the endoplasmic
reticulum." J. Biol. Chem., vol. 267, no. 18, pp. 12753-12760.
MacDonald, ML, Lamerdin, J, Owens, S, Keon, BH et al. 2006, "Identifying off-target
effects and hidden phenotypes of drugs in human cells." Nat Chem Biol, vol. 2, no.
6, pp. 329-337.
Marciniak, SJ, Yun, CY, Oyadomari, S, Novoa, I et al. 2004, "CHOP induces death by
promoting protein synthesis and oxidation in the stressed endoplasmic reticulum."
Genes & Development, vol. 18, no. 24, pp. 3066-77.
274
- Chapter 4 -
Marquis, JC, Hillier, SM, Dinaut, AN, Rodrigues, D et al. 2005, "Disruption of gene
expression and induction of apoptosis in prostate cancer cells by a DNA-
damaging agent tethered to an androgen receptor ligand." Chemistry & Biology,
vol. 12, no. 7, pp. 779-87.
McCullough, KD, Martindale, JL, Klotz, LO, Aw, TY & Holbrook, NJ 2001, "Gadd153
sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and
perturbing the cellular redox state." Molecular and Cellular Biology, vol. 21, no.
4, pp. 1249-59.
McDonnell, TJ, Troncoso, P, Brisbay, SM, Logothetis, C et al. 1992, "Expression of the
Protooncogene bcl-2 in the Prostate and Its Association with Emergence of
Androgen-independent Prostate Cancer." Cancer Res, vol. 52, no. 24, pp. 6940-
6944.
Moncur, JT, Park, JP, Memoli, VA, Mohandas, TK & Kinlaw, WB 1998, "The "Spot 14"
gene resides on the telomeric end of the 11q13 amplicon and is expressed in
lipogenic breast cancers: implications for control of tumor metabolism."
Proceedings of the National Academy of Sciences of the United States ofAmerica,
vol. 95, no. 12, pp. 6989-94.
Nelson, PS, Clegg, N, Arnold, H, Ferguson, C et al. 2002, "The program of androgen-
responsive genes in neoplastic prostate epithelium." Proceedings of the National
Academy of Sciences of the United States ofAmerica, vol. 99, no. 18, pp. 11890-
11895.
Ngan, S, Stronach, EA, Photiou, A, Waxman, J et al. "Microarray coupled to quantitative
RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer
cells." Oncogene.
Obeng, EA, Carlson, LM, Gutman, DM, Harrington, WJ et al. 2006, "Proteasome
inhibitors induce a terminal unfolded protein response in multiple myeloma
cells." Blood, vol. 107, no. 12, pp. 4907-4916.
Pandini, G, Genua, M, Frasca, F, Vigneri, R & Belfiore, A 2009, "Sex steroids upregulate
the IGF-1R in prostate cancer cells through a nongenotropic pathway." Annals of
the New York Academy ofSciences, vol. 1155, pp. 263-7.
Prozialeck, WC & Weiss, B 1982, "Inhibition of calmodulin by phenothiazines and
related drugs: structure-activity relationships." The Journal ofPharmacology and
Experimental Therapeutics, vol. 222, no. 3, pp. 509-16.
Radhakrishnan, A, Ikeda, Y, Kwon, HJ, Brown, MS & Goldstein, JL 2007, "Sterol-
regulated transport of SREBPs from endoplasmic reticulum to Golgi: Oxysterols
block transport by binding to Insig." Proceedings of the National Academy of
Sciences, vol. 104, no. 16, pp. 6511-6518.
275
- Chapter 4 -
Rao, RV, Castro-Obregon, S, Frankowski, H, Schuler, M et al. 2002, "Coupling
Endoplasmic Reticulum Stress to the Cell Death Program. An Apaf-1
Independent Intrinsic Pathway." J. Biol. Chem., vol. 277, no. 24, pp. 21836-21842.
Rouault, JP, Falette, N, Gu6henneux, F, Guillot, C et al. 1996, "Identification of BTG2,
an antiproliferative p53-dependent component of the DNA damage cellular
response pathway." Nature Genetics, vol. 14, no. 4, pp. 482-6.
Rozen, S & Skaletsky, HJ 2000, Bioinformatics Methods and Protocols: Methods in
Molecular Biology S Krawetz & S Misener (eds), Humana Press, Totowa, NJ.
Shuda, M, Kondoh, N, Imazeki, N, Tanaka, K et al. 2003, "Activation of the ATF6,
XBPI and grp78 genes in human hepatocellular carcinoma: a possible
involvement of the ER stress pathway in hepatocarcinogenesis." Journal of
Hepatology, vol. 38, no. 5, pp. 605-14.
Smyth, G 2005, "limma: Linear Models for Microarray Data," in Bioinformatics and
Computational Biology Solutions Using R and Bioconductor,pp. 397-420.
Song, MS, Park, YK, Lee, J & Park, K 2001, "Induction of Glucose-regulated Protein 78
by Chronic Hypoxia in Human Gastric Tumor Cells through a Protein Kinase C-
{epsilon}/ERK/AP-1 Signaling Cascade." Cancer Res, vol. 61, no. 22, pp. 8322-
8330.
Tong, M & Tai, HH 2000, "Induction of NAD(+)-linked 15-hydroxyprostaglandin
dehydrogenase expression by androgens in human prostate cancer cells."
Biochemical and Biophysical Research Communications, vol. 276, no. 1, pp. 77-
81.
Wang, X, Lawson, B, Brewer, J, Zinszner, H et al. 1996, "Signals from the stressed
endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153)."
Mol. Cell. Biol., vol. 16, no. 8, pp. 4273-4280.
Weinbach, EC & Garbus, J 1969, "Mechanism of action of reagents that uncouple
oxidative phosphorylation." Nature, vol. 221, no. 5185, pp. 1016-8.
Weiss, B, Prozialeck, W, Cimino, M, Barnette, MS & Wallace, TL 1980,
"Pharmacological regulation of calmodulin." Annals of the New York Academy of
Sciences, vol. 356, pp. 319-45.
Wu, Y, Fabritius, M & Ip, C 2009, "Chemotherapeutic sensitization by endoplasmic
reticulum stress: increasing the efficacy of taxane against prostate cancer."
Cancer Biology & Therapy, vol. 8, no. 2, pp. 146-52.
276
- Chapter 4 -
Xu, LL, Shanmugam, N, Segawa, T, Sesterhenn, IA et al. 2000, "A novel androgen-
regulated gene, PMEPA1, located on chromosome 20q 13 exhibits high level
expression in prostate." Genomics, vol. 66, no. 3, pp. 257-63.
Yabe, D, Brown, MS & Goldstein, JL 2002, "Insig-2, a second endoplasmic reticulum
protein that binds SCAP and blocks export of sterol regulatory element-binding
proteins." Proceedings of the National Academy of Sciences of the United States
ofAmerica, vol. 99, no. 20, pp. 12753-8.
Yang, H, Chen, D, Cui, QC, Yuan, X & Dou, QP 2006, "Celastrol, a Triterpene Extracted
from the Chinese "Thunder of God Vine," Is a Potent Proteasome Inhibitor and
Suppresses Human Prostate Cancer Growth in Nude Mice." Cancer Res, vol. 66,
no. 9, pp. 4758-4765.
Yang, H, Shi, G & Dou, QP 2007, "The Tumor Proteasome Is a Primary Target for the
Natural Anticancer Compound Withaferin A Isolated from "Indian Winter
Cherry"." Mol Pharmacol, vol. 71, no. 2, pp. 426-437.
Yang, T, Espenshade, PJ, Wright, ME, Yabe, D et al. 2002, "Crucial step in cholesterol
homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein
that facilitates retention of SREBPs in ER." Cell, vol. 110, no. 4, pp. 489-500.
Ye, J, Rawson, RB, Komuro, R, Chen, X et al. 2000, "ER stress induces cleavage of
membrane-bound ATF6 by the same proteases that process SREBPs." Molecular
Cell, vol. 6, no. 6, pp. 1355-64.
Yoshida, H, Matsui, T, Yamamoto, A, Okada, T & Mori, K 2001, "XBP1 mRNA Is
Induced by ATF6 and Spliced by IRE in Response to ER Stress to Produce a
Highly Active Transcription Factor." Cell, vol. 107, no. 7, pp. 881-891.
Zhijin Wu, Rafael A . Irizarry, Robert Gentleman, Francisco Martinez-Murillo & Forrest
Spencer 2008, "A Model-Based Background Adjustment for Oligonucleotide
Expression Arrays."
Zinszner, H, Kuroda, M, Wang, X, Batchvarova, N et al. 1998, "CHOP is implicated in
programmed cell death in response to impaired function of the endoplasmic
reticulum." Genes & Development, vol. 12, no. 7, pp. 982-995.
277
278
Kyle David Proffitt
proffitt@mit.edu
EDUCATION
RESEARCH
EXPERIENCE
HONORS
PROFESSIONAL
AFFILIATIONS
MANUSCRIPTS &
PRESENTATIONS
Department of Chemistry
77 Massachusetts Ave.
Room 56-670
Cambridge, MA 02139
Tel: (617) 253-5772
Massachusetts Institute of Technology, Cambridge, Mass.
Doctor of Philosophy Candidate: Biological Chemistry 2009 Expected
University of South Carolina (Honors College), Columbia, S.C.
Bachelor of Science in Chemistry; GPA 3.735/4.0 2002
Massachusetts Institute of Technology Cambridge, Mass.
Departments of Chemistry and Biological Engineering 2002-Present
Advisor: Dr. John M. Essigmann
Proposed Thesis Title: "Interaction of the Novel DNA Damaging Anticancer
Agent 11/3 with the Androgen Receptor"
* Demonstrated that the molecule I I P can cause AR phosphorylation, nuclear
localization, and binding at the PSA promoter, while also inhibiting the N/C
terminal interaction and activation of androgen-regulated genes caused by
dihydrotestosterone
* Performed genome-wide analysis of transcription, identifying new effects of
this compound on genes related to cell cycle progression, cholesterol
biosynthesis, and unfolded protein response
* Synthesized a control compound with identical structure but with 10-fold
reduced AR binding affinity to test for AR-dependent toxicity
* Gained proficiency in techniques of Western blotting, RT-PCR, mammalian
cell culture, mouse xenograft models, siRNA, DNA microarray, molecular
biology, and transcriptional reporter assays
University of South Carolina Columbia, S.C.
Department of Chemistry 2002
Advisor: Advisor: Dr. Brian A. Salvatore
Honors Thesis Title: "Toward the Development of Synthetic Peptide Ion
Channels"
MIT National Cancer Institute Training Grant (2003-2006)
MIT Presidential Fellow (2002)
Phi Beta Kappa (2002)
Golden Key National Honor Society (2002)
Harper Award: Highest GPA in Chemistry at USC (2002)
American Association for Cancer Research
American Chemical Society
Proffitt, K.D.; Essigmann, J.M.; Croy, R.G. Involvement of the Androgen
Receptor in Toxicity of the DNA Damaging Agent 11 toward Prostate Cancer
Cells. In Preparation.
279
Proffitt, K.D.; Fuangthong, M.; Fry, R.C.; Essigmann, J.M.; Croy, R.G. The
Anticancer Agent 11P Elicits a Robust Transcriptional Response Including
Altered Expression of Genes Involved in Cell Cycle Control, Cholesterol
Biosynthesis, and the Unfolded Protein Response in Prostate Cancer Cells. In
Preparation.
Kyle Proffitt, John C. Marquis, A. Nicole Dinaut, John M. Essigmann, Robert
G. Croy, "Role of the Androgen Receptor in Toxicity of the Novel Anticancer
Compound 110," American Association for Cancer Research National Meeting,
Washington, DC, March, 2006, Abstract #567.
Kyle Proffitt, Shawn M. Hillier, Mayuree Fuangthong, Rebecca Fry, John M.
Essigmann, Robert G. Croy, "Interaction of the Novel DNA Damaging
Anticancer Agent 110 with the Androgen Receptor," American Association for
Cancer Research, Translational Cancer Medicine Series, Singapore, November
2007, Abstract #A22.
280
